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CHAPTER 1 
 
INTRODUCTION 
 
1.1. Non-Invasive Imaging  
There is a critical need to develop and rigorously validate biomarkers to aid in 
tumor diagnosis, predict clinical outcome, and quantify response to therapeutic 
interventions. Conventional biomarkers in oncology typically require invasive 
procurement of limited quantities of tumor tissue with attendant risks and sampling errors 
due to heterogeneity. Furthermore, serial biopsy, as required to assess treatment 
response longitudinally, is clinically impractical in many instances. Non-invasive imaging 
circumvents these limitations and offers potential advantages over traditional biopsy-
based procedures.  
Imaging techniques routinely used in clinical oncology include magnetic 
resonance imaging (MRI), X-ray computed tomography (CT), ultrasound imaging (US), 
and positron emission tomography (PET). Emerging techniques also include optical 
imaging based approaches, however, current applications tend to be focused towards 
skin cancer evaluation (1) and fluorescence-guided surgery (2). The current imaging 
criteria used for evaluating tumor development and response to therapeutic regimens is 
based on the anatomically derived Response Evaluation Criteria in Solid Tumors 
(RECIST) guidelines (3). RECIST was originally developed to assess response to 
cytotoxic chemotherapeutic agents in solid state tumors by monitoring deviations in 
tumor size throughout the course of treatment. As this approach is solely dependent on 
changes in tumor size, many limitations have been observed in situations regarding 
molecularly targeted therapies patients with specific genomic mutations (3,4). In 
addition, molecular and cellular responses to therapy can precede changes in tumor size 
1
 and would be overlooked when determining therapeutic response using conventional 
approaches. These pitfalls, coupled with clinical rise of multiplex, combination therapies, 
accentuate a pressing clinical need for imaging approaches which can report and 
monitor early and ongoing molecular and cellular changes in tumor cells. Such 
techniques are needed not only for individualized response assessment but also for 
guiding treatment planning; so as to advance the current clinical trend to personalized 
medicine. 
Towards fulfilling this need, molecular imaging has emerged as a non-invasive 
means of improving our understanding of the fundamental biological determinants of 
disease initiation and formation; the details of which will be discussed further in Chapter 
2. As defined by the Molecular Imaging Center of Excellence (MICoE) in 2007, 
“molecular imaging is the visualization, characterization, and measurement of biological 
processes at the molecular and cellular levels in humans and other living systems” (5). 
This is distinct from traditional diagnostic imaging provides information regarding the end 
effects of tumor molecular abnormalities rather than the base determinants. Molecular 
imaging strategies can employ many of the routinely used modalities previously defined 
(MR, CT, US, PET, SPECT, and Optical) and are dependent on the use of molecular 
imaging agents, or probes, to “visualize, characterize, and measure biological processes 
in living systems” (5).  
Of these approaches, the sensitivity and quantitative nature of positron emission 
tomography (PET), coupled with the ability to readily produce biologically active 
compounds bearing positron emitting isotopes, renders PET imaging one the most 
attractive techniques for detecting tumors and profiling their molecular features. The 
most widely used PET agent in oncology is 2-deoxy-2-(18F)fluoro-D-glucose ([18F]FDG) 
and has become a mainstream tool for cancer detection and assessment. However, 
[18F]FDG PET has several key limitations and efficacy gaps; the details of which will be 
2
 discussed throughout Chapter 2 and Chapter 4. Despite this, the diversity of PET 
agents currently available for profiling tumors, and accordingly the breadth of biological 
questions measurable by PET, is limited.  
Unmet needs in clinical oncology provide the impetus for PET agent 
development in order to address such clinical needs as: enabling detection of clinically 
important cancer precursor lesions and tumors with elevated malignancy potential; 
tracers that allow disambiguation of benign lesions from cancer; tracers to quantify early 
responses of tumors to therapy; and tracers that allow measurement of signaling 
pathway activity and are capable of detecting specific genetic events. Within this context, 
the primary molecular targets for PET agent development discussed throughout this 
dissertation will leverage biologically orthogonal facets of cancer cell death and 
metabolism, with emphasis on mitochondrial energetics and homeostasis. Within this 
theme, agents were developed and/or evaluated as tools for targeting molecular events 
associated with apoptosis, glutamine metabolism, and cholesterol metabolism. 
 
1.2. Specific Aims 
This dissertation seeks to develop PET imaging biomarkers that quantitatively 
inform mitochondrial-dependent cell processes in gastrointestinal (GI) cancers, 
particularly colon and pancreatic. As a nexus of cell pathways, the mitochondria serves 
as a prime target for cross-functional probe development (Fig. 1.1) and the imaging of 
physiologically, orthogonal metabolic processes, such as cell death (6-8), carbon and 
nitrogen sourcing (8-10), oxidative stress response (11), and steroidogenesis (12,13). 
Within this context, this dissertation focused on the study of three specific aims. 
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 Aim 1. To develop and evaluate a novel PET imaging agent of programmed cell death  
A known caspase inhibitor, the modified tripeptide sequence Val-Ala-Asp(OMe)-
fluoromethylketone (VAD-FMK), was utilized as a scaffold for positron emission 
tomography (PET) probe development (14). A lead compound was identified and 
radiolabeled with fluorine-18. The potential for noninvasive, in vivo detection of caspase 
activity was determined in response to aurora kinase inhibition as well as a multi-drug 
regimen that combined an inhibitor of mutant BRAF and a dual PI3K/mTOR inhibitor in 
the setting of V600E colon cancer. These studies illuminate the VAD-FMK peptide as a 
promising scaffold for molecular imaging of caspase activity and response to molecularly 
targeted therapy using positron emission tomography. 
 
Aim 2. To evaluate glutamine metabolism PET to detect oncogenic pathway activity 
A radiolabeled analogue of glutamine, [18F](2S,4R)4F-GLN, was explored as a 
PET imaging agent for reporting therapeutic response to an expansive regime of 
molecularly target drug therapies in BRAFV600E-expressing and mutant PI3K colon 
cancers. In vivo comparisons were made to imaging agents of other amino acid 
metabolic fuel sources; mainly glucose and glutamate. Additional studies explored the 
relationship between mutant Kras expression and glutamine uptake in transgenic mouse 
models of colon cancer using [18F](2S,4R)4F-GLN PET imaging. These findings not only 
provide a greater understanding of the role that glutaminolysis plays in CRC, but also 
illuminate the potential impact that glutaminolysis-derived PET could have towards 
guiding drug development clinical trials. 
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Figure 1.1. The mitochondria is a link between cell pro-life and pro-death 
processes. Many cell pathways are linked through molecular regulations occurring 
within the mitochondria. Relevant to this dissertation, the complex and highly regulated 
processes of apoptotic cell death, amino acid metabolism, oxidative stress management, 
and steroidogenesis are connected, and some cases dependent on one another, 
through mitochondrial regulated mechanisms. The specifics of these relationships will be 
discussed in greater detail in Chapter 2. 
 
Aim 3. To explore TSPO as an early determinant in GI cancers  
The translocator protein (TSPO) was explored as an early biomarker in the 
development and progression of GI cancers, mainly colorectal and pancreatic neoplasia. 
TSPO expression was evaluated in low- and high-grade human CRC samples as well as 
a diverse sampling of pre-malignant colon adenomas. Further studies elucidated the 
potential of TSPO as an imaging target of early pancreatic lesions in genetically 
engineered mice. In contrast to conventional thought, which associates elevated TSPO 
expression with advanced tumors, this work revealed TSPO expression to be a 
biomarker of early disease progression in GI cancers. This discovery could provide the 
basis for developing non-invasive imaging metrics for the detection and screening of 
patients possessing early colonic and pancreatic precursor lesions. 
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 1.3. Dissertation Outline 
Within the context of the specific aims, the core chapters of this dissertation will 
discuss PET imaging probe development, evaluation, and validation specifically relevant 
to: determining caspase-dependent apoptotic cell death in response to molecular 
targeted therapies (Chapter 3), exploring oncogenic determinants of glutamine 
metabolism (Chapter 4), and evaluating TSPO as an early biomarker in GI cancers 
(Chapter 5). A complete summary of conclusions, clinical relevance, and directions for 
future studies will be provided in Chapter 6. Other topics relevant broadly to molecular 
imaging as a field will be covered in the appendices and include discussions on: 
fluorescence imaging of pH heterogeneity in tumors (Appendix 1) (15), a comparison 
and evaluation of fluorescence optical imaging probes and imaging systems (Appendix 
2), and exploration of microfluidic radiochemistry towards streamlining the PET probe 
radiochemical development process (Appendix 3). More generally, as molecular 
imaging is a highly interdisciplinary science, this dissertation will deal with many cross-
discipline fundamentals relevant to probe development/evaluation and cover concepts 
which span many scientific disciplines (Fig. 1.2). 
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Figure 1.2. PET probe development and molecular imaging workflow. A general 
outline of the fundamental steps involved in the development and evaluation of novel 
and known PET imaging probes and how each dissertation chapter is integrated into this 
process. This process pulls from multiple scientific disciplines, including chemistry and 
radiochemistry (orange), molecular and cancer biology (blue), and preclinical imaging 
and image analysis (green). 
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CHAPTER 2 
 
BACKGROUND AND SIGNIFICANCE 
 
2.1. Molecular Imaging Modalities and Agents 
Medical imaging methods have become an indispensable clinical component in 
the capacity of disease detection and diagnosis. Prominent medical imaging modalities, 
such as planar X-Ray, computed tomography (CT), magnetic resonance imaging (MRI), 
and ultrasound imaging, have become integrated into the standard of care for many 
patients. However, these methods have relied upon the detection of gross anatomy or 
structural anomalies, leaving the biological function and molecular determinants of the 
disease poorly understood. To circumvent this, molecular imaging has arisen as a 
promising clinical and research tool with applications towards early detection, disease 
diagnosis and prognosis, assessment of therapeutic efficacy and response, treatment 
planning, and drug development. 
Broadly defined, molecular imaging is the in vivo visualization, characterization, 
and measurement of biological processes at the molecular and cellular level (1,2). In 
terms of application, perhaps the most defining feature of molecular imaging is the 
utilization of an imaging agent, or probe. Regardless of application, all molecular imaging 
agents possess a targeting moiety, or carrier, which is specific to a particular biological 
process or molecular event, and a signaling moiety, or label, which emits or produces a 
signal which can be detected using an appropriate imaging system (3). Common 
targeting moieties include small molecules, functionalized nanomaterials, peptides, 
proteins, and antibodies, while signaling moieties may vary between fluorophores, 
hyperpolarized molecules, metal chelates, nanoparticles, microbubbles, and short-lived 
and long-lived radionuclides, depending on the imaging modality employed. Of prevalent 
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imaging modalities, the following have been utilized in a molecular imaging capacity in 
both preclinical and clinical settings (4): nuclear imaging modalities including positron 
emission tomography (PET) and single-photon emission computed tomography 
(SPECT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy 
(MRS), computed tomography (CT), and ultrasound (US). In addition, optical imaging 
modalities (fluorescence, bioluminescence, and Cerenkov luminescence imaging) have 
been explored in largely a preclinical research capacity (4), though clinical applications 
for fluorescence imaging have recently been explored in very specific circumstances. 
While many of these techniques measure exogenous agents, external materials which 
are administered to an organism, subsets of optical imaging (5), MRI (6), and MRS (7) 
can detect endogenous materials, which are inherent in an organism. To summarize the 
topics discussed throughout this section, a comparison of the performance 
characteristics of common molecular imaging modalities relevant to preclinical and 
clinical applications can be found in Table 2.1. Additionally, the fundamentals of 
molecular imaging modalities and comparisons of these approaches has been 
extensively reviewed in many publications (3,4,8). 
 
Table 2.1. Comparison of molecular imaging modalities. ‘P’ and ‘C’ stand for 
‘preclinical’ and ‘clinical’ applications, respectively, and ‘NA’ for ‘not applicable.’ Asterisks 
(*) were used to indicate the relative cost of each modality, where an increasing number 
of asterisks corresponds to an increase in financial cost. Two value ranges are provided 
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for ultrasound spatial resolution as this magnitude is highest for superficial scans and 
decreases with tissue depth. Sensitivity values are shown in terms of mol/L (M). The 
contents of this table were adapted from cited works (3,4,8). 
 
PET and SPECT imaging are the most common molecular imaging modalities in 
clinical use. Being nuclear based, signaling moieties include a range of radionuclides. 
For PET imaging, these include positron emitting isotopes [carbon-11 (11C), oxygen-15 
(15O), nitrogen-13 (13N), fluorine-18 (18F), copper-64 (64Cu), zirconium-89 (89Zr), and 
gallium-68 (68Ga)] that are typically short-lived, with radioactive half-lives being in terms 
of hours or days rather than days or weeks (9). Radionuclides for SPECT are longer-
lived and possess half-lives spanning between several hours to days and even weeks 
and include gamma-emitters such as iodine-123 (123I) and the radiometals technetium-
99m (99mTc), indium-111 (111In), and gallium-67 (67Ga) (10). One of the greatest strengths 
of PET and SPECT imaging lies in their high sensitivity in both a preclinical and clinical 
settings (10-11-10-12 for PET and 10-10-10-11 for SPECT) (2-4). Furthermore, the increased 
sensitivity of these modalities allows for relatively low quantities of imaging agents used. 
This is commonly referred to as the ‘tracer level’, meaning that concentrations of imaging 
agents (pmol-nmols of material) are below the threshold for elucidating a physiological 
response, and as such, are essentially nontoxic. While SPECT has slightly lower 
sensitivity, compared to PET, and lower resolution in the clinical setting (8–10 mm 
compared to 5–7mm with clinical PET) (11), higher resolution can be achieved with 
preclinical imaging due to specialized hardware. SPECT also possesses some 
multiplexing capabilities, which PET lacks, due to differences in gamma ray energy 
produced by the radioactive decay of SPECT isotopes. 
While common MRI applications trend towards structural and anatomical 
imaging, recent years have seen the development and use of many MR specific imaging 
agents. Signal moieties can range from the inclusion of chelated magnetic metals to 
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metal nanoparticles (12) and are selected to effect either the T1 or T2 relaxation times of 
the hydrogen atoms in water, such as gadolinium (Fig. 2.1) or superparamagnetic iron 
oxide particles, respectively. Imaging strategies for detecting alterations in fluorine-19 
relaxation times, rather than hydrogen, have also been developed. Compared to nuclear 
imaging modalities, MRI benefits from the absence of ionizing radiation and high spatial 
resolutions (clinical: 1 mm compared to 5–7 mm for PET, preclinical: micrometers 
compared to millimeter for PET) (4). However, a major limitation of MRI is its modest 
sensitivity. This pitfall can not only lead to extended acquisition times but may also 
require the use of imaging agent quantities that exceed the ‘tracer level’ limit. This can 
be problematic, as high levels of imaging agent may both alter the molecular processes 
being studied as well as introduce concerns for toxicity. 
 
Figure 2.1. General schematic for a gadolinium-derived T1-weighted MR molecular 
imaging agent. Of the eight MR contrast agents currently approved for clinical use in 
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the United States, seven of the eight are the product of paramagnetic metal ion chelation 
(shown above). For these agents, relaxation times of hydrogen atoms in water within an 
organism’s tissues are enhanced, improving image contrast. When functionalized with 
targeting moieties, these agents can be used towards molecular imaging applications. 
This figure was modified for publication in 2011 (13). 
 
Though commonly known as Nuclear Magnetic Resonance (NMR) spectroscopy 
in the fields of chemistry, in the clinical setting NMR is widely referred to as magnetic 
resonance spectroscopy (MRS). MRS is commonly utilized as a means to detect the 
spectral properties, or an induced chemical shift, of abundant endogenous molecules 
and metabolites such as creatine, lactate, glutamine, glutamate, alanine, lipids, and most 
notably choline, in which case high levels of choline-containing metabolites have been 
identified in nearly all types of cancer (14). Beyond hydrogen, chemical shift changes of 
other nuclei can also be detected using MRS, including carbon-13, fluorine-19, 
phosphorus-31, sodium-23, and nitrogen-15. MRS suffers from low sensitivity due to the 
lower concentration of endogenous molecules relative to water, but can be combined 
with high-resolution anatomical MRI in order to provide additional biochemical 
information. 
Unlike traditional planar X-ray imaging techniques, CT is tomography-based and 
produces high-resolution, three-dimensional anatomical images of hard tissues, in 
contrast to MRI which benefits from high contrast in soft tissue. Iodinated contrast 
agents are commonly used during CT imaging to improve spatial resolution and soft 
tissue contrast. CT possesses limited potential as a molecular imaging modality, similar 
to MRI, due to the large concentrations of agents required in order to generate contrast. 
Despite this, the rise in nanomaterial development has produced functionalized 
nanoparticles that have begun to be explored for targeted CT imaging applications (15). 
Though molecular imaging applications are still limited, CT imaging remains a widely 
available, relatively cost-effective, and highly efficient morphological tool in clinical 
practice. 
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Medical US is a real-time, largely morphological imaging modality that exploits 
the properties and behavior of high-frequency sound waves as they travel through soft 
tissues. In this setting, infrared (IR) light pulses locally heat tissue causing thermoelastic 
expansion and subsequent production of ultrasound waves, which are then detected 
superficially. Common contrast agents utilized for US include gas-filled microbubbles, 
which are several orders of magnitude more reflective than blood. While microbubbles 
themselves do not enable targeted imaging of a cellular or molecular functions, the 
surfaces can be functionalized with peptides or antibodies for molecular imaging 
applications (16).  While studies employing microbubbles for targeted imaging have 
yielded interesting results, particularly in the context of angiogenesis (17), such studies 
have been largely preclinical leaving clinical applications unexplored. 
 Optical imaging approaches benefit from high sensitivity and compared to 
nuclear imaging modalities, analogous to nuclear imaging modalities, but are typically 
more cost-effective. For fluorescence imaging, the diversity of imaging agents available, 
both commercially and custom, is expansive given the breadth of fluorophores available 
as signal moieties as well as the number of peptides, proteins, antibodies, and 
nanomaterials available as targeting moieties. However, fluorescence imaging 
possesses a number of pitfalls. These include short penetration depths (~1 cm), limited 
due to the scattering and absorbance of incident and fluorescent photons by biological 
tissues, as well as interference from tissue autofluorescence. The combination of which 
ultimately reduces sensitivity. These limitations have kept fluorescence imaging focused 
largely towards preclinical applications. However, emerging clinical techniques have 
begun to incorporate fluorescence imaging in applications specific towards skin cancer 
evaluation (18) and fluorescence guided surgery (19). 
 Bioluminescent imaging (BLI) is a largely preclinical optical imaging modality 
which utilizes reporter genes, typically expressing luciferase, that cleave injected 
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luciferin to biochemically produce photons of light. Due to the higher sensitivity related to 
enzymatic amplification of signal, compared to fluorescence imaging which requires an 
external excitation wavelength source, BLI possess high sensitivity and signal-to-noise 
ratios. As with fluorescence imaging, the most prominent limitation of BLI is related to 
poor tissue penetration and photon scattering. 
 In recent years, another luminescence modality known as Cerenkov 
luminescence imaging (CLI) has emerged. CLI relies on the phenomenon that 
radionuclides can emit visible light consistent with a form of electromagnetic radiation 
produced when a charged particle exceeds the speed of light while traveling in a 
dielectric medium (known as Cerenkov radiation) (4). Since its discovery, CLI utilizing 
many common nuclear imaging tracers, such as [18F]2-fluoro-2-deoxyglucose 
([18F]FDG), have begun to be explored for optical imaging applications (20,21). 
 
2.2. PET Imaging  
 PET is ideally suited for monitoring molecular and cellular events during the early 
onset of diseases, making it a powerful tool in many medical fields (e.g. oncology, 
neuroscience, cardiology, and pharmacology) given its capacity towards early detection, 
diagnosis, prognosis, and drug development (22,23). The fundamentals of PET imaging 
are built upon the unique decay properties of positron emitting radioactive isotopes, a 
process known as β+ decay (Fig. 2.2). These radioisotopes are inherently unstable due 
to an excess of protons within the nuclei. Stability is obtained through the transformation 
of a proton to a neutron, positron (e+), and a neutrino (v); the latter two being 
subsequently released from the isotope. Once ejected into surrounding tissue, the short-
lived positron rapidly loses kinetic energy and eventually collides with an electron (e-) 
resulting in matter-antimatter annihilation. This annihilation converts the mass of the two 
particles into two gamma rays, with energies of 511 keV, which travel opposite one 
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another at 180° to eventually be detected by sensors built into the PET scanner (24). 
The PET detectors themselves take the form of a closed ring that surrounds the object 
or organism being imaged and converts electrical signals created through the detection 
of the millions of gamma rays into sinograms that can be reconstructed through a series 
of algorithms into three-dimensional, tomographic images. During post-processing, 
corrections for dead-time, attenuation, scatter, the subtraction of random coincidences, 
and detector normalization are accounted for (25-27). 
 
Figure 2.2. Fundamentals of PET imaging detection. Proton enriched radioisotopes 
(e.g. 15O, 13N, 11C, 68Ga, 18F, 64Cu, 89Zr) undergo β+ radioactive decay to yield a beta 
particle, or positron (e+), and an electron neutrino (v). This form of decay results in 
nuclear transmutation of the parent isotope to a new isotope with a chemical element of 
less than one atomic number unit (e.g. 18F to 18O). Upon positron interaction with an 
electron (e-), an antimatter-matter annihilation occurs resulting in the release of two 511 
keV gamma rays (γ) at 180° apart from one another. These particles are subsequently 
measured by a ring of detectors, or scintillators, built into the PET imaging scanner. This 
figure was adapted from cited works (24). 
 
In its most elementary state, PET images provide a visual means for non-
invasively detecting and localizing in vivo accumulation of imaging agents in target 
tissue. While this can be useful in a qualitative sense, comparison of images across 
subjects can be difficult due to differences in injected dose, image windowing, and 
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physiological variables. As the inherent quantitative nature of PET is one of its unique 
advantages as a molecular imaging modality, rigorous quantitative analysis can be 
performed. Accumulation, or specific uptake, of an imaging agent can be quantified in 
terms of percent injected dose per gram (%ID/g) or standardized uptake value (SUV) by 
normalizing the number of events, or counts, measured within a defined region of 
interest (ROI) to the injected dose of activity and subject’s weight (28). This information 
can be obtained through analysis of what is commonly referred to as a ‘static scan’; a 
PET image whose sum of frames are collected over a specific period of time, typically 
over the span of minutes, after the imaging agent has been delivered and allowed to 
reach a steady state. Kinetic properties of imaging agents can also be determined 
through analysis of ‘dynamic scans’, images where sequential frames are acquired 
starting immediately upon delivery of the dose and extending until steady state is 
achieved, using a series of techniques called compartment modeling. In compartment 
modeling, it is assumed that accumulation of an agent can be separated into 
physiologically distinct pools, or compartments. As compartment models are developed 
specifically for a particular imaging agent, many variants of this method exist and are 
reviewed in referenced work (29).  
 
2.3. PET Agent Development 
 In clinical oncology, the most widely used PET imaging agent is 2-[18F]fluoro-2-
deoxyglucose ([18F]FDG), a glucose analog used to imaging the abnormal dependency 
that cancer cells have on aerobic glycolysis for energy production, the Warburg effect. 
Though the first PET imaging agent to be approved by the Food and Drug Administration 
(FDA), [18F]FDG bears many limitations, such as accumulation in tissues that possess 
increased glycolytic metabolism (e.g. brain, brown adipose tissue, fast-dividing tissues, 
and sites of inflammation) (30) as well as poor detection of tumors with low metabolism, 
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small tumors, tumors of low cell density, and [18F]FDG indifferent cancers (e.g. bladder, 
prostate, and renal cancer) (31). These drawbacks have pushed the development of 
many novel PET imaging agents which possess alternative physiological properties and 
target moieties. 
Novel PET agents ideally arise in response to an unmet clinical need and begins 
with the identification of a molecular target that is differentially expressed in the condition 
of interest. This leads to the selection of a targeting moiety that can serve as a scaffold 
for subsequent agent development (Fig. 2.3). Ideally, a molecular target would be 
expressed either uniquely or in abnormal quantities in the condition of interest, thus 
minimizing agent accumulation in surrounding and normal tissues. Once a targeting 
moiety is selected, chemical synthesis and screening can be used to synthesize, 
identify, and validate a lead compound for radiochemical labeling of the sensor moiety. 
 
Figure 2.3. General strategy for PET imaging agent research and development. 
The advancement of a novel PET imaging agent to the clinical setting typically requires 
many distinct developmental steps. This process begins with the selection of a chemical 
scaffold which will serve as the basis of the targeting moiety. From this, a chemical 
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library can be developed and screened using in vitro techniques to evaluate biological 
affinity and selectivity for a molecular target. From this screening, the most promising 
hits will be advanced for radiochemical development and further screening and 
optimization. Upon successful radiolabeling, an imaging agent can then be advanced to 
preclinical imaging studies and in vivo evaluation. Eventually, these studies can lead to 
clinical advancement of a novel imaging agent. 
 
Radiochemical synthetic methodologies require considerations and 
accommodations that differ from traditional bench-top organic synthesis (24,32,33). 
Many, but not all, of the signaling moieties used for PET agent development require the 
use of a cyclotron to generate the short-lived isotopes. Cyclotrons are particle 
accelerators that direct beams of protons or deuterons to a target material with sufficient 
energy to overcome repulsion of the positively charged nuclei in order to generate the 
desired isotope (24,32). For example, one of the most common PET isotopes, fluorine-
18 (t1/2 = 109.77 min), is produced through proton bombardment of an oxygen-18 target 
in heavy water. Other common cyclotron produced radioisotopes include carbon-11 (t1/2 
= 20.33 min), nitrogen-13 (t1/2 = 9.97 min), oxygen-15 (t1/2 = 2.04 min). Non-traditional 
radioisotopes, such as gallium-68 (t1/2 = 67.71 min), can be produced using a generator 
composed of a long-lived germanium-68 (t1/2 = 271 days) source. Radioisotope 
generators provide a more cost-effective alternative for facilities that cannot afford the 
base cost and/or upkeep required by cyclotron operation (34).  
Upon production, PET radioisotopes are transferred using a stream of inert gas 
to a ‘hot cell’; a lead-lined fume-hood equipped with lead glass windows and robotic-
manipulators all designed to reduce the radiation exposure of a user. Once transferred, 
the entire radiochemical synthesis is performed using a computer-controlled automated 
system that has been pre-equipped with reagents necessary to perform the synthesis. 
Many variations of these automated systems are commercially available and can be 
optimized for custom radiolabeling. Successful radiochemical synthesis of any PET 
imaging agent requires a minimum of two chemical components: a precursor, the 
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starting reagent and targeting moiety, and a non-radioactive, or ‘cold’, chemical standard 
of the authentic imaging agent. Due to both radiation safety restrictions as well as the 
relatively short periods of time allotted for synthesis involving short lived-isotopes 
(typically two to three half-lives), standard synthetic methods for compound validation 
(e.g. NMR, mass spectrometry, elemental analysis, etc.) are not feasible. Most 
commonly, analytical high performance liquid chromatography (HPLC) systems are used 
to run the authentic radiolabeled compound against the ‘cold’ standard in order to 
validate the radiolabeling and approve the product for imaging use. For clinical 
radiosynthesis, additional good manufacturing process (GMP) quality controls may be 
needed to ensure safe use in human patients. 
 
2.4. Mitochondrial Cell Pathways 
 Within the field of cancer detection and evaluation, many PET imaging agents 
have been developed as tools for elucidating the molecular regulators of cancer cell 
reprogramming of cell metabolism, proliferation, angiogenesis, hypoxia, and apoptosis 
(3). Despite the ensemble of agents and targets available for PET imaging, many, if not 
all, possess limitations that are inherent either in the chemical and physiological 
characteristics of the agent or in the molecular and cellular information provided by the 
target detected, such as non-specificity. As such, there is a pressing need to develop 
novel PET imaging agents which target unique molecular events relevant to cancer 
research. Towards this end, mitochondrial dependent processes could serve as a prime 
candidate pool for selecting novel imaging targets given its critical role in many biological 
processes as the ‘gate-keeper’ of a cell’s viability (35).  
Though mutations in cancer cell mitochondrial genes have been recognized 
since the 1990’s (36), conventional interest in the role that such alterations play in 
cancer cells began with the discovery of gene mutations in the tricarboxylic acid (TCA) 
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cycle, also known as the citric acid cycle or Krebs (37,38). Beyond metabolic defects, 
mitochondrial dysfunction in the initiation of apoptotic cell death, reactive oxygen species 
(ROS) regulation, and biosynthetic pathways (e.g. steroidogenesis) have also been 
linked to cancer cell growth and progression (35,39,40). Remarkably, these processes 
are connected through a complex series of molecularly controlled mechanisms that can 
be better understood using molecular imaging (Fig. 2.4).  
 
Figure 2.4. Mechanistic rationale for targeting mitochondrial-centric cellular 
pathways for molecular imaging agent development. The interplay between 
mitochondrial-regulated cell processes offers many molecular targets that could be 
highly informative towards the advancement of cancer imaging research. The connection 
between many of the imaging agents that will be discussed throughout this dissertation, 
shown in yellow, as well as the means in which they inform mitochondrial processes is 
illustrated above. This figure was adapted using information provided in the following 
cited works (35,39-43). 
 
22
Alterations in the cellular consumption and carbon sourcing of glucose, 
glutamine, and other fuels for cancer have become well documented and are the topics 
for numerous review articles (44-48). Cancer cell metabolic reprogramming is 
characterized mainly by increases in aerobic glycolysis (48), the Warburg effect, and an 
increased dependency on glutamine as a fuel source (49,50). Glucose can be taken up 
by cells in a regulated manner using glucose transporters (GLUTs) (51) and converted to 
pyruvate through a series of glycolytic transformations. Pyruvate can then be transported 
into the mitochondria and used in the tricarboxylic acid cycle (TCA) cycle to produce two 
adenosine triphosphate (ATP) and six nicotinamide adenine dinucleotide (NADH) 
molecules per glucose. Similarly, glutamine can be transported to the cytosol by the 
alanine, serine, cysteine transporter (ASCT2) where it is converted to glutamate by 
glutaminase. Glutamate can also be taken into the cell directly using the XCT, or Xc-, 
family of amino acid transporters. Cytosolic glutamate can be either transported into the 
mitochondria, where it is converted to α-ketoglutarate and used for the TCA cycle, or 
used in the synthesis of glutathione (GSH), a major intracellular thiol compound which 
serves as the main antioxidant defense against ROS. GSH can then be transported to 
the mitochondria (mGSH) where it regulates mitochondrial ROS levels and electrophile 
detoxification (40). 
 The ability to adapt to oxidative stress through regulation of ROS-mediated cell 
death is a necessary component of cancer cell survival. In vitro and in vivo studies using 
the natural product piperlongumine have shown that this cytotoxic agent induces cell 
death by decreasing GSH levels and inducing alterations in mitochondrial morphology 
and function (52,53). Further studies have suggested initiating the depletion of mGSH 
and promotion of ROS generation through administration of chemotherapeutic drugs in 
order to induce cancer cell death (54,55). Interestingly, as mGSH levels can be 
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influenced by mitochondrial cholesterol (56,57) and calcium ion levels (58), a potential 
link may exist between glutamate consumption and the translocator protein (TSPO). 
Formerly termed peripheral benzodiazepine receptor (PBR), TSPO is an outer 
mitochondrial membrane (OMM) protein suggested to play a role in steroidogenesis by 
transporting cholesterol to the inner mitochondrial membrane (IMM) (59,60). Elevated 
TSPO expression has been linked with disease progression and diminished survival in 
patients presenting with several types of cancer, including oral (61), colorectal (62), 
breast (63), and brain (64). Additionally, elevated TSPO levels appear to be associated 
with aggressive, metastatic behavior in breast, colorectal, and prostate cancer (65). 
Beyond steroidogenesis, TSPO is also thought to participate in the regulation of cell 
death as a structural marker of the mitochondrial permeability transition (MPT) pore, the 
formation of which is currently believed to be controlled by the voltage-dependent anion 
channel (VDAC), adenine nucleotide translocase (ANT), TSPO (66), and the BCL-2 
protein family (35). The MPT pore results in an increase in mitochondrial membrane 
permeability and can subsequently lead to apoptotic and necrotic cell death 
mechanisms. 
Apoptosis, or programmed cell death, is a mechanism of cell death where 
signaling cascades are regulated largely by a family of cysteine aspartic acid-specific 
proteases, the caspases. Deviations from normal apoptotic programs are frequently 
associated with human diseases such as cancer (67) and the induction of apoptosis in 
cancer cells is a common goal in many anti-cancer therapies. The mitochondria is an 
essential component of apoptosis initiation, specifically the intrinsic pathway, through its 
controlled release of cytochrome c into the cytosol. Surprisingly, mitochondrial apoptosis 
regulators can also feedback into other cell pathways, particularly TCA dependent 
metabolism (42). Though major determinants of apoptosis, some of the proapoptotic Bcl-
2 family of proteins (e.g. Bax, Bak, Bid, Bim, Bad, Puma, and Noxa) have recently been 
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shown to exhibit a dual apoptotic-metabolic nature. For example, Boohaker, et.al. report 
that Bax-deficient cells display decreased oxygen consumption, decreased ATP levels, 
and increased glycolysis (68). In other studies, Bad has been suggested to be a key 
regulator of glucose metabolism in its proposed role as a scaffold for formation of a 
glucokinase (GK)-derived complex necessary for normal glycolytic function (69). 
Conversely, metabolic dysregulation can be a factor in apoptosis induction through the 
BH3-only proteins Puma (70) and Noxa (71), which have been linked to glucose 
deprivation-induced apoptosis. Upstream apoptotic factors can also influence 
mitochondrial metabolism as the tumor suppressor p53, one of the most-studied proteins 
in cancer biology characterized as a stress-induced pro-apoptotic protein, can inhibit 
glycolytic flux (72) while in parallel promoting metabolic glutamine dependency (73,74). 
 Given the complexity of the effects that mitochondrial homeostasis has towards 
cancer development and progression, molecular imaging agents that illuminate 
mechanistic relationships between the processes of apoptosis, metabolism, ROS 
defense, and steroidogenesis could be highly informative towards advancing means of 
cancer detection, assessment of therapeutic response, and drug discovery. Subsequent 
chapters in this dissertation will seek to explore this potential by assessing imaging 
agents which specifically target key regulators in these cancer mitochondrial pathways. 
Chapter 3 outlines the discovery, characterization, and validation of a novel PET 
imaging probe, [18F]FB-VAD-FMK, for in vivo caspase activity detection (75). In Chapter 
4, PET imaging of cancer cell nutrient uptake and metabolism will be evaluated as a 
measure of molecular response to targeted therapy as well as means for reporting 
activation of oncogenic pathways in genetically engineered mice. Exploring novel 
biomarkers in early stage disease, Chapter 5 will describe the relevance of the 
translocator protein (TSPO) expression in early gastrointestinal (GI) neoplasia. 
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 CHAPTER 3 
 
A PEPTIDE-BASED PET PROBE FOR THE DETECTION OF CASPASE ACTIVITY IN 
APOPTOTIC CELLS 
 
3.1. Abstract 
Apoptosis, or programmed cell death, can be leveraged as a surrogate 
measure of response to therapeutic interventions in medicine. Cysteine aspartic acid-
specific proteases, or caspases, are essential determinants of apoptosis signaling 
cascades and represent promising targets for molecular imaging.  
To this end, we reported in Clinical Cancer Research that [18F]4-
fluorobenzylcarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone ([18F]FB-VAD-FMK), a novel 
and potentially translatable molecular probe, enables quantification of caspase activity in 
vivo using positron emission tomography (PET) imaging. Supported by molecular 
modeling studies and subsequent in vitro assays suggesting probe feasibility the 
labeled pan-caspase inhibitory peptide, [18F]FB-VAD-FMK, was produced in high 
radiochemical yield and purity using a simple two-step, radiofluorination. The 
biodistribution of [18F]FB-VAD-FMK in normal tissue and its efficacy to predict 
response to molecularly targeted therapy in tumors was evaluated using microPET 
imaging of mouse models of human colorectal cancer (CRC). Accumulation of [18F]FB-
VAD-FMK was found to agree with elevated caspase-3 activity in response to Aurora B 
kinase inhibition as well as a multi-drug regimen that combined an inhibitor of mutant 
BRAF and a dual PI3K/mTOR inhibitor in V600EBRAF colon cancer. In both scenarios, 
noninvasive imaging of caspase activity provided molecular insights into treatment 
response not previously captured by imaging phosphatidylserine externalization. 
[18F]FB-VAD-FMK PET was also elevated in the tumors of cohorts that exhibited 
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 reduction in size in response to combined inhibition of mutant BRAF and PI3K/mTOR. 
These studies illuminate [18F]FB-VAD-FMK as a promising PET imaging probe to 
detect apoptosis in tumors and as a novel, potentially translatable biomarker for 
predicting response to personalized medicine. 
 
3.2. Introduction 
Cell death proceeds through multiple, mechanistically distinct processes that 
include necrosis, autophagy, mitotic catastrophe, and apoptosis (1,2). Apoptosis, or 
programmed cell death, is an orchestrated process that facilitates elimination of 
unnecessary, damaged, or compromised cells to confer an overall advantage to the host 
organism. As such, apoptosis is an essential component of embryonic development, 
tissue homeostasis, and immunological competence. Deviations from normal apoptotic 
programs are frequently associated with human diseases such as cancer (3). Since 
many anti-cancer therapies aim to selectively induce apoptosis in tumor cells (4,5), 
quantitative, non-invasive imaging biomarkers that reflect apoptosis represent promising 
tools to improve drug discovery and predict early responses in patients (6-10). 
Clinically robust molecular imaging biomarkers of apoptosis have been sought 
after for many years, but none have yet proven optimal. Classically, molecular imaging 
measures of apoptosis have relied upon labeled forms of the 36 kDa protein Annexin V, 
which binds to externalized phosphatidylserine on the plasma membrane of cells 
undergoing apoptosis (7,11). Though functionalization of Annexin V for optical (9,10), 
single-photon emission computed tomography (SPECT) (12,13), and positron emission 
tomography (PET) (14,15) imaging have been reported, imaging probes based on 
Annexin V generally suffer from limitations that include suboptimal biodistribution and 
pharmacokinetics, calcium ion-dependency (16), and a lack of specificity (17-19). 
Another promising approach that capitalizes upon cell membrane alterations associated 
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 with apoptosis utilizes a small molecule known as 18F-ML-10, which has been evaluated 
in a limited number of patients (20,21). The strengths and weaknesses of this approach 
are under investigation at a number of institutions. Other intracellular molecular targets 
within the apoptosis signaling cascade represent opportunities for molecular probe 
development. For example, as regulators of extrinsic and intrinsic apoptosis (Fig. 3.1), 
caspases have been suggested as promising targets for molecular imaging and for drug 
development (6,22).  
 
Figure 3.1. The role of caspases in programmed cell death. Apoptosis can proceed 
through two pathways; an extrinsic mechanism initiated by ligand-mediated interactions 
with cell-surface death receptors and an intrinsic mechanism initiated primarily through 
the mitochondria (2). Both pathways are highly regulated by cysteine aspartic acid 
specific proteases (caspases) which consist of initiators, caspase-2/8/9/10, and 
effectors, caspases 3/6/7. The nature of apoptosis regulation distinguishes it from other 
cell death mechanisms, such as necrosis and autophagy (1,2). 
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 The goal of this study was to explore the utility of a peptide-based pan-caspase 
inhibitor, the modified tripeptide sequence Val-Ala-Asp(OMe)-fluoromethylketone (VAD-
FMK) (23,24), to serve as the basis for developing a PET imaging probe for detecting 
apoptosis. Successful functionalization of VAD-FMK and similar FMK peptides with 
fluorescent labels (25-28) suggest the feasibility of developing PET agents based on this 
sequence that possess translational potential. To this end, we reported in Clinical 
Cancer Research that [18F]4-fluorobenzylcarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone 
([18F]FB-VAD-FMK), a novel and potentially translatable molecular probe, enables 
quantification of caspase activity in vivo using PET imaging (29). Utilizing small animal 
microPET imaging of multiple models of human colorectal cancer (CRC), we 
demonstrate that in vivo tumor accumulation of [18F]FB-VAD-FMK accurately reflects 
elevated caspase-3 activity in response to Aurora B kinase inhibition as well as a multi-
drug regimen that combined an inhibitor of mutant BRAF and a dual PI3K/mTOR 
inhibitor. Furthermore, though these studies illuminate [18F]FB-VAD-FMK as a promising 
tool compound, more generally, these studies suggest that labeled VAD-FMK peptides 
warrant further development as potential scaffolds for development of translational 
molecular imaging probes. 
 
3.3. Materials and Methods 
 
Chemicals 
VAD-FMK (American Peptide) and Z-VAD-FMK (TOCRIS Bioscience, #2163) 
were obtained commercially and used without further purification. Unless otherwise 
indicated, all other chemicals, reagents, and solvents were purchased from Sigma-
Aldrich and used as received. 
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 Molecular Modeling 
Co-crystal structures for the caspase-3 protein with an aza-peptide epoxide 
inhibitor (PDB ID 2CNN) (30) and a covalently bound β-strand peptidomimetic inhibitor 
(PDB ID 3KJF) (31) were obtained from the Brookhaven Protein Data Bank and used to 
evaluate the potential of prosthetically labeled VAD-FMK, and deviations thereof, to be 
accommodated within the active caspase-3 binding domain. Structural alignment of both 
caspase-3 inhibitor co-crystal structures was performed using PyMOL (Molecular 
Graphics System, Version 1.5.0.4, Schrödinger, LLC) to reveal a minor 0.22 angstrom β-
carbon protein backbone coordinate root mean squared deviation (RMSD). Both 
caspase-3 inhibitor-binding sites were treated as energetically equivalent and the 
smaller β-strand peptidomimetic inhibitor structure (PDB ID 3KJF) was chosen as the 
starting point for molecular docking calculations. Following removal of the co-crystallized 
covalent inhibitor ligand, molecular docking was performed using the high resolution, 
flexible SurflexDock GeomX protocol as implemented in SYBYL-X 2.0 (Tripos 
International, 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA), with a protomol 
target based on the β-strand peptidomimetic inhibitor structure with the addition of a 2.0 
angstrom bloat parameter. Best scoring energy-minimized docked poses were ranked 
using the Tripos SYBYL Surflex-Dock flexible protein scoring function, PF-score (Crash 
parameter) for FB-VAD-FMK, Z-VAD-FMK, IZ-VAD-FMK and VAD-FMK were 
determined for comparison of physically plausible, low energy minimized conformations 
in the bound state across the proposed peptide ligand modifications.  
 
Synthesis of [19F]4-Succinimidyl-4-Fluorobenzoate ([19F]SFB) (1) 
4-[19F]Fluorobenzoic acid and N,N,N',N'-tetramethyl-O-(N-succinimidyl)uronium 
tetrafluoroborate (1:1.5) were combined in a round bottom flask with acetonitrile for a 
final 4-[19F]fluorobenzoic acid concentration of 71.4 mM. Upon reaching the final reaction 
37
 temperature, 45-50 °C, solid tetramethylammonium hydroxide (TMAH, 1.5 eq) was 
added to the reaction mixture. The reaction vessel was flushed with positive N2(g) 
pressure and held at this temperature overnight (16-18 h) with stirring. [19F]SFB (1) 
formation was monitored by normal phase thin layer chromatography (TLC) (1:1, ethyl 
acetate:chloroform, RF = 0.76). Purification was performed by flash chromatography with 
SNAP silica cartridges using an hexanes:ethyl acetate gradient (100% 0-1 min, 100-70% 
1-10 min, 70% 10-15 min, 70-30% 15-25 min, 30% 25-35 min; all percentiles with 
respect to hexanes) on a Biotage flash purification system to give the final, pure product 
in up to 85% yield. 1H-NMR characterization matched that of commercially available 
authentic compound purchased from Advanced Biochemical Compounds (ABX). 
 
Synthesis of [19F]4-fluorobenzylcarbonyl-VAD-FMK ([19F]FB-VAD-FMK) (3) 
 
Upon synthesis, (1) was conjugated to VAD-FMK peptide (2) (American Peptide 
Company) through the N-terminus to form the non-radioactive probe analogue, [19F]FB-
VAD-FMK (3) (Fig. 3.2A). Compounds (1) and (2) were reconstituted separately in 
anhydrous dimethylformamide (DMF) with equimolar amounts of N,N-
diisopropylethylamine (DIPEA). Solution (2) was added drop-wise to solution (1) for a 
final compound (2) concentration of 37.5 mM and final molar equivalencies: 1:2:2 
[(1):(2):DIPEA]. The reaction vessel was then flushed with positive N2(g) pressure, heated 
to 55 °C, and held at that temperature overnight (16-18 h) with stirring. Product formation 
was monitored by TLC [6:4, dichloromethane (DCM):(chloroform:methanol:triethylamine 
(TEA), 8:1.8:0.2), RF = 0.5]. Authentic compound was isolated from free peptide and 
unconjugated [19F]SFB using reversed-phase high-performance liquid chromatography 
(HPLC) (Varian Dynamax, Microsorb C18, 8 µm, 21.4 x 250 mm, λ = 254 nm). The 
product eluted between 22-24 min using a phosphate buffer (1 mM):acetonitrile gradient 
(85% 0-2 min, 85-60% 2-10 min, 60% 10-15 min, 60-30% 15-22 min, 30% 22-40 min; all 
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 percentiles with respect to aqueous phase) at a flow rate of 10 mL/min. The final product 
was rinsed with ethyl acetate and obtained in up to 65% yield. 
 
Figure 3.2. Cold compound synthesis. [19F]FB-VAD-FMK (3) (A) and [127I]IZ-VAD-
FMK (5) (B) synthetic routes (29). 
 
High-resolution mass spectroscopy (HRMS) was performed using a Waters 
Synapt Quadrupole Time-of-Flight high-resolution mass spectrometer equipped with a 
dual channel ESCI ion source. HRMS calculated for C21H28F2N3O6 m/z = 456.1946 (M)+, 
found 456.1945. 1H, 13C, and 19F nuclear magnetic resonance (NMR) spectra were 
recorded on a Bruker 400 MHz spectrometer. Chemical shifts are reported in ppm using 
residual DMSO as the internal standard (2.50 ppm for 1H, 39.51 ppm for 13C). The 
following abbreviations are used for multiplicity of NMR signals: s = singlet, d = doublet, 
dd = doublet of doublets, t = triplet, q = quartet, sep = septet, m = multiplet. 1H-NMR 
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 ((CD3)2SO, 400 MHz) δ: 8.62 (d, 1H, J = 7.41 Hz), 8.48 (d, 1H, J = 7.88 Hz), 8.35-8.27 
(m, 2H), 7.94 (m, 2H), 7.28 (t, 2H, J = 8.45 Hz), 5.32-5.04 (m, 2H), 4.64 (q, 1H, J = 6.90 
Hz), 4.48 (q, 1H, J = 6.84 Hz), 4.28 (t, 1H, J = 8.17 Hz), 4.22-4.12 (m, 1H), 3.59 (s, 3H), 
2.86-2.79 (m, 1H), 2.67-2.58 (m, 1H), 2.09 (sep, 1H, J = 6.84 Hz), 1.21 (dd, 3H, J = 7.08 
Hz, J = 3.73 Hz), 0.95-0.89 (m, 6H). 13C-NMR ((CD3)2SO, 400 MHz, 1H decoupled) δ: 
197.87, 197.73, 197.52, 197.38, 168.54, 168.41, 166.63, 166.57, 166.28, 166.10, 
161.07, 161.05, 160.60, 158.13, 125.73, 125.64, 110.65, 110.44, 54.27, 47.76, 47.15, 
47.12, 47.01, 44.07, 43.74, 29.51, 29.23, 25.56, 14.65, 14.31, 14.28, 12.82, 12.73. 19F-
NMR ((CD3)2SO, 400 MHz, 1H decoupled) δ: -107.36, -230.90, -231.06.  
 
Synthesis of [127I]4-iodobenzyl chloroformate (4) 
[127I]4-Iodobenzyl alcohol was solubilized in chilled anhydrous dichloromethane 
(DCM) (0 °C) and added drop-wise to solid triphosgene (1:1) in a reaction vessel under 
positive N2(g) pressure, with stirring, at 0 °C. Final concentration of 4-[127I]iodobenzyl 
alcohol and triphosgene was 674 mM. Reaction mixture was maintained at 0 °C with 
stirring for 15 min, then brought to room temperature and stirred overnight (16-18 h) 
protected from light. [127I]4-iodobenzyl chloroformate (4) formation was monitored by 
normal phase TLC (2:8, ethyl acetate:hexanes, RF = 0.64). The reaction solvent was 
removed by rotary evaporation to obtain a mixture of an off-white solid and a brown-
colored liquid. The mixture was subsequently washed with hexanes and the liquid phase 
extracted. Hexanes were removed to obtain (4) as a brown-liquid that was used 
immediately without further purification. 
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 Synthesis of [127I]4-iodobenzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone 
([127I]IZ-VAD-FMK) (5) 
[127I]IZ-VAD-FMK was synthesized as the para-iodinated regioisomer. Here, (4) 
was conjugated to (2) to form (5) (Fig. 3.2B). Compounds (4) and (2) were reconstituted 
separately in chilled anhydrous DCM (0 °C) with TEA. Solution (4) was added drop-wise 
to (2) in a reaction vessel under positive N2(g) pressure, with stirring, at 0 °C for a final 
compound (2) concentration of 60 mM and final molar equivalencies: 4:1:2 [(4):(2):TEA]. 
The reaction mixture was maintained at 0 °C with stirring for 15 min, then brought to 
room temperature and subsequently heated at 55 °C, with stirring, for 12 h, protected 
from light. Product formation was monitored by TLC [6:4, 
DCM:(chloroform:methanol:TEA, 8:1.8:0.2), RF = 0.30]. The authentic compound was 
isolated from free peptide and (4) using HPLC (Varian Dynamax, Microsorb C18, 8 µm, 
21.4 x 250 mm, λ = 254 nm). The product eluted between 22-24 min using a phosphate 
buffer (1 mM):acetonitrile gradient (85% 0-2 min, 85-60% 2-10 min, 60% 10-15 min, 60-
30% 15-22 min, 30% 22-40 min; all percentiles with respect to the aqueous phase) at a 
flow rate of 10 mL/min. The final product was received in approximately 15% yield. 
High-resolution mass spectroscopy (HRMS) was performed using a Waters 
Synapt Quadrupole Time-of-Flight high-resolution mass spectrometer equipped with a 
dual channel ESCI ion source. HRMS calculated for C22H30FIN3O7 m/z = 594.1113 (M)+, 
found 594.1107. 1H- and 13C-NMR spectra were recorded on a Bruker 500 MHz 
spectrometer. Chemical shifts are reported in ppm using residual chloroform as the 
internal standard (7.26 ppm for 1H, 77.36 ppm for 13C). The following abbreviations are 
used for multiplicity of NMR signals: s = singlet, br s = broad singlet, d = doublet, t = 
triplet, m = multiplet. 1H-NMR (CDCl3, 500 MHz) δ: 7.69 (d, 2H, J = 8.28 Hz), 7.10 (m, 
2H), 6.48 (br s, 1H), 5.36 (m, 1H), 5.23-5.18 (m, 1H), 5.13-4.97 (m, 4H), 4.91 (m, 1H), 
4.52-4.45 (m, 1H), 3.97 (t, 1H, J = 6.82 Hz), 3.68 (s, 3H), 3.13-3.08 (m, 1H), 3.03-2.98 
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 (m, 1), 2.91-2.84 (m, 1), 2.17-2.09 (m, 1H), 1.42-1.37 (m, 4H), 1.25 (s, 2H), 0.98-0.92 
(m, 7H). 13C-NMR (CDCl3, 500 MHz, 1H decoupled) δ: 202.56, 172.39, 171.68, 171.62, 
156.80, 138.06, 136.05, 130.32, 130.27, 94.33, 85.35, 85.26, 83.89, 83.80, 66.94, 61.00, 
52.64, 52.31, 49.33, 35.17, 31.14, 30.05, 19.58, 18.31, 18.10, 8.96.  
 
Enzyme Selectivity Assay 
Relative enzyme inhibition of [19F]FB-VAD-FMK was evaluated against caspase-
3/6/7/8 using homogeneous caspase fluorescence assay kits (BPS Bioscience) and 
compared to parent peptide. Caspase inhibitor dissolved in caspase assay buffer and 
1% DMSO (0.0003 – 10 µM) was combined with the caspase assay substrate and 
enzyme at room temperature for 30 min in accordance with the manufacturer’s 
instructions. Fluorescence intensity was measured at an excitation of 360 nm and an 
emission of 460 nm using an Infinite M1000 microplate reader (Tecan).  
 
Analysis of Lipophilicity 
Lipophilicity characterization of compounds (3) and (5), as well as Z-VAD-FMK, 
was performed through log P7.5 quantification using methodology analogous to those 
previously reported (32). Using reversed phase HPLC (Phenomenex Luna C18, 5 µm, 
100 Å, 4.6 x 250 mm) and a (85:15) phosphate buffer (2 mM, pH 7.5) isocratic system (1 
mL/min), log P7.5 values were calculated using an average of compound retention times 
from three individual runs and standard curve derived linear regression. The following 
standards with known log P values were used for curve development: catechol, aniline, 
benzene, bromobenzene, toluene, ethylbenzene, 2-chlorobiphenyl, biphenyl, 1-
chloronaphthalene, 1,2,3-trimethylbenzene, 1,2,3,4-tetrachlorobenzene, 1,2,4,5-
tetrabromobenzene, and pentachlorobenzene. Log P7.5 values were found to be 1.41, 
2.38, and 2.20 for (3), (5), and Z-VAD-FMK, respectively. 
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Biochemical Caspase-3 Inhibition Assay 
Caspase-Glo 3/7 (Promega) was employed as a readout of inhibition where by a 
caspase-cleavable protected luciferase substrate is directly sensitive to caspase-3/7 
activity and quantifiable by bioluminescence (33). Caspase inhibitor dissolved in DMSO 
(0, 0.1, 1, 10, 100, 1000, or 10000 nM) was combined with recombinant human 
caspase-3 enzyme (C1224-10UG, Sigma) (100 nM) in 1X phosphate buffered saline 
(PBS) in microcentrifuge tubes, vortexed, and incubated at 37°C for 30 min. After 
incubation, Caspase-Glo 3/7 reagent (Promega) was added in accordance with the 
manufacturer’s instructions. Solutions were vortexed, incubated for an additional 30 min, 
and dispensed into opaque wall/bottom 384-well plates (BD Biosciences) for 
measurement of caspase activity. Sample luminescence was measured using a Synergy 
4 plate reader (BioTek). 
 
Cellular Caspase Inhibition Assay  
DiFi cells were propagated in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Mediatech) and supplemented with 10% fetal bovine serum (Atlanta Biologicals) and 1 
mg/mL gentamycin sulfate (Gibco) in a 95% humidity, 5% CO2, 37°C atmosphere. Cells 
were seeded as sub-confluent monolayer cultures at a density of 1 x 104 per well into 96-
well, black wall/bottom plates (BD Biosciences) and allowed to adhere for 24 h at 37°C. 
For evaluation of caspase-3/7 inhibition concomitant with drug exposure, DiFi cells were 
incubated with cetuximab (0.5 µg/mL) for 24 h, based on our experience from previous 
work (9). Cell media was then replaced with 1X PBS containing inhibitor (0, 10, 100, 
1000, 10000 nM) and incubated at 37°C for 30 min. Inhibition was assessed using 
Caspase-Glo 3/7 reagent in accordance with the manufacturer’s instructions. 
Luminescence was quantified using a Synergy 4 plate reader. 
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Radiochemical Production of [18F]4-fluorobenzylcarbonyl-VAD-FMK ([18F]FB-VAD-FMK) 
(11) 
[18F]SFB was prepared using commercial GE TRACERlab-Synthesizer MX 
production kits (ABX) with a BIOSCAN Coincidence radiochemistry module. The 
automated synthetic route included flourine-18 radiolabeling of 4-[1,1-dimethylethyl 
ester]-N,N,N-trimethyl-benzenammonium triflate (6) to 4-[18F]-1,1-dimethylethyl ester 
benzoic acid (7), deprotection of 4-[18F]fluorobenzoic acid (8) through alcoholic 
saponification, and subsequent formation of the activated ester [18F]SFB (9) from (8) 
(Fig. 3.3A). Radiochemical purity (95 ± 2%) was determined by analytical HPLC (Hitachi 
High Technologies LaChrom C18, 5 µm, 4.6 x 150 mm, 1 mL/min, 20-70% 
acetonitrile:water over 15 min, retention time (RT) = 11.5 min, λ = 254 nm). [18F]SFB was 
delivered in approximately 3 mL of 4:1 acetonitrile:water, a decay-corrected 
radiochemical yield of 36 ± 4%, and concentrated to < 0.5 mL using positive nitrogen 
pressure and heating at 55 °C. Once concentrated, VAD-FMK (10 mg/mL DMF) and 
DIPEA (30 µmol) were added to [18F]SFB (7.4-13.0 GBq) and heated in a sealed vessel 
at 55 °C for 45 min (Fig. 3.3B). [18F]FB-VAD-FMK was purified using semi-prep 
reversed-phase HPLC (Waters Sunfire C18, 5 µm, 10 x 150 mm) and eluted between 
17.7-19 min using a phosphate buffer (1 mM):acetonitrile gradient (85% 0-5 min, 85-60% 
5-15 min, 60% 15-25 min, 60-30% 25-45 min; all percentiles in respect to aqueous 
phase) with a 4 mL/min flow rate (Fig. 3.3C). The product fraction was diluted 100-fold 
with water and passed through a C18 Sep-Pak (Waters). Labeled peptide was eluted 
with ethanol into a sterile flask and loaded with normal saline (0.9%). Volumes of eluent 
were modified as needed to ensure a final concentration of 74-185 MBq/mL (1/9, 
ethanol/saline) with a decay corrected radiochemical yield of 24 ± 8%. [18F]SFB 
conjugation efficiency of crude product (55 ± 6%) and radiochemical purity of final post-
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 prep product (98 ± 1%) were determined using analytical HPLC (Phenomenex Luna 
C18, 5 µm, 100 Å, 4.6 x 250 mm) and the following phosphate buffer (1 mM): acetonitrile 
gradient: 85% 0-2 min, 85-30% 2-10 min, 30% 10-35 min; all percentiles in respect to 
aqueous phase (flow rate = 1 mL/min, RT = 12.3 min). Specific activities for [18F]SFB (83 
± 56 TBq/mmol) and [18F]FB-VAD-FMK (5 ± 3 TBq/mmol) were calculated using an 
HPLC-derived standard curve. Radiochemical purity, specific activity, and other 
synthesis results for both [18F]SFB and [18F]FB-VAD-FMK are summarized in Table 3.1. 
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Figure 3.3. Radiosynthesis and purification. [18F]SFB (9) (A) and [18F]FB-VAD-FMK 
(11) (B) synthetic schemes. Compound (9) radiosynthesis was performed systematically 
using an automated radiochemistry module. HPLC radiochromatogram of post-prep (11) 
(blue, bottom) is shown overlaid with UV-chromatogram of [19F]standard (3) (pink, top) 
(C). 
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Table 3.1. Representative summary of various radiochemical productions. Decay 
corrected radiochemical yields (cRCY), radiochemical purities (RCP), and specific 
activities (SA) for [18F]SFB and [18F]FB-VAD-FMK. Percent [18F]SFB conjugation (Conj.) 
to peptide is also provided. 
 
Synthesis of NIR800-Annexin V 
Annexin V labeled with a near-infrared dye (NIR800-Annexin V), suitable for in 
vivo imaging, was prepared by fluorescently labeling Annexin V with IRDye 800CW NHS 
Ester (LiCor Biosciences) using methods analogous to previously reported work (9,10). 
In place of dialysis, labeled protein was purified from unconjugated dye using Zeba 
Desalting Spin Columns (Thermo Scientific).  
 
Radiochemical Production of [99mTc]HYNIC-Annexin V 
Annexin V (Sigma) conjugation with succinimidyl-HYNIC hydrochloride (ABX) 
and subsequent radiolabeling with technetium-99m was prepared analogously to 
previously reported methods (12). In place of dialysis, labeled protein was purified from 
unconjugated HYNIC using Zeba Desalting Spin Columns (Thermo Scientific). 
 
Cell Cycle Assays 
For cell cycle analysis, SW620 and DLD-1 cells were propagated to 50% 
confluency in 6 cm plates and treated with AZD-1152-hydroxyquinazoline pyrazol anilide 
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 (HQPA) (Selleckchem), 0, 10, 100, 1000, or 5000 nM, for 24 or 48 hrs and prepared for 
flow cytometry as described (9). Propidium iodide (PI)-stained cells were analyzed by 
flow cytometry (FACStar PLUS, Becton-Dickinson). Data analysis was performed using 
CellQuest software (Becton-Dickinson) by manually gating to define and quantify sub-
G0, G1, S, G2/M, and polyploidy populations. For assay of apoptosis following in vitro 
AZD-1152-HQPA exposure, SW620 and DLD-1 cells were seeded as sub-confluent 
monolayer cultures at a density of 1 x 104 per well into 96-well, black wall/bottom plates 
(BD Biosciences), allowed to adhere for 24 h, and treated with AZD-1152-HQPA, 0, 10, 
50, 75, 100, or 1,000 nM, for 24 or 48 hrs. Apoptosis was assessed using the Caspase-
Glo 3/7 reagent, in accordance with manufacturer’s instructions, and analyzed using a 
Synergy 4 plate reader. 
 
Immunoblotting 
After 24 h of drug exposure, in vitro cell samples were collected from 10-cm 
plates. Medium was removed and cell monolayers washed with 1X phosphate buffered 
saline (PBS) followed by addition of 450 mL of lysis buffer containing: 7 mL of CelLytic M 
lysis buffer (Sigma), mini protease inhibitor cocktail (Roche), and 100 mL of 
phosphatase inhibitor cocktail 1 and 2 (Sigma). Protein concentrations were normalized 
using a bicinchoninic acid assay. All samples were vortexed and centrifuged prior to final 
cell lysate collection. 
Immunoblotting was performed by loading 20-40 µg of protein into 7.5-12% SDS 
PAGE gels and resolved by electrophoresis. Membranes were incubated with antibodies 
to cleaved PARP (Cell Signaling, 9541S), cleaved caspase-3 (Cell Signaling, 9664), or 
GAPDH (Millipore, MAB374) and imaged on a Xenogen IVIS 200 using Western 
Lightning Plus-ECL (PerkinElmer) substrate. 
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 Animal Models 
Studies involving animals were conducted in accordance with federal and 
institutional guidelines. Biodistribution studies were performed using male C57BL/6 
mice. Dual xenograft-bearing mice were sequentially injected with 1 x 107 SW620 and 5 
x 106 DLD-1 human CRC cells subcutaneously onto the left or right hind limbs 
(respectively) of 5- to 6-week old female, athymic nude mice (Harlan Sprague-Dawley). 
Palpable tumors were observed 2-3 weeks following inoculation. Animals bearing 
SW620 and DLD-1 xenograft tumors were treated with vehicle or AZD-1152 (25 mg/kg, 
DMSO) via intraperitoneal injection once daily for five days, analogous to previous work 
(34). In vivo PET imaging studies were performed on Day 5, approximately 4-6 h after 
treatment.  
COLO-205 and LIM-2405 xenografts were generated by subcutaneously injecting 
1 x 107 cells onto the right flank of 5- to 6-week old female, athymic nude mice (Harlan 
Sprague-Dawley). Palpable tumors were observed within three weeks following 
inoculation. For BEZ-235 (Selleckchem) and PLX-4720 (synthesized using reported 
methods) (35) single-agent treatment, animals were administered vehicle, BEZ-235 (35 
mg/kg, 0.1% Tween 80 and 0.5% methyl cellulose) or PLX-4720 (60 mg/kg, DMSO) via 
oral gavage once daily for four days. For BEZ-235 and PLX-4720 combination treatment, 
BEZ-235 (35 mg/kg, 0.1% Tween 80 and 0.5% methyl cellulose) and PLX-4720 (60 
mg/kg, DMSO) were administered via oral gavage as separate doses (respectively) 
approximately 7-8 h apart. To monitor tumor growth, tumor volumes were measured on 
Days 1 and 4 of treatment using a previously established ultrasound imaging based 
methodology (36). In vivo imaging studies were performed on the 4th day (PET), based 
on our previous experience with BRAF inhibition in vivo (37). 
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 In Vivo Imaging and Analysis 
For all imaging studies, mice were maintained under 2% isofluorane anesthesia 
in 100% oxygen at 2 L/min and kept warm via a circulating water heating pad for the 
duration of the PET scan. Small-animal PET imaging was performed using a dedicated 
Concorde Microsystems Focus 220 microPET scanner (Siemens Preclinical Solutions). 
Animals were administered 7.4-9.3 MBq of [18F]FB-VAD-FMK via intravenous injection. 
Both static and dynamic data sets were acquired. For static scans, animals were allowed 
free access to food and water during a 20–40 minute uptake period, followed by 
anesthetization and a 20-minute image acquisition. Analogously, sixty minute dynamic 
acquisitions for all xenografts were initiated at the time of [18F]FB-VAD-FMK injection.  
PET data were reconstructed using a three-dimensional (3D) ordered subset 
expectation maximization/maximum a posteriori (OSEM3D/MAP) algorithm. Dynamic 
data was binned into twelve 5 s (0-1 min) and fifty-nine 60 s (2-60 min) frames. The 
resulting three-dimensional reconstructions had an x-y voxel size of 0.474 mm and inter-
slice distance of 0.796 mm. ASIPro software (Siemens Preclinical Solutions) was used 
to manually draw three-dimensional regions of interest (ROI) in the tumor volume. Areas 
of perceived necrosis were excluded when drawing ROIs. [18F]FB-VAD-FMK uptake was 
quantified as the percentage of the injected dose per gram of tissue (%ID/g); for dynamic 
scans, only data points collected within the time frame analyzed for analogous static 
scans were considered.  
For optical imaging studies using NIR800-Annexin V, 1 nmol of labeled protein 
was administered via retro-orbital injection. Imaging was performed using a Pearl 
Impulse near-infrared fluorescence imaging system (LiCor) 24 h after probe 
administration (5th day of treatment). ROI analysis was used to assess tumor-to-normal 
(T/N) contrast ratios where T/N = [(tumor tissue mean pixel intensity/unit area)/(normal 
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 tissue mean pixel intensity/unit area)]. Probe uptake in normal tissue was assessed 
using ROIs drawn over the scapular region. 
SPECT imaging studies were performed using a NanoSPECT/CT scanner 
(Bioscan) with image reconstruction and co-registration carried out using HiSPECT in 
the corresponding InVivoScope software. Animals were administered 33.3-37.0 MBq of 
[99mTc]HYNIC-Annexin V via intravenous injection and imaged 3 h after probe 
administration. During the uptake phase, animals were allowed free access to food and 
water. Three-dimensional ROIs were manually drawn in the tumor volume using the free 
computer software, Amide. Probe uptake was quantified as %ID/g. 
 
Immunohistochemistry (IHC) 
Tumor tissues were harvested immediately following conclusion of imaging, fixed 
for 24 h in 5% buffered formalin, and blocked in paraffin. Immunohistochemistry for 
cleaved caspase-3 (Cell Signaling, #9664) was carried out as previously described (9). 
Tissues were stained using standard H&E methods and reviewed by an expert 
gastrointestinal pathologist (M. Kay Washington). Images displayed are representative of 
three randomly selected high-power fields (40x).  
 
Semi-Quantitative IHC Analysis 
For semi-quantitative analysis of cleaved caspase-3 IHC, the public domain 
image processing software ImageJ was used to selectively measure the area of positive 
staining of each cohort through manual threshold manipulation of hue, pixel saturation, 
and brightness. Analysis was performed for multiple low field (2.5x) tissue micrographs 
and values reported as the percent area of positive staining over total staining. 
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 Statistical Methods 
Unless otherwise stated, experimental replicates are reported as the arithmetic 
mean ± standard deviation. Statistical significance of in vitro and in vivo data sets was 
evaluated using an unpaired, two-tailed t-test. Differences were assessed within the 
GraphPad Prism 6.01 software package and considered statistically significant if p < 
0.05. 
 
3.4. Results 
 
Caspase-3 Active Site Accommodates N-Terminal Functionalization of VAD-FMK 
Imaging labels should impart minimal, if any, effects upon the biological and 
chemical properties of the parent molecule. Given this, we initially used a molecular 
modeling approach to explore multiple N-terminally functionalized analogues of VAD-
FMK (Fig. 3.4A), two of which would result in PET/SPECT imaging probes: FB-VAD-
FMK, benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (Z-VAD-FMK), 4-
iodobenzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (IZ-VAD-FMK) (38), and 
VAD-FMK. Molecular docking of each peptide into an irreversible inhibitor bound protein 
structure of caspase-3 (PDB ID, 3KJF) (31) enabled predictions to be drawn regarding 
the accommodation of modified peptides into the caspase-3 active site (Fig. 3.4B-F). 
Flexible docking calculations were performed employing post-docking energy 
minimization for each peptide to assess potential energetic perturbations that result from 
N-terminal modification. Only docked poses that positioned the C-terminal fluoro-methyl 
ketone moiety within 5.0 angstroms of the caspase-3 active site cysteine 163 thiol 
moiety were considered in our analysis. All four peptides exhibited predicted binding 
energy scores that fell within the micromolar to nanomolar range (Total Score) and 
ranked by the steric bump parameter (Crash) using SurflexDock in Tripos SYBYL-X 2.0 
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 (Table 3.2). The Surflex-Dock scoring term for Polar contacts suggested that the FB-
VAD-FMK peptide had greater potential to form hydrogen bonds with active caspase-3 
site residues relative to other candidate structures, including the parent peptide, while 
displaying less internal ligand Strain scores. Of note, IZ-VAD-FMK produced docking 
scores that reflected a lower-scoring Polar term and demonstrated that more poses 
buried the larger, lipophilic iodo-moiety toward the protein active site, suggesting greater 
lipophilicity than FB-VAD-FMK. Though exploratory in nature, these studies suggested 
both tolerance to functionalization of VAD-FMK at the N-terminus with the FB prosthesis 
and that the resulting PET imaging probe might possess favorable physical and 
chemical properties relative to parent peptide and the IZ-labeled form. 
 
Figure 3.4. Prioritization of FB-modified VAD-FMK peptide caspase inhibitor. 
Chemical structures for R1 substitution of VAD-FMK peptide inhibitor scaffold (A). FB-
VAD-FMK (green capped sticks) (B), Z-VAD-FMK (orange capped sticks) (C), IZ-VAD-
FMK (orange capped sticks) (D), and VAD-FMK (yellow capped sticks) (E) shown 
docked into the caspase-3 protein structure (PDB ID 3KJF) (F) with covalent inhibitor 
removed. Covalent inhibitor protein attachment at Cys163 is shown in yellow and white 
VDW spheres; red circle indicates covalent inhibitor protein attachment site. Atom 
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 colors: oxygen = red; nitrogen = blue; iodine = purple, carbon = grey. Grey VDW 
surfaces indicate the space-filling shape of the covalent bound inhibitor in PDB ID 3KJF. 
 
Compound 
Total Score 
(-log Kd) Crash Polar Strain Similarity 
FB-VAD-FMK 6.2458 0.861 5.676 0.7802 0.2979 
Z-VAD-FMK 8.6257 1.004 4.6776 3.0018 0.5373 
IZ-VAD-FMK 9.5465 1.381 4.3824 1.4081 0.5396 
VAD-FMK 6.1466 1.155 4.8703 2.567 0.4582 
 
Table 3.2. Structural effects of peptide modification on binding to caspase-3. 
Docking scores are reported as ranked by the Crash (steric repulsion) score from the 
protein flexibility (PF-score) scoring function of the Tripos SYBYL-X v2.0 software suite 
that also features (among other scoring parameters) comparison with SurflexDock 
Total_Score (statistical estimate of binding affinity, -log Kd), Polar (measure of polar 
contacts), Strain (measure of internal ligand energetic strain) and Similarity (index of 
shape-based morphological similarity to reference covalent inhibitor compound) term 
score parameters. Proposed N-terminal modifications to the VAD-FMK peptide scaffold 
all scored comparably using these criteria indicating minimal predicted perturbation to 
interactions with the caspase-3 protein target (29). 
 
Enzyme Selectivity of VAD-FMK Peptide Analogues 
 From the binding mechanism of VAD-FMK-type peptides (23,39), we anticipated 
that FB-VAD-FMK would exhibit caspase selectivity similar to that of the parent peptide. 
To explore this, we evaluated the relative affinity of [19F]FB-VAD-FMK against activated 
caspases-3/6/7/8 (Fig. 3.5A). Addition of the FB-prosthesis had little impact on caspase 
selectivity compared to that of the parent peptide, where both peptides inhibited 
caspases-3/6/7 with single micro molar potency and caspase-8 with slightly greater 
potency. Caspase-3 was used in subsequent characterization and validation studies as 
a representative of other relevant caspases. 
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Figure 3.5. [19F]FB-VAD-FMK and parent peptide enzyme selectivity and activity. 
Biochemistry, fluorescence measured IC50 values, collected as duplicates, of the parent 
peptide, VAD-FMK, and [19F]FB-VAD-FMK against caspases-3/6/7/8 (A). Mean IC50 
values (n ≥ 3) of inhibition of human recombinant caspase-3 by VAD-FMK and 
analogues as assessed using a luminescence biochemistry assay-based method 
(Conc = concentration) (B). Caspase-3/7 inhibition with [19F]FB-VAD-FMK (C) or VAD-
FMK (D) in untreated or cetuximab-treated DiFi cells (n = 4). 
 
Lipophilicity of VAD-FMK Peptide Analogues 
To validate the predicted physical properties of the labeled VAD-FMK derivatives, 
lipophilicity studies were undertaken using [19F]FB-VAD-FMK, Z-VAD-FMK, and [127I]IZ-
VAD-FMK. We determined that the FB-modified peptide (logP7.5 = 1.41) was between 50 
– 100 times less lipophilic than both Z-VAD-FMK (logP7.5 = 2.20) and [127I]IZ-VAD-FMK 
(logP7.5 = 2.38), in support of the predicted Polar contact scores determined by 
molecular modeling. These findings also agree with a previous report of IZ-VAD-FMK, 
which suggested this compound to be too lipophilic for in vivo use (38). 
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 [19F]FB-VAD-FMK Potently Inhibits Active Caspase Activity 
The biological activity of labeled VAD-FMK derivatives was validated with 
recombinant caspase-3 enzyme using a commercially available chemiluminescent 
caspase activity assay. Nonlinear regression analysis of the resultant inhibitory profiles 
yielded a mean (n ≥ 3) fifty-percent inhibitory concentration (IC50) of approximately 225 ± 
70 nM for [19F]FB-VAD-FMK (Fig. 3.5B). Though all peptides exhibited reasonable 
potencies that were in line with predicted affinities, [19F]FB-VAD-FMK demonstrated the 
greatest potency towards caspase-3 inhibition. Similar to biochemical analysis, [19F]FB-
VAD-FMK inhibited caspase-3/7 activity at nanomolar concentrations analogously to the 
parent in CRC cells (DiFi) in log-phase growth (Fig. 3.5C, D). When apoptosis was 
induced in DiFi cells by exposure to the EGFR monoclonal antibody cetuximab (9), 
[19F]FB-VAD-FMK inhibited caspase-3/7 activity with comparable efficacy to the parent 
peptide. Combined with studies demonstrating acceptable physical properties, these 
investigations illustrated that [19F]FB-VAD-FMK exhibited caspase affinity similar to the 
parent VAD-FMK peptide and was subsequently prioritized for radiochemical 
development. 
 
In Vivo Normal Tissue Uptake and Metabolism of [18F]FB-VAD-FMK 
The in vivo biodistribution of [18F]FB-VAD-FMK was evaluated by ex vivo tissue 
counting at 60 min post-administration and correlative PET imaging up to 75 min post-
administration. Upon intravenous administration, [18F]FB-VAD-FMK was widely 
distributed throughout a range of normal tissues, with the greatest activity in kidneys and 
liver after 60 minutes of uptake (Fig. 3.6A). Very little radioactivity was found in brain, 
lung, or bone. Summed dynamic PET acquisitions following [18F]FB-VAD-FMK 
administration, 0 – 75 min (Fig. 3.6B, C), agreed with tissue counting measurements 
and provided evidence of renal and hepatobiliary excretion. This was confirmed by 
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 HPLC radiometabolite analysis, using a protocol analogous to that described for 
radiochemical purity analysis, which revealed largely parent compound, approximately 
50% or greater, in bile and urine samples (n = 3) at 60 min post injection. 
 
 
Figure 3.6. In vivo biodistribution of [19F]FB-VAD-FMK in normal tissue. Probe 
biodistribution as assessed from ex vivo tissue count studies in male C57BL/6 mice (n 
= 4) (A), and a representative PET imaged maximum intensity projection (MIP) (B), A 
= administration site, Bl = bladder, Bo = bowel, G = gallbladder, K = kidney, L = 
liver, and corresponding time-activity curves (C) for normal tissues of a non-tumor 
bearing athymic nude mouse (29). 
 
[18F]FB-VAD-FMK PET Reflects AZD-1152-dependent Caspase-3 Activity in Tumors 
In vivo uptake of [18F]FB-VAD-FMK in tumor was evaluated in SW620 and DLD-1 
human CRC cell line xenografts given the in vitro data which demonstrated, in concert 
with polyploidy (Fig. 3.7A), AZD-1152-HQPA concentration-dependent increases in 
cleaved PARP and cleaved caspase-3 levels (Fig. 3.7B, C). These results, in addition to 
previously reported in vivo findings (40), suggest that quantification of caspase activity 
may reflect response to Aurora B kinase inhibition in these models. 
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Figure 3.7. AZD-1152-HQPA in vitro exposure results in cell death in DLD-1 and 
SW620 cell lines. Cell cycle analysis by PI flow cytometry (A), caspase-3/7 activity (n = 
5) (B), and western blot analysis of cleaved PARP and cleaved caspase-3 (C) 24 h 
post drug administration. Drug concentrations for western blotting were: 0, 10, 100, 500, 
1000, or 5000 nM (29). 
 
In vivo [18F]FB-VAD-FMK PET was explored as a means to reflect response to 
AZD-1152 compared to vehicle. Animals were treated for five days and subjected to 
imaging after treatment on the fifth day. While vehicle treatment did not result in 
significant accumulation of [18F]FB-VAD-FMK in either xenograft model, AZD-1152 
treatment increased [18F]FB-VAD-FMK uptake relative to vehicle in SW620 xenografts 
(0.79 ± 0.15 %ID/g and 0.42 ± 0.25 %ID/g respectively, p = 0.030) (Fig. 3.8A-C), which 
was in agreement with in vitro studies. Interestingly, [18F]FB-VAD-FMK uptake was 
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 absent in areas of central necrosis, as evident from 3D PET images (Fig. 3.8A). 
Interestingly, unlike in vitro studies that illustrated the sensitivity of DLD-1 cells to AZD-
1152, probe accumulation was similar between AZD-1152-treated and vehicle-treated 
DLD-1 xenografts (0.57 ± 0.14 %ID/g and 0.49 ± 0.22 %ID/g respectively, p = 0.510).  
 
Figure 3.8. [18F]FB-VAD-FMK uptake reflects molecular response to Aurora B 
kinase inhibition in vivo. Representative [18F]FB-VAD-FMK transverse PET images of 
DLD-1/SW620 xenograft-bearing mice treated with vehicle or AZD-1152; tumors denoted 
by white arrows. Probe accumulation was absent in areas of central necrosis, as 
denoted by orange asterisks (A). Representative [18F]FB-VAD-FMK time- activity curves 
for vehicle- and drug-treated DLD-1 and SW620 xenograft tumors. Vehicle- and drug- 
treated DLD-1 tumors exhibited similar washout, while greater retention in drug- 
versus vehicle-treated xenografts was observed for SW620 tumors (B). Quantification 
of tissue %ID/g revealed a statistical significant difference between vehicle- and drug-
treated SW620 (p = 0.030) tumors but not for analogously treated DLD-1 tumors (p = 
0.510) (C). Representative high- power white-light photo micrographs (40x) of caspase-3 
immunohistochemical and H&E stained DLD-1 and SW620 tissues obtained from 
xenografts collected immediately following imaging (D) (29). 
 
59
 To validate imaging, xenograft tissues were harvested for histology immediately 
following imaging. In agreement with [18F]FB-VAD-FMK PET, caspase-3 
immunoreactivity appeared modest in both vehicle-treated SW620 and DLD-1 
xenografts (Fig. 3.8D). Furthermore, AZD-1152 treatment led to elevated caspase-3 
immunoreactivity compared to vehicle-treatment in SW620 but not DLD-1 xenografts as 
verified with semi-quantitative IHC analysis (Fig. 3.9). AZD-1152-treated SW620 
xenografts demonstrated evidence of drug exposure given the presence of enlarged 
nuclei evident by hematoxylin and eosin (H&E) staining (40). Conversely, the lack of in 
vivo effects of AZD-1152 in DLD-1 xenografts, predicted by [18F]FB-VAD-FMK PET, 
could possibly be attributed to poor drug exposure as little evidence of polyploidy was 
observed by H&E staining (Fig. 3.8D).   
 
Figure 3.9. Validation of AZD-1152 induced caspase-3 activity by IHC semi-
quantification. Semi-quantitative analysis of cleaved caspase-3 histological samples of 
DLD-1 and SW620 xenograft tumors treated with vehicle or AZD-1152. Evaluation of 
multiple low field (2.5x) micrographs revealed a statistical significant difference between 
vehicle- and drug-treated SW620 (p < 0.0001) tumors but not for analogously treated 
DLD-1 tumors (p = 0.524) (29). 
 
[18F]FB-VAD-FMK PET Reflects Response to Combination Therapy 
Rational combination therapy for V600EBRAF melanoma (41,42) and colon cancer 
(37) include an inhibitor of mutant BRAF and a PI3K family inhibitor. Leveraging this 
concept, [18F]FB-VAD-FMK uptake was evaluated in V600EBRAF-expressing CRC 
xenograft-bearing mice (COLO-205 and LIM-2405) treated with vehicle, single-agent 
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 PI3K/mTOR inhibitor (BEZ-235), single-agent BRAF inhibitor (PLX-4720), or 
combination therapy (BEZ-235/PLX-4720). Animals were imaged by PET after treatment 
on Day 4. Elevated probe uptake in COLO-205 xenografts, relative to vehicle treatment 
(0.84 ± 0.16 %ID/g), was observed in the dual-agent-treated cohort (1.54 ± 0.55 %ID/g, 
p = 0.007) but not for either the BEZ-235 or PLX-4720 single agent cohorts (0.94 ± 0.09 
%ID/g, p = 0.14 and 0.87 ± 0.13 %ID/g, p = 0.69, respectively) (Fig. 3.10A, B). 
Strikingly, probe uptake in LIM-2405 xenografts was non-differential, relative to vehicle 
treatment (0.95 ± 0.13 %ID/g), across treatment cohorts: 1.08 ± 0.25 %ID/g, p = 0.22 
(BEZ-235), 0.92 ± 0.23 %ID/g, p = 0.81 (PLX-4720), and 0.78 ± 0.20 %ID/g, p = 0.10 
(BEZ-235/PLX-4720). Representative xenograft tissue was harvested immediately 
following imaging. In agreement with [18F]FB-VAD-FMK PET, caspase-3 
immunoreactivity appeared modest in vehicle- and single-agent-treated COLO-205 and 
LIM-2405 xenografts, while combination treatment increased caspase-3 
immunoreactivity in COLO-205 but not LIM-2405 xenografts (Fig. 3.10C). These 
observations were confirmed with semi-quantitative IHC analysis (Fig. 3.11). In concert 
with elevated probe uptake, after four days of treatment a significant reduction in tumor 
size (p = 0.023) was observed in COLO-205 xenografts treated with combination therapy 
(Fig. 3.10D). In contrast, statistically significant changes in tumor growth compared to 
vehicle were not found for single agent therapies in COLO-205 xenografts or any drug 
therapies in LIM-2405 cohorts. 
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 Figure 3.10. [ 18F]FB -VAD-FMK uptake reflects molecular response to combination 
therapy in vivo. Representative [18F]FB-VAD-FMK coronal PET images of COLO-205 
and LIM-2405 xenograft tumor- bearing vehicle or BEZ-235/PLX-4720-treated mice. 
Tumors are denoted by white arrows (A). PET quantification of tissue %ID/g revealed a 
significant difference between vehicle and BEZ-235/PLX-4720- treated COLO-205 (p = 
0.007) xenografts but not for analogously treated LIM-2405 xenografts (p = 0.102) (B). 
Representative high-power white-light photo micrographs (40x) of caspase-3 
immunohistochemical stained COLO-205 and LIM-2405 tissues obtained from 
xenografts collected immediately following imaging (C). Changes in COLO-205 and LIM-
2405 tumor volumes by Day 4 of treatment, shown as percent change from Day 1 
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 baseline, revealed a significant difference compared to vehicle-treated mice (p = 0.023) 
for BEZ-235/PLX-4720-treated COLO-205 tumors only (D) (29). 
 
 
 
Figure 3.11. Validation of AZD-1152 induced caspase-3 activity by IHC semi-
quantification. Semi-quantitative analysis of multiple low field (2.5x) micrographs of 
cleaved caspase-3 histological samples of cleaved caspase-3 histological samples of 
COLO-205 and LIM-2405 treatment cohorts revealed a statistical significant difference 
between vehicle-treated and combination-treated COLO-205 (p = 0.025) tumors but not for 
analogously treated LIM-2405 tumors (p = 0.325) (29). 
 
Phosphatidylserine Imaging to Assess Cell Death Chemotherapeutic Response  
To compare the performance of [18F]FB-VAD-FMK PET with another imaging 
metric of apoptosis, we evaluated Annexin V uptake in each of the described models. 
Annexin V labeled with a near-infrared dye (NIR800-Annexin V) did not accumulate 
differentially between vehicle- and AZD-1152-treated DLD-1 xenografts (Fig. 3.12A, B). 
In SW-620 xenografts, we observed a trend towards elevated Annexin V accumulation in 
AZD-1152-treated xenografts compared to vehicle treatment, but unlike [18F]FB-VAD-
FMK PET, the difference between these two groups was not statistically significant (p = 
0.127). Annexin V radiolabeled with technetium-99m ([99mTc]HYNIC-Annexin V) 
accumulation in dual-agent combination-treated COLO-205 xenografts did not differ from 
controls (p = 0.258) (Fig. 3.12C, D) and did not correlate with elevated caspase-3 
activity, as determined by histology (Fig. 3.10C). Lack of probe accumulation was also 
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 noted in single-agent-treated COLO-205 and LIM-2405 xenograft tumors. These results 
suggest that [18F]FB-VAD-FMK PET may be more sensitive than NIR-dye labeled and 
technetium-99m radiolabeled forms of Annexin V for quantifying apoptosis in preclinical 
imaging studies.  
 
Figure 3.12. Annexin V uptake did not reflect therapeutic response in CRC 
xenografts. Near-infrared fluorescence images of NIR800-Annexin V uptake (24 hr p.i.) 
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 in dual DLD-1 and SW-620 bearing vehicle and AZD-1152 treated mice (A). 
Fluorescence images are displayed as white light image overlays. Tumor accumulation 
was assessed through tumor-to-normal (T/N) ratio quantification and did not reflect 
statistically significant differences between vehicle- and AZD1152-treated mice in either 
DLD-1 (p = 0.666) or SW-620 (p = 0.127) xenografts (B). Co-registered SPECT/MRI 
images of 99mTc-HYNIC-Annexin V uptake (3 hr p.i.) in COLO-205 or LIM-2405 bearing 
vehicle-, BEZ-235-, PLX-4720-, and BEZ-235/PLX-4720-treated mice (C). Quantification 
of tissue %ID/g did not reveal a statistically significant difference between vehicle- and 
BEZ-235/PLX-4720-treated COLO-205 (p = 0.258) and LIM-2405 (p = 0.068) xenograft 
tumors (D). 
 
3.5. Discussion 
Irreversible caspase binding ligands are frequently utilized as tool compound 
inhibitors in vitro and in vivo (23,24). Among the known inhibitors, we sought to extend 
the utility of VAD-FMK-type peptides to PET imaging probe development. 
Mechanistically, VAD-FMK peptides irreversibly bind active caspase through 
condensation of the fluoromethyl ketone moiety with a cysteine thiol, Cys163 for 
caspase-3, within the active site, permanently inactivating the enzyme (31,43). As a 
molecular imaging probe, irreversible binding may confer certain advantages, such as 
enhanced retention in apoptotic versus healthy cells, due to slow dissociation kinetics. 
We believe this study is the first to report development and in vivo validation of a 
novel PET imaging probe derived from the VAD-FMK peptide sequence. In general, the 
VAD-FMK sequence is known to be quite versatile and has been previously 
functionalized with fluorophores (25-28) and a radioisotope (38) for in vitro and certain 
preclinical applications. The probe developed here possesses all of the inherent 
advantages of a PET imaging agent, which include sensitivity, depth, and quantification 
(44,45). Furthermore, the FB derivative exhibits certain physical properties, such as 
improved water solubility which was a previously reported limitation of another reported 
labeled peptide IZ-VAD-FMK.  
Inhibitor-caspase interactions have been reported (31) and provide reasonable 
structural templates for the design of inhibitor-based probes. The molecular modeling 
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 approaches employed in this study were confirmed by in vitro biochemical studies and 
suggested that FB-VAD-FMK would be accommodated in the caspase-3 active site 
without significant perturbation of physically plausible low-energy complex structures. 
We interpret our results, which identified a best-scoring docked pose for FB-VAD-FMK 
with the FB-prosthesis pointed away from the active site and towards solvent, to suggest 
that further chemical modification of the N-terminus may be feasible in an effort to tune 
the physical properties of the peptide and optimize biodistribution in future studies. 
These studies suggest that the imaging prosthesis should likely be tuned to match the 
solvent/protein milieu. In support of the modeling hypothesis, in vitro biochemical and 
cell assays validated that [19F]FB-VAD-FMK maintained similar potency against 
caspase-3/7 compared to the parent peptide and exhibited favorable physical properties. 
Using established radiochemical methods, [18F]FB-VAD-FMK was produced with 
activity and purity suitable for use in small animal PET imaging studies. [18F]FB-VAD-
FMK was initially evaluated in vivo in two CRC cell line models (SW620 and DLD-1) in 
response to prodrug (AZD-1152) treatment. Upon conversion to the active form of AZD-
1152-HQPA in plasma, AZD-1152-HQPA inhibits Aurora B kinase activity (40,46) and 
induces 4N DNA accumulation, endoreduplication, and polyploidy (40). As demonstrated 
here and elsewhere (34), these events lead to apoptosis-induced cell death and 
elevated caspase activity in SW620 tumor cells. We demonstrated that [18F]FB-VAD-
FMK PET could be used to monitor response in this setting and that imaging accurately 
reflected elevated levels of apoptosis in prodrug- versus vehicle-treated tumors and was 
validated by immunohistochemistry analysis. Caspase-3 activity corresponded 
accordingly with evidence of drug exposure as determined by tumor polyploidic events in 
tissue. Interestingly, in DLD-1 xenografts, [18F]FB-VAD-FMK uptake was not differential 
between drug-treated and vehicle-treated tumors. Tissues collected from these animals 
agreed with these findings and revealed little evidence of drug activity, as noted by the 
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 absence of polyploidy and caspase-3 activity. We anticipate that these finding reflect 
poor delivery of the therapeutic agent, a common phenomenon in subcutaneous 
xenografts. Thus, in this model, [18F]FB-VAD-FMK PET quantization reflected a lack of 
efficacy that appeared to be the result of poor therapeutic delivery.  
Interestingly, using Annexin V optical imaging, we were unable to discern a 
correlation between AZD-1152 treatment and cell death similar to that observed in this 
model by in vivo PET imaging and IHC. A limitation of Annexin V is its tendency to 
accumulate in necrosis (47), which may have contributed to both the significant tumor 
accumulation of Annexin V in control animals as well as the overall insensitivity of 
Annexin V imaging to detect treatment-response in these models. [18F]FB-VAD-FMK did 
not accumulate in areas of necrosis, as evident from the 3D PET images. 
Next, [18F]FB-VAD-FMK PET was used to evaluate response to a multi-drug 
therapeutic regimen, which included an inhibitor of mutant BRAF and a PI3K/mTOR 
inhibitor in V600EBRAF-expressing CRC models. A non-invasive imaging metric that can 
be used to elucidate the basis of response to complicated therapeutic multidrug 
regimens would be very attractive within the setting of drug development clinical trials. 
[18F]FB-VAD-FMK PET imaging demonstrated that combination therapy led to elevated 
apoptosis in one of two models compared to vehicle-treated or single-agent-treated CRC 
xenograft bearing mice. We found that changes in tumor growth closely correlated with 
levels of caspase activity detected by both [18F]FB-VAD-FMK PET and IHC analysis.  
To evaluate the relative sensitivity of [18F]FB-VAD-FMK PET compared to 
phosphatidylserine targeted imaging metrics in the context of multi-drug therapeutic 
response, [99mTc]HYNIC-Annexin V SPECT was explored in analogous studies. 
Importantly, phosphatidylserine targeted imaging was unable to detect response to 
combination BRAF and PI3K/mTOR inhibition as observed by in vivo PET imaging and 
histology. Given the close relationship between [18F]FB-VAD-FMK uptake, caspase 
67
 activity, and apoptosis, these studies suggest that in this setting, [18F]FB-VAD-FMK may 
possess greater sensitivity than [99mTc]HYNIC-Annexin V SPECT. 
These studies illuminate the potential for caspase-specific PET imaging probes, 
such as [18F]FB-VAD-FMK, to be utilized in the assessment of early clinical response to 
therapeutics. A possible limitation of this probe was the relatively modest uptake 
observed in target tissue responding to therapy (0.8 – 2.5 %ID/g). However, other 
caspase-targeted PET agents reported in the literature and under clinical development 
are also known to exhibit modest uptake, including the promising isatin sulfonamide 
chemical class (48-50) and a PEG-functionalized ‘DEVD-A’ penta-peptide analogue, 
[18F]-CP18 (51,52). From the current work (29), as well as that from previous reports (48-
52), it is not clear that improvements in the overall tumor uptake, which might result in 
greater signal-to-noise ratio, would result in a probe that better reflects the underlying 
determinants of apoptosis. Future head-to-head comparisons would be beneficial 
towards sorting this out. Continued work should also evaluate the advantages and 
limitations inherent in the use of a pan-caspase targeting probe, where extrinsic and 
intrinsic apoptosis pathways are indistinguishable, compared with more selective 
compound classes. 
 
3.6. Conclusions 
These studies illuminate the VAD-FMK peptide as a promising scaffold for 
molecular imaging of caspase activity and response to molecularly targeted therapy 
using positron emission tomography. Among these peptides, [18F]FB-VAD-FMK appears 
to be an attractive PET imaging probe for non-invasive quantification of apoptosis in 
tumors and may represent a potentially translatable biomarker of therapeutic efficacy in 
personalized medicine. 
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CHAPTER 4 
 
GLUTAMINE METABOLISM AS A TARGET IN THE EVALUATION OF COLORECTAL 
CANCER DEVELOPMENT AND THERAPEUTIC RESPONSE 
 
4.1. Abstract 
Beyond a predilection for glycolysis, cancer cells may possess other unique 
metabolic characteristics, such as increased glutamine uptake. Given this, quantitative 
measures of glutaminolysis may reflect critical processes in oncology. The objective of 
these studies was to elucidate the feasibility of [18F]4-fluoroglutamine ([18F]4-F-GLN) 
PET to evaluate both molecular response to targeted drug therapies and the activation 
of oncogenic pathways in colorectal cancer (CRC). Given this, [18F]4-F-GLN PET was 
evaluated in preclinical models of BRAFV600E-expressing and mutant PI3K CRC as a 
means of detecting molecular responses to targeted therapeutics. Simulating a clinical 
trial proposed in Vanderbilt’s GI SPORE program, the regimen included an inhibitor of 
mutant BRAF, a PI3K/mTOR inhibitor, and the combination thereof. For PI3K mutant 
CRC, additional therapeutic regimens included MEK and/or BCL-2 family inhibitors. 
Strikingly, [18F]4-F-GLN PET was found to be sensitive to pathways of drug response, in 
contrast to [18F]FDG PET, and trended with measurements obtained using the known 
radiolabeled glutamate amino acid derivative (4S)-4-3-[18F]fluoropropyl)-L-glutamate 
([18F]FSPG). Further studies using a genetically engineered mouse model of colon 
cancer revealed [18F]4-F-GLN to be a potential diagnostic marker of the Kras oncogene. 
We believe that these findings not only provide a greater understanding of the role that 
glutaminolysis plays in CRC but also illuminate the potential impact that glutaminolysis 
derived PET could have towards guiding drug development clinical trials as an imaging 
metric for detecting early therapeutic response. 
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 4.2. Introduction 
The metabolic properties of cancer cells diverge significantly from those of 
normal cells. Energy production in cancer cells is abnormally dependent on aerobic 
glycolysis (1,2), the Warburg effect, and is routinely analyzed by PET imaging using 2-
[18F]fluoro-2-deoxy-D-glucose ([18F]FDG). Even though glycolysis is enhanced in many 
tumors, it is not necessarily a tumor-specific molecular processes (3,4). Like glucose, 
[18F]FDG accumulates in other tissues that possess increased glycolytic metabolism, 
including the brain, brown adipose tissue, fast-dividing tissues, and sites of inflammation. 
Conversely, [18F]FDG PET bears limitations in the detection of tumors with low 
metabolism, such as bladder, prostate, and renal cancer, in addition to small tumors, 
tumors of low cell density, and other [18F]FDG-indifferent cancers. Furthermore, 
[18F]FDG PET has been found to be indifferent to various therapeutics and reported to 
be incapable of accurately detecting response to mutant BRAF and/or PI3K/mTOR 
inhibition in mutant BRAFV600E tumors (5,6). Accordingly, these limitations and 
drawbacks necessitate alternative metabolic targets and respective PET imaging 
probes.  
In addition to dependency on glycolysis, cancer cells have other atypical 
metabolic characteristics, such as increased fatty acid synthesis and increased 
dependency on the natural amino acid glutamine as a fuel source, a phenomenon 
commonly described as glutamine addiction (7). This is contrary to what is observed in 
normal cells where glutamine is a conditionally essential nutrient; becoming essential 
under conditions of cell stress. In cancer cells, both glucose and glutamine serve as key 
carbon sources for ATP production and biosynthesis (Fig. 4.1). Glutamine also 
participates in protein synthesis and is a nitrogen source for the production of certain 
amino acids and nucleotides (8).  
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 Figure 4.1. Comparative overview of the molecular implications of [18F]FDG, [18F]4-
F-GLN, and [18F]FSPG. Glucose can be taken up by cells in a regulated manner using 
glucose transporters (GLUTs) (9) and converted to pyruvate through a series of 
glycolytic transformations. Pyruvate can then be transported into the mitochondria and 
used in the tricarboxylic acid (TCA) cycle to produce two adenosine triphosphate (ATP) 
and six nicotinamide adenine dinucleotide (NADH) molecules per glucose. Similarly, 
glutamine can be transported to the cytosol by the alanine, serine, cysteine transporter 
(ASCT) family (10) where it is converted to glutamate by glutaminase. Glutamate can 
also be taken into the cell directly using the XCT, or Xc-, family of amino acid transporters 
(11). Cytosolic glutamate can be either transported into the mitochondria, where it is 
converted to α-ketoglutarate and used for the TCA cycle, or used in the synthesis of 
glutathione (GSH), a major intracellular thiol compound which serves as the main 
antioxidant defense against reactive oxygen species (ROS). 
 
Emerging evidence suggests that glutamine uptake in cancer cells is controlled 
by oncogenic signaling pathways (12-16). Given this, quantitative measures of 
glutamine uptake may reflect critical processes in oncology that are difficult to measure 
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using existing imaging metrics. For example, the role of glutamine in nucleotide 
synthesis suggests that measures of glutamine uptake could provide an estimate of de 
novo thymidine synthesis associated with proliferation, a process unmeasurable by 3'-
deoxy-3'[(18)F]-fluorothymidine [18F]FLT PET; a molecular marker of cellular proliferation. 
Using glioma cells, Wise and colleagues demonstrated that MYC regulates 
glutaminolysis and results in PI3K-independent glutamine addition (17). Other studies 
have revealed a role of the KRAS oncogene in the regulation of glutamine-derived 
cancer cell metabolism; a mutation found in 17-25% of all cancers (18), 30-50% of colon 
cancers (19-22) and up to 95% of pancreatic cancers (23,24). In pancreatic 
adenocarcinomas (PDAC), oncogenic KRAS has been shown to modulate the 
expression of key genes enabling the glutamine-utilizing transaminase pathway that is 
required for growth in PDAC, but not normal, cells (25). Accordingly, PET imaging 
agents targeting glutamine uptake, such as [18F]4-fluoroglutamine ([18F]4-F-GLN), have 
been reported and used in preclinical models of cancer (26,27). This agent, as well as 
others, have already shown potential in the context of glioblastomas and mammary 
tumors (26-28).  
The objectives of these studies were to explore the potential of [18F]4-F-GLN PET 
to monitor molecular markers of colorectal cancer (CRC) development, growth, and 
therapeutic response. Towards this goal, [18F]4-F-GLN PET was evaluated as a 
measure of targeted therapeutic response in preclinical models of BRAFV600E-expressing 
and mutant PI3K CRC. Strikingly, [18F]4-F-GLN PET was found to be sensitive to 
pathways of drug response, in contrast to [18F]FDG PET, and trended with 
measurements obtained using the known radiolabeled glutamate amino acid derivative 
(4S)-4-3-[18F]fluoropropyl)-L-glutamate (11), also known as [18F]FSPG or [18F]BAY 94-
9392, which follows the cysteine pathway into the cell. Additional studies in genetically 
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engineered mouse models of colon cancer revealed [18F]4-F-GLN to be a potential 
diagnostic marker of Kras oncogene activation.  
 
4.3. Materials and Methods 
 
Chemicals 
Unless otherwise indicated, all other chemicals, reagents, and solvents were 
purchased from Sigma-Aldrich and used as received. MLC-37-3 was applied to cells, 
analogously to targeted drug treatments, as a negative control in both cell lines. PLX-
4720 (29) and MLC-37-3 (30) were synthesized analogously to previously reported 
methods. 
 
In Vitro Western Blots 
After 24 h of exposure with vehicle, BEZ-235 (Selleckchem), PLX-4720, AZD-
6244/Selumetinib (Selleckchem), and ABT-263/Navitoclax (Ontario Chemicals Inc.) 
single agent or combination treatments, in vitro cell samples were collected from 10-cm 
plates. Medium was removed and cell monolayers washed with 1X phosphate buffered 
saline (PBS) followed by addition of 450 mL of lysis buffer containing: 7 mL of CelLytic M 
lysis buffer (Sigma), mini protease inhibitor cocktail (Roche), and 100 mL of 
phosphatase inhibitor cocktail 1 and 2 (Sigma). Protein concentrations were normalized 
using a bicinchoninic acid assay. All samples were vortexed and centrifuged prior to final 
cell lysate collection. 
Immunoblotting was performed by loading 20-40 µg of protein into 7.5-12% SDS 
PAGE gels and resolved by electrophoresis. Membranes were incubated with antibodies 
to cleaved PARP (Cell Signaling, 9541S), cleaved caspase-3 (Cell Signaling, 9664), p-
ERK 1/2 Thr202/Tyr204 (Cell Signaling, 4370), p-AKT Ser473 (Cell Signaling, 4060), or 
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GAPDH (Millipore, MAB374) and imaged on a Xenogen IVIS 200 using Western 
Lightning Plus-ECL (PerkinElmer) substrate. 
 
In Vitro [3H]Glutamine Assays  
Live-cell glutamine uptake assays featuring drug treatments which mimicked 
proposed preclinical imaging cohorts were carried out using COLO-205 and HCT-116 
cells. Cells were propagated in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Mediatech) and supplemented with 10% fetal bovine serum (Atlanta Biologicals) and 1 
mg/mL gentamycin sulfate (Gibco) in a 95% humidity, 5% CO2, 37°C atmosphere. Upon 
reaching 50% confluency, cells were treated with 100 nM or 1 µM of one of the following 
therapeutic agents, or combination thereof, in DMSO and allowed to incubate for 24 h: 
vehicle, BEZ-235, PLX-4720, AZD-6244/Selumetinib, and ABT-263/Navitoclax. The 
novel ASCT2 (SLC1A5) inhibitor MLC-37-3 was applied to cells, analogously to targeted 
drug treatments, as a negative control in both cell lines. PLX-4720 was synthesized 
analogously to previously reported methods (29). For combination treatments, agents 
were delivered concomitantly at individual concentrations of 100 nM or 1 µM. Following 
treatment, cells were seeded as sub-confluent monolayer cultures at a density of 5 x 104 
cells per well into 96-well, white wall/bottom plates (CulturPlate-96, Perkin Elmer) and 
allowed to adhere for an additional 24 h at 37°C. Each set of conditions was carried out 
in at least triplicate.  
Upon assay commencement, cells were washed three times with 100 uL of an 
assay buffer comprising of 137 mM NaCl, 5.1 mM KCl, 0.77 mM KH2PO4, 0.71 mM 
MgSO4·7H2O, 1.1 mM CaCl2, 10 mM D-glucose, and 10 mM HEPES at pH 6.0. 
Subsequently, L-[3,4-3H(N)]-glutamine (Perkin Elmer), henceforth referred to as 
[3H]glutamine or [3H]GLN, in assay buffer (500 nM) was added to cells and allowed to 
incubate for 15 min at 37°C; after which [3H]glutamine was removed and the cells 
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washed three times with assay buffer. Using 50 uL of NaOH (1M), cells were lysed and 
150 uL of scintillation fluid (Microscint 40, Perkin Elmer) added to each well. Prepared 
plates were rocked, at room temperature, prior to be measured on a Topcount 
scintillation counter (Perkin Elmer). 
 
LC-MRM Proteomic Analysis 
In collaboration with Daniel Liebler and Lisa Zimmerman, liquid chromatography-
multiple reaction monitoring (LC-MRM) targeted proteomic analysis has been explored 
to identify molecular, metabolic responses to targeted-drug therapies in CRC cells. As 
opposed to shotgun liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
proteomics, LC-MRM utilizes an optimized library of protein-specific peptides to assess 
levels of protein expression in cell and/or tissue lysates. Using COLO-205 and HCT-116 
cells, which mimicked therapeutic cohorts explored in small animal imaging studies, 
peptides for identification of 69 proteins were explored and represented upstream and 
downstream metabolic events involved in glycolysis, glutaminolysis, glutamate 
consumption, and the tricarboxylic acid (TCA) cycle. Though still in queue, the results 
from these studies could provide useful insights towards connecting in vitro and in vivo 
observations of therapeutic response mechanisms (Fig. 4.2).  
 
Figure 4.2. The experimental significance of LC-MRM proteomics analysis. A Venn 
diagram which illustrates the link that LC-MRM proteomics may play in furthering 
understanding of molecular changes observed from in vitro cell assay/western blot (WB) 
analysis and small animal PET imaging studies. 
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  [18F]4-F-Gln 
[18F]4-F-Gln and tosylate precursor were produced using methodologies 
analogous to those previously reported (27,31). Cyclotron-produced [18F]fluoride ion in 
[18O]water was trapped on a Waters QMA-carbonate form Sep-Pak and eluted using a 
solution of 18-crown-6 (10.2 mg) and potassium bicarbonate (1.8 mg) in 1.4 mL of an 
acetonitrile and water solution (9.3:1.7). The mixture was dried down at 99C under a 
stream of helium at reduced pressure and subjected to azeotropic drying via iterative 
addition of anhydrous acetonitrile. Subsequently, tosylate precursor (6.0 mg+/-0.5 mg in 
0.5 mL of anhydrous acetonitrile), provided by collaborators within the Manning group, 
was added directly to [18F]fluoride and the reaction mixture heated to 80C for 20 
minutes. Following cooling to 30C, 10 mL of a 5% acetonitrile solution was added to the 
mixture and passed through a preconditioned Waters HLB Plus cartridge followed by 2 
mL of pure water. Activity was eluted using 2 mL of acetonitrile and the solvent removed 
under a gentle stream of nitrogen gas at 40C. To the dried product was added a 
solution of trifluoroacetic acid (0.595 mL) and anisole (0.005 mL), which was heated to 
60C for 10 minutes. The solvent was once again removed under a gentle stream of 
nitrogen gas and the dried product taken up in sterile water for. The final solution was 
filtered through a 0.45-micron filter directly into the sterile vial and the pH adjusted to a 
range of 5–8 units. Overall product yields ranged from 185–5569 MBq (5.0–150.5 mCi) 
(n=10). Radiochemical purity and optical purity were determined by chiral HPLC (Chirex 
3216 Penicillamine 150 x 4.6 mm 5uM (P/N: 00F-3126-E0) column [Phenomenex], 1.0 
mM CuSO4, 1.0 mL/min, ultraviolet 254-nm and γ-detector). Radiochemical purity and 
optical purity were greater than 90% and 95% (n=10), respectively, as determined by 
analytical HPLC. 
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 [18F]FDG  
[18F]FDG was purchased from PETNET with an average radiochemical purity of 
98.5% and specific activity (SA) of greater than 1,000 Ci/mmol. 
 
[18F]FSPG  
[18F]FSPG and tosylate precursor were produced using methodologies 
analogous to those previously reported (32). Cyclotron-produced [18F]fluoride ion in 
[18O]water was trapped on a Waters QMA-carbonate form Sep-Pak and eluted using a 
solution of Kryptofix 2.2.2. (12.5 mg) and potassium carbonate (7 mg) in 50% 
acetonitrile/water (0.6 mL). The mixture was then dried down at 99C under a stream of 
helium at reduced pressure, followed by azeotropic drying via iterative addition of 
anhydrous acetonitrile. Once dry, the tosylate precursor (5.0 mg+/-0.5 mg in 1.0 mL of 
anhydrous acetonitrile), provided by collaborators within the Manning group, and was 
added directly to the fluoride and the reaction mixture heated to 70C for 5 minutes. The 
reaction mixture was then cooled to 30C and a 2 M HCl solution (2 mL) was added.  
The reaction was then sealed, stirred and heated to 100C for a period of 7 minutes 
followed by cooling to 30C. The reaction mixture was then diluted with water to a total 
volume of 70 mL and passed through a preconditioned Waters MCX Plus cartridge 
followed by pure water (2 mL). Subsequently, activity was eluted using 5 mL of a 
solution comprised of 560 mg of anhydrous Na2HPO4 and 600 mg NaCl in 100 mL of 
deionized water. The solution was then filtered through a 0.22-micron filter directly into 
the final vial and the pH adjusted to a range of 5–8. Quality control on the final product 
solution was done by normal phase silica radio-TLC with a solvent system of n-
butanol/acetic acid/water/ethanol (12/3/5/1.5) (Rf of product: 0.4). Overall product yields 
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ranged between 1.85 – 15.43 GBq (50 – 417 mCi) (n=8) with radiochemical purities of 
no less than 98%. 
 
Human Cell Line-Bearing Mouse Models 
All studies involving small animals were conducted in accordance with both 
federal and institutional guidelines. COLO-205 and HCT-116 cell line xenografts were 
generated by subcutaneously injecting 1 x 107 cells onto the right flank of 5- to 6-week 
old female, athymic nude mice (Harlan Sprague-Dawley). Palpable tumors were 
observed within one to two weeks and two to three weeks, respectively, following 
inoculation. For chemotherapeutic studies, BEZ-235 (Selleckchem), AZD-
6244/Selumetinib (Selleckchem), and ABT-263/Navitoclax (Ontario Chemicals Inc.) were 
obtained commercially through indicated vendors. PLX-4720 was synthesized 
analogously to previously reported methods (29).  
All therapeutic agents were administered via oral gavage for four continuous 
days as follows: BEZ-235 (35 mg/kg) once daily in 0.1% Tween 80 and 0.5% methyl 
cellulose; PLX-4720 (60 mg/kg) once daily in DMSO; AZD-6244 (25 mg/kg) twice daily in 
0.1% Tween 80 and 0.5% methyl cellulose; ABT-263 once daily in a cocktail of 60% 
Phosal 50 PG (Lipoid), 30% PEG-400 (Rigaku), and 10% EtOH. For all combination 
treatments, agents were administered as separate doses. BEZ-235/PLX-4720 cohorts 
were treated initially with BEZ-235 followed by administration of PLX-4720 seven to eight 
hours later. For combinations involving MEK inhibition, the first dose of AZD-6244 was 
delivered one to two hours prior treatment with BEZ-235 or ABT-263. Secondary dosing 
with AZD-6244 was performed seven to eight hours after the initial AZD-6244 treatment 
and five to six hours after treatment with BEZ-235 or ABT-263. The duration between 
administrations of therapeutic agents was shortened to two to three hours for 
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combination cohorts on the fourth day of treatment in order to accommodate PET 
imaging acquisition. 
Tumor growth rates were monitored by measuring tumor volumes on the first and 
fourth days of treatment using an established ultrasound imaging-based methodology 
(33). Dose preparation and administration, treatment duration, and imaging time-points 
were determined based on our previous experience in these models (5,6,34) as well as 
reports from similarly performed studies (35). 
 
Genetically Engineered Mouse Models 
Stem cell-derived colon cancer mice were provided by Dr. Robert J. Coffey, and 
colleagues, as part of a collaborative effort within the Vanderbilt GI SPORE program 
which built upon previous work where Lrig1-CreERT2/+ mice (36) were crossed with 
Apcfl/+ mice to generate the Lrig1-CreERT2/+;Apcfl/+ model (37). Briefly, administration of 
4-hydroxytamoxifen enemas to Lrig1-CreERT2/+;Apcfl/fl mice results in loss of both APC 
alleles in Lrig1-expressing cells, whereas administration to Lrig1-
CreERT2/+;Apcfl/fl;KrasG12D mice results in loss of both APC alleles and activation of 
mutant Kras. Colonic tumors developed in both models. Detailed methodologies of 
mouse model generation will be described in future publications from the Coffey lab.  
 
PET Imaging and Analysis 
Animal handling methods in preparation for and during all PET imaging studies, 
including [18F]FDG, [18F]4-F-Gln and [18F]FSPG, were derived from protocol standards 
established for [18F]FDG (38-40). Prior to imaging, animals were fasted between six to 
eight hours and allowed to acclimate to facility environment for at least one hour in a 
warmed chamber at 31.5°C. Animals were administered 10.4-11.8 MBq of PET imaging 
agent via intravenous injection and imaged using a dedicated Concorde Microsystems 
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Focus 220 microPET scanner (Siemens Preclinical Solutions). Animals were maintained 
under 2% isofluorane anesthesia in 100% oxygen at 2 L/min and kept warm for the 
duration of the PET scan. 
 [18F]4-F-Gln and [18F]FSPG PET images in xenograft-bearing mice were 
acquired as 20 min static data sets following a 40 min uptake period and anesthetization. 
Similarly, [18F]FDG PET images were collected as 10 min static data sets following a 50 
min uptake period and anesthetization. Animals were conscious, allowed free access to 
water, and kept in the 31.5 °C warmed chamber for the duration of the uptake period. 
Imaging in models of therapeutic response was performed on the fourth day of treatment 
within three to four hours following single agent administration. For combination cohorts, 
imaging was performed approximately four to five hours and two to three hours following 
the first and second therapeutic treatments, respectively. [18F]4-F-Gln PET imaging in 
genetically engineered mice was collected as either 20 min static acquisitions following a 
40 min uptake period or 60 min dynamic acquisitions initiated upon PET agent injection. 
Images were acquired longitudinally starting before induction with tamoxifen and 
proceeding to two and four weeks after. 
PET data were reconstructed using a three-dimensional (3D) ordered subset 
expectation maximization/maximum a posteriori (OSEM3D/MAP) algorithm. Dynamic 
data was binned into twelve 5 s (0-1 min) and fifty-nine 60 s (2-60 min) frames. The 
resulting three-dimensional reconstructions had an x-y voxel size of 0.474 mm and inter-
slice distance of 0.796 mm. ASIPro software (Siemens Preclinical Solutions) was used 
to manually draw three-dimensional regions of interest (ROI) surrounding the entire 
tumor volume. PET agent uptake was quantified as the percentage of the injected dose 
per gram of tissue (%ID/g). For dynamic scans, only data points collected within the time 
frame analyzed for analogous static scans were considered.  
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Immunohistochemistry and Semi-Quantitative Analysis 
Tumor tissues were harvested immediately following conclusion of imaging, fixed 
for 24 h in 5% buffered formalin, and blocked in paraffin. Immunohistochemistry for Ki67 
(1:100, Dako M7240) activity was carried out as previously described (5). Tissues were 
similarly stained using standard H&E methods and reviewed by an expert 
gastrointestinal pathologist (M. Kay Washington). For semi-quantitative analysis of Ki67 
IHC, high-resolution bright field images of whole tissue sections were obtained using a 
Leica SCN400 Slide Scanner. Tissue sections were scored to determine the percentage 
of positive cells using the accompanied Ariol Analysis software. 
For immunofluorescence studies, formalin-fixed-paraffin-embedded tissues were 
sectioned to 4 µm thickness and stained for ASCT2. Briefly, tissue samples were de-
paraffinized, rehydrated, and incubated in PBS with 0.3% Triton X-100 for 10 minutes. 
Antigen retrieval was performed using citrate buffer (pH = 6.0) solution for 20 minutes at 
105°C followed by a 10 minute cooling period at room temperature. Samples were then 
treated with 3% hydrogen peroxide for 10 minutes and blocked with 3%BSA/10% 
donkey serum in PBS for 30 minutes. Slides were incubated with primary antibody 
overnight (1:500, Sigma HPA035240) at 4°C and subsequently washed with PBS. For 
secondary antibody detection, samples were incubated with species-specific secondary 
Donkey IgG conjugated to either Cy3 or Cy5 (1:100) for 1 hour at room temperature with 
DAPI (10 μg/mL) and subsequently washed with PBS. Slides were mounted with 
antifade media for imaging on an Olympus IX81 inverted fluorescent microscope at 20x 
magnification. 
 
Tissue Immunoassays 
 Upon tissue collection, tumor samples that were not fixed in 5% buffered formalin 
were flash-frozen in liquid nitrogen and stored at -80°C. For immunoreactivity studies, 
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tissue samples were diluted to 100 mg/mL in lysis buffer (#7018s, Cell Signaling 
Technology) and subsequently homogenized, sonicated, and spun at 3.5K RPM for 1 
min. Lysate samples were then screened against an array of target-specific capture 
antibodies using PathScan Intracellular Signaling Array Kits (#7323, Cell Signaling 
Technology) in accordance with the manufacturer’s instructions and developed using 
HyBlot CL autoradiography film (#e3012, Denville Scientific Inc.). Processed films were 
digitized using an Epson Perfection V600 Photo scanner and the relative pixel intensities 
for each blot quantified using the public domain image processing software ImageJ. 
Complementary western blot studies were performed by loading 20-40 µg of 
protein into 7.5-12% SDS PAGE gels, transferred to PVDF membranes (PerkinElmer), 
and resolved by electrophoresis. Membranes were blocked overnight at 4°C in tris-
buffered saline 0.1% Tween-20 (TBST) containing 5% w/v nonfat dry milk powder and 
subsequently incubated with antibodies to p-ERK 1/2 Thr202/Tyr204 (Cell Signaling, 
4370), p-AKT Ser473 (Cell Signaling, 4060), b-tubulin (Novus Biologicals, NB600-936); 
in which case membranes were probed for one hour in TBST with 3% bovine serum 
albumin (BSA) and subsequently incubated for another hour with horseradish 
peroxidase-conjugated secondary antibody (Jackson ImmunoResearch) diluted 1:5000 
in TBST containing 3% BSA. Finally, membrane chemiluminescence was imaged on a 
Xenogen IVIS 200 system using Western Lightning Plus-ECL (PerkinElmer) substrate. 
 
Statistical Methods 
Experimental replicates are reported as the arithmetic mean ± standard 
deviation. The Wilcoxon Rank Sum (Mann-Whitney U) test was used to evaluate 
statistical significance for both in vitro and in vivo data sets. Differences were assessed 
within the GraphPad Prism 6.01 software package and considered statistically significant 
if p < 0.05. 
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 4.4. Results 
 
In Vitro Evaluation of Therapeutic Cohorts 
Though many of the therapeutic agents and combinations have been reportedly 
previously in COLO- (5,6,34) and HCT-116 (35) cell lines, targeted drug treatment 
efficacy was evaluated in vitro by western blot. As expected from our previous work in 
this model, BRAFV600E-expressing COLO-205 cells showed activation of cell death 
pathways with exposure to BEZ-235/PLX-4720 combination-therapy and sensitivity to 
inhibition of PI3K/mTOR as noted by decreases in p-AKT (473) (Fig. 4.3A). Mutant PI3K 
and wild type BRAF HCT-116 cells were resistant PLX-4720 and combination BEZ-
235/PLX-4720 treatment and sensitive to BEZ-235 treatment; as noted by changes in p-
AKT (473) and p-ERK (Fig. 4.3B). Interestingly, combined inhibition of MEK and Bcl-
2/Bcl-XL/Bcl-w induced cell death in high concentrations. Changes in BIM expression in 
response to ABT-263 and AZD-6244 single agent and combination treatments (Fig. 
4.3C) were in agreement with previous reports for this cell line (35).  
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 Figure 4.3. Efficacy of targeted therapies were confirmed in vitro. Western blot 
analysis of cleaved PARP, cleaved caspase-3 p-AKT (473), p-ERK, and BIM 24 h 
post-drug administration in response to a variety of targeted therapeutics in BRAFV600E-
expressing COLO-205 and mutant PI3K HCT-116 cells. 
 
Molecularly Targeted Therapeutics Effect In Vitro Glutamine Metabolism  
Initial evaluation of the effects of targeted therapies on glutamine uptake in CRC 
was explored in vitro using COLO-205 and HCT-116 cells (Fig. 4.4). Treatment cohorts 
modeled those employed for small animal imaging studies. Incorporation of 
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[3H]glutamine in living COLO-205 cells revealed a reduction, compared to vehicle-
treated, in 1 µM BEZ-235/PLX-4720 combination-treated cells only (p = 0.0286). In HCT-
116 cells, reduction in [3H]glutamine uptake was observed for BEZ-235 single agent-
treated (p = 0.0283) as well as AZD-6244/BEZ-235 (p = 0.0081) and AZD-6244/ABT-263 
(p = 0.0485) combination-treated cohorts. 
 
Figure 4.4. [3H]Glutamine in living cells reflected molecular response to targeted 
therapies. Incorporation of [3H]glutamine is reported as percent change relative to 
vehicle-treated cells, which was manually set as 100%. A novel ASCT2 (SLC1A5) 
inhibitor MLC-37-3 (30) was applied to cells, analogously to targeted drug treatments, as 
a positive control in both cell lines. 
 
PET Imaging of Therapeutic Response in BRAFV600E Colon Cancer 
In vivo [18F]4-F-Gln PET was explored as a means to reflect response to targeted 
therapies in BRAFV600E COLO-205 xenograft-bearing mice (Fig. 4.5A). [18F]4-F-Gln 
tumor accumulation in vehicle-treated mice averaged 6.34 ± 0.93 %ID/g. When treated 
with a duel inhibitor of PI3K and mTOR activity (BEZ-235), PET agent accumulation in 
tumor tissue remained unchanged (6.07 ± 0.72 %ID/g, p = 0.5161). While a reduction in 
[18F]4-F-Gln tumor uptake (5.30 ± 0.91 %ID/g) was observed in tumors treated with a 
mutant BRAF inhibitor (PLX-4720), this trend was not found to be significant (p = 
0.0608). Strikingly, [18F]4-F-Gln accumulation was found to be significantly reduced (4.76 
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± 1.07 %ID/g, p = 0.0021) when COLO-205 xenograft tumors were treated with a 
combination of BEZ-235 and PLX-4720. 
In comparative studies, [18F]FDG (Fig. 4.5B) and [18F]FSPG (Fig. 4.5C) PET 
imaging were similarly explored. Unlike [18F]4-F-Gln accumulation, [18F]FDG tumor 
uptake was significantly reduced from vehicle (4.72 ± 0.86 %ID/g) in both single 
treatment cohorts (3.06 ± 0.38 %ID/g, p = 0.0006  and 3.34 ± 0.85 %ID/g, p = 0.0205 for 
BEZ-235 and PLX-4720, respectively) as well as for the BEZ-235/PLX-4720 
combination-treated mice (2.06 ± 0.60 %ID/g, p = 0.0002). Interestingly, [18F]FSPG 
trends were similar to that of [18F]4-F-Gln as accumulation in vehicle-treated mice (1.89 ± 
0.24 %ID/g) was similar to single agent BEZ-235 and PLX-4720-treated xenografts (2.06 
± 0.59 %ID/g, p = 0.3869 and 1.72 ± 0.45 %ID/g, p = 0.6031 for BEZ-235 and PLX-4720, 
respectively) but was reduced in BEZ-235/PLX-4720 combination-treated tumors (1.34 ± 
0.28 %ID/g, p = 0.0022). 
In concert with reduced [18F]4-F-Gln uptake, after four days of treatment a 
significant reduction in tumor size (p < 0.0001) was observed only in COLO-205 
xenografts treated with a combination of BEZ-235 and PLX-4720 (Fig. 4.5D) and agreed 
with our previous experience with this model (34). In contrast, statistically significant 
changes in tumor growth, compared to vehicle, were not found for single agent 
therapies. To further validate observations derived from PET imaging, xenograft tissues 
were harvested for histology immediately following imaging conclusion. In agreement 
with [18F]4-F-Gln PET, [18F]FSPG PET, and tumor growth trends, semi-quantitative 
analysis of Ki67 immunoreactivity revealed a reduction in proliferation (p < 0.0001), 
compared to vehicle-treatment, for the combination-treated cohort only (Fig. 4.5E). 
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 Figure 4.5. [18F]4-F-Gln uptake reflected molecular response to mutant BRAF and 
PI3K/mTOR therapy in vivo. Representative transverse and coronal [18F]4-F-Gln (A), 
[18F]FDG (B), and [18F]FSPG (C) PET images of COLO-205 xenograft tumor-bearing 
vehicle or BEZ-235/PLX-4720-treated mice; tumors are denoted by white arrows. PET 
quantification of tissue %ID/g revealed a significant difference between vehicle and BEZ-
235/PLX-4720- treated xenografts for all imaging agents, however, only [18F]4-F-Gln and 
[18F]FSPG showed sensitivity to just the combination treatment. Changes in COLO-205 
tumor volume by the fourth day of treatment (N ≥ 8 for all cohorts), shown as percent 
change from day one baseline, revealed a significant reduction in size from vehicle-
treated mice for BEZ-235/PLX-4720-treated tumors only (p < 0.0001) (D). Similar 
observations were observed by semi-quantitative analysis of Ki67 immunoreactivity 
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sections (N ≥ 10 for all cohorts), where the relative percent of positively-stained cells was 
evaluated for an entire tumor tissue section per animal (E). 
 
PET Imaging of Therapeutic Response in Mutant PI3K Colon Cancer 
In parallel to imaging studies in mutant BRAF xenograft tumors, [18F]4-F-Gln was 
also explored as a diagnostic marker of therapeutic response in PI3K mutant HCT-116 
xenograft-bearing mice (Fig. 4.6A, B). [18F]4-F-Gln tumor accumulation in vehicle 
treated mice was found to average 3.66 ± 0.71 %ID/g. In addition to BEZ-235 and PLX-
4720, additional therapeutic inhibitors of Bcl-2/Bcl-XL/Bcl-w (ABT-263) and/or MEK 
(AZD-6244) were employed. [18F]4-F-Gln uptake in most drug treated tumors was 
comparable to that observed in vehicle-treated tissues: 4.26 ± 0.78 %ID/g, p = 0.1783 
(BEZ-235), 4.48 ± 1.56 %ID/g, p = 0.3983 (PLX-4720), 4.15 ± 0.71 %ID/g, p = 0.3337 
(BEZ-235/PLX-4720), 4.25 ± 1.13 %ID/g, p = 0.4242 (ABT-263), 3.73 ± 0.84 %ID/g, p = 
0.7524 (AZD-6244), and 4.42 ± 0.54 %ID/g, p = 0.1143 (AZD-6244/BEZ-235). 
Interestingly, imaging agent uptake was significantly reduced when using combined 
targeted inhibition of MEK and Bcl-2/Bcl-XL/Bcl-w activity upon administration of AZD-
6244 and ABT-263 (2.39 ± 0.43 %ID/g, p = 0.0381). 
In comparative studies, [18F]FDG and [18F]FSPG PET imaging were similarly 
explored (Fig. 4.6A, B). Unlike [18F]4-F-Gln accumulation, [18F]FDG tumor uptake was 
significantly reduced from vehicle (5.23 ± 0.68 %ID/g) in all single agent and 
combination-treated cohorts: 4.18 ± 0.51 %ID/g, p = 0.0070 (BEZ-235), 4.45 ± 0.58 
%ID/g, p = 0.0401 (PLX-4720), 4.36 ± 0.61 %ID/g, p = 0.0093 (BEZ-235/PLX-4720), 
4.34 ± 0.81 %ID/g, p = 0.0111 (ABT-263), 3.83 ± 0.85 %ID/g, p = 0.0289 (AZD-6244), 
3.15 ± 1.32 %ID/g, p = 0.0262 (AZD-6244/BEZ-235), and 3.96 ± 0.99 %ID/g, p = 0.0008 
(AZD-6244/ABT-263). As also observed for COLO-205 xenograft-treated tumors, 
[18F]FSPG trends in drug treated HCT-116 xenografts were similar to that of [18F]4-F-Gln. 
Accumulation in vehicle-treated mice (2.64 ± 0.45 %ID/g) was similar to all therapeutic 
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cohorts with the exception of AZD-6244/ABT-263 combination-treated mice. Uptake 
values were found to be: 2.45 ± 0.72 %ID/g, p = 0.4945 (BEZ-235), 2.71 ± 0.75 %ID/g, p 
= 0.7515 (PLX-4720), 2.19 ± 0.38 %ID/g, p = 0.1197 (BEZ-235/PLX-4720), 2.35 ± 0.43 
%ID/g, p = 0.2720 (ABT-263), 2.46 ± 0.55 %ID/g, p = 0.9293 (AZD-6244), 2.16 ± 0.53 
%ID/g, p = 0.1778 (AZD-6244/BEZ-235), and 2.02 ± 0.37 %ID/g, p = 0.0186 (AZD-
6244/ABT-263).  
After four days of treatment, a significant reduction in tumor size was observed in 
tumors treated with AZD-6244 (p = 0.0001), AZD-6244/BEZ-235 (p < 0.0001), and AZD-
6244/ABT-263 (p < 0.0001) (Fig. 4.6C). These trends agreed with previously reported 
findings in this model (35). To explore potential imaging correlations with a marker of cell 
proliferation, semi-quantification of Ki67 immunohistochemistry was performed in 
excised tissue (Fig. 4.6D). Contrary to variations in tumor growth rates, significantly 
reduced Ki67 activity, compared to vehicle-treated tissue, was observed for AZD-
6244/BEZ-235 (p = 0.0037) combination-treated tumor. 
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 Figure 4.6. [18F]4-F-Gln uptake exhibited sensitivity to targeted inhibition of Bcl-
2/Bcl-XL/Bcl-w and MEK in vivo. Representative [18F]4-F-Gln, [18F]FDG, and 
[18F]FSPG PET transverse images (A) of HCT-116 xenograft tumor-bearing vehicle, 
BEZ-235/PLX-4720, AZD-6244/BEZ-235, AZD-6244/ABT-263-treated mice; tumors are 
denoted by white arrows. PET quantification of tissue %ID/g (B) revealed a significant 
difference between vehicle and AZD-6244/ABT-263-treated xenografts for [18F]4-F-Gln 
and [18F]FSPG, however, only [18F]FDG uptake was significantly different from vehicle-
treated tumors for all treatment cohorts. Changes in HCT-116 tumor volume by the 
fourth day of treatment (N ≥ 9 for all cohorts), shown as percent change from day one 
baseline, revealed a significant reduction in size from vehicle-treated mice for all MEK 
inhibitor cohorts (C). Semi-quantitative analysis of Ki67 histological samples obtained 
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from imaged animals (N ≥ 7 for all cohorts), where the relative percent of positively 
stained cells was evaluated for an entire tumor tissue section per animal, is also shown 
(E). 
 
Molecular Response to Targeted Therapy in Xenograft Tissues 
 Using flash-frozen tumor samples obtained from PET imaged CRC xenograft-
bearing mice, antibody array and western blot analysis was performed to assess 
molecular therapeutic response in these tissues. In support of an mTOR mediated pro-
survival response to targeted therapy previously reported in mutant BRAFV600E tumors 
(6), mTOR and p38 levels were elevated compared to vehicle-treated tumors (p = 
0.0382 and p = 0.0153, respectively) in COLO-205 tissue lysate (Fig. 4.7A). 
Interestingly, mTOR levels were moderately down in therapeutic cohorts treated with a 
combination of BRAF and PI3K/mTOR inhibitors (p = 0.0378) or MEK and BCL-2 family 
inhibitors (p = 0.0280) and greatly decreased for treatments using a single-agent MEK 
inhibitor only (p = 0.0028) (Fig. 4.7B). Western blot of COLO-205 tumor tissues (Fig. 
4.7C) revealed changes in p-AKT (ser473) and p-ERK levels and were analogous to 
those previously reported (6).  
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Figure 4.7. Measures of drug response in xenograft tissues. Chemiluminescent 
measured mTOR and p38 activity in COLO-205 xenograft tissue lysate (N = 3) illustrated 
elevation in PLX-4720 treated tissues only (A); similar to previously reported works (5,6). 
Analogously measured mTOR activity in HCT-116 xenograft tissue lysate (N = 3) 
revealed modest decreases in BEZ-235/PLX-4720 and AZD-6244/ABT-263 treated 
tumors while a greater decrease was observed in AZD-6244 single agent-treated tumors 
(B). Western blot of representative xenograft tissue lysate illustrated decreased p-ERK 
levels in PLX-4720 and BEZ-235/PLX-4720 combination-treated tumors (C).  
 
[18F]4-F-Gln PET Detects Activation of Mutant Kras 
 Using genetically engineered mice which mimicked common genetic profiles 
observed in human colon cancer, glutamine uptake was observed to associate with 
mutant Kras oncogene activation (Fig. 4.8). In collaboration with Eliot T. McKinley, 
histological evaluation of Asct2 expression, a sodium-dependent, neutral amino acid 
transporter of glutamine encoded by the gene Slc1a5, was explored using an 
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immunofluorescence methodology in tissue samples obtained from an Lrig1-
CreERT2/+;Apcfl/fl and an Lrig1-CreERT2/+;Apcfl/fl;KrasG12D mice (Fig. 4.8A, B). 
Interestingly, we observed elevated Asct2 at the tissue level when mutations in Kras 
were introduced. These results spurred further in vivo experiments employing [18F]4-F-
Gln PET imaging in these models. Not surprisingly, elevated uptake of [18F]4-F-Gln was 
observed in tumors arising in an Lrig1-CreERT2/+;Apcfl/fl;KrasG12D compared to an Lrig1-
CreERT2/+;Apcfl/fl mice (Fig. 4.8C-F) as determined by image contrast between the distal 
colon, where Kras expression was induced, and normal muscle tissues (Fig. 4.8E). 
Contrast ratios, defined as C/M, were found to be longitudinally consistent over time for 
an Lrig1-CreERT2/+;Apcfl/fl both before and after tamoxifen induction: 1.05 ± 0.11 (pre-
induction), 1.03 ± 0.15, p > 0.9999 (14-16 days), and 1.14 ± 0.14, p = 0.4939 (27-29 
days). For an Lrig1-CreERT2/+;Apcfl/fl;KrasG12D mice after induction, [18F]4-F-Gln uptake 
was elevated from both the baseline time-point as well as the Lrig1-CreERT2/+;Apcfl/fl 
animal model: 1.05 ± 0.04 (pre-induction), 1.53 ± 0.24 (14-16 days), and 1.59 ± 0.22 (27-
29 days). Analogously performed [18F]FSPG PET did not reveal increased agent 
accumulation in Lrig1-CreERT2/+;Apcfl/fl;KrasG12D mouse tissues (p = 0.4857) (Fig. 4.8G); 
potentially suggesting that, unlike glutaminolysis, cysteine and glutamate cellular 
transport may not be mediated by mutations in Kras. In comparison studies, [18F]4-F-Gln 
PET in a single Lrig1-CreERT2/+;KrasG12D mouse revealed targeted accumulation in oral 
lesions (Fig. 4.8H). Though a sampling of one, this finding suggests that [18F]4-F-Gln 
PET could be an appropriate imaging metric for evaluating amino acid metabolism and 
the effects of mutations in APC, a major initiator of CRC. 
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 Figure 4.8. [18F]4-F-GLN uptake associated with expression of mutant Kras. 
Immunofluorescence histological evaluation of Asct2 expression (red) in genetically 
engineered mouse tissues (A/B). Representative [18F]4-F-Gln PET sagittal images of an 
Lrig1-CreERT2/+;Apcfl/fl (C) and an Lrig1-CreERT2/+;Apcfl/fl;KrasG12D (D) mice four weeks 
after tamoxifen induction. White brackets denote the relative areas defined as distal 
colon during post-processing. PET quantification of tissue contrast (Distal 
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Colon/Muscle or C/M) (E) revealed a significant difference between pre- and post-
induction with tamoxifen in an Lrig1-CreERT2/+;Apcfl/fl;KrasG12D as well as between Kras and 
non-Kras mutant mice. A representative time activity curve (TAC) for a Lrig1-
CreERT2/+;Apcfl/fl;KrasG12D mouse (F), four weeks post-induction, revealed modest 
washout of glutamine imaging agent over a 60 min period with accumulation reaching 
equilibrium within the last 20 min. In comparative PET studies, [18F]FSPG accumulation 
in was not elevated in the distal colon tissue of Lrig1-CreERT2/+;Apcfl/fl;KrasG12D mice 20-
22 day post-induction (G). Preliminary evaluations of [18F]4-F-Gln PET in a single Lrig1-
CreERT2/+;KrasG12D mouse revealed targeted accumulation in oral lesions (H). 
 
4.5. Discussion 
Emerging evidence has implicated oncogenic signaling with metabolic and 
nutrient uptake reprogramming in cancer cells (41,42). For example, cellular uptake of 
glucose can be controlled by activation of oncogenic pathways (43,44), such as PI3K, 
RAS, BRAF and MYC, while glutamine dependency has been linked to mutations in 
MYC (45-49)  and KRAS (14,50). An observed consequence of oncogenic glutamine up-
regulation has been the enhanced expression of a sodium-dependent transporter of 
glutamine, ASCT2 (gene symbol SLC1A5). ASCT2 has been suggested to play a role in 
metabolism, growth, and survival of lung cancer (10,51) with comparable observations 
being observed in clinical CRC tissue samples (52,53). Similar histological studies in 
clinical samples of primary colon tumors and advanced disease obtained from Vanderbilt 
Medical Center patients (data not shown) agree with these reports and found ASCT2 
expression to be elevated in primary tumor tissue compared to metastatic disease (65% 
vs. 33%) and normal tissue (65% vs. 5%). Given the cellular and molecular implications 
of cancer metabolic reprogramming beyond glycolysis and the Warburg effect, there is a 
pressing need to characterize and evaluate non-invasive imaging metrics that could 
serve as supplementary or even alternative tools to conventional [18F]FDG PET imaging. 
Towards this end, these studies sought to elucidate the feasibility of [18F]4-F-GLN PET 
to report on therapeutic response and genetic mutations in CRC. To the current 
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knowledge of the authors, this is the first report to explore glutamine-derived PET as a 
means of evaluating targeted drug response in vivo.  
A multi-drug therapeutic regimen that includes an inhibitor of mutant BRAF and a 
PI3K/mTOR inhibitor has been shown to be a rational therapeutic approach for 
BRAFV600E melanoma (54,55) and CRC (5,6,34). Our previous work in this setting 
illustrated [18F]FDG PET to be insufficient for observing activation of pro-survival 
signaling pathways that were detectable by [18F]FLT PET (6) when using BRAF/PI3K 
targeted therapy in  BRAFV600E mutant CRC preclinical models. Analogously, a novel 
imaging agent for the detection of caspase activity in vivo, [18F]FB-VAD-FMK, was 
capable of reflecting apoptotic cell death induced from combined inhibition of mutant 
BRAF and PI3K/mTOR whereas single agent therapeutics were ineffective (34). 
Stemming from this work, metabolic responses to targeted therapy were explored in 
unbiased microarray profiling of COLO-205 xenograft tumors treated with vehicle or 
PLX-4720, an inhibitor of mutant BRAF, revealed 267 statistically significant genes 
differentially expressed between these two groups (data not shown). Five solute carrier 
family genes were found to be up-regulated in resistant tumors. Among these, (SNAT5, 
gene symbol SLC38A5), a sodium-coupled neutral amino acid transporter of glutamine 
and other neutral amino acids (56), was identified as a potentially novel biomarker of 
resistance. Though not previously associated with carcinogenesis, SNAT5 expression 
has previously been observed in the kidney (56) and retina (57). The observation that 
SNAT5 expression is elevated in colon cancer cells that resist targeted therapy suggests 
an opportunity to use non-invasive imaging assays of glutamine uptake to predict 
resistance in this setting. 
Towards this end, [18F]4-F-Gln PET was used to evaluate response to a multi-
drug therapy using PLX-4720 and BEZ-235, a PI3K/mTOR inhibitor, in BRAFV600E-
expressing COLO-205 xenograft-bearing mice. In both in vitro and in vivo studies, which 
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measured cellular uptake of [3H]glutamine and [18F]4-F-Gln respectively, decreased 
glutamine accumulation was observed in COLO-205 cells and tissues treated with a 
combination of BRAF and PI3K/mTOR inhibitors. Given the increasingly reported 
phenomena of MYC-regulated glutamine addiction in cancer cells (45-49), it is possible 
that [18F]4-F-Gln PET acts, at least in this setting, as a measure of events downstream to 
PI3K/mTOR and BRAF inhibition and the subsequent loss of p-AKT and p-ERK activity; 
as validated by immunoblotting experiments of drug activity in both cells and resected 
tissue. As expected from our previous findings in COLO-205 xenografts (6), [18F]FDG 
PET was incapable of discerning pro-survival feedback mechanisms against single 
agent PLX-4720 therapy and did not agree with evidence of drug response by 
immunoblotting. Interestingly, measurement of glutamate cell-dependency by [18F]FSPG 
PET agreed with those observed by [18F]4-F-Gln PET. While it is unclear from the 
current work which molecular responses and pathways may be involved in regulating 
[18F]FSPG uptake, changes observed by PET for combination-treated animals could be 
related to mitochondrial stress and reactive oxygen species (ROS)-induced cell death 
due to the role that glutamate plays in the biosynthesis of glutathione (GSH) (32,58), a 
major intracellular thiol compound which serves as the main antioxidant defense against 
ROS. This hypothesis agrees with the apoptotic cell death response observed for BEZ-
235/PLX-4720 combination-treated COLO-205 tumors in our previous work (34). Though 
the mechanism(s) behind these observations are still largely exploratory, greater 
understanding will hopefully be gained through the ongoing LC-MRM proteomic studies 
that have been pursued in collaboration with Daniel Liebler and Lisa Zimmerman. 
When compared to other measures of therapeutic response, changes in [18F]4-F-
Gln accumulation in COLO-205 xenografts trended with measures of anti-proliferation 
response as tumor volumes and Ki67 IHC were found to be significantly reduced for 
BEZ-235/PLX-4720 combination-treated animals. Due to the role of glutamine in 
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nucleotide synthesis, [18F]4-F-Gln PET may provide an estimate of de novo thymidine 
synthesis associated with proliferation, a process un-measurable by [18F]-FLT PET; 
however, this potential correlation would need to be more rigorously explored in future 
work. 
Given the promise of [18F]4-F-GLN PET observed in COLO-205 treated tumors, 
we proceeded to explore this imaging metric as a measure of response to multi-drug 
therapies in wild type BRAF, mutant PI3K HCT-116 xenograft tumors. Serving as a 
negative control to BRAFV600E mutant COLO-205 tumors, combined inhibition of BRAF 
and PI3K/mTOR was found to be largely ineffective by immunoblotting, tumor growth, 
and Ki67 IHC analysis; as expected due to BRAF mediated resistance (5,6). 
Accordingly, [18F]4-F-GLN and [18F]FSPG PET were not sensitive to any therapeutic 
cohorts utilizing BEZ-235 and/or PLX-4720. Expanding these studies to drug regimens in 
which sensitivity has been reported in HCT-116 tumors (35), all three imaging agents 
were evaluated as measures of MEK and/or Bcl-2/Bcl-XL/Bcl-w inhibition using AZD-
6244 and ABT-263. Initial in vitro studies of [3H]glutamine uptake suggested modest 
sensitivity to MEK and BCL-2 family inhibition with greater response reported for MEK 
and PI3K/mTOR inhibition. In vivo PET imaging using [18F]4-F-GLN and [18F]FSPG 
disagreed with in vitro predictions as well as with Ki67 IHC and detected changes only in 
AZD-6244/ABT-263 combination-treated tumors. While these findings support previous 
works which claim combined MEK/BCL-XL inhibition to be a potential therapeutic 
approach for KRAS mutant cancers, it is presently unclear whether the observations 
gained from glutamine and glutamate PET imaging were a consequence of specific 
oncogenic regulatory pathways or the effects of cellular stress. Similar to observations in 
COLO-205 tumors, [18F]FDG PET reported sensitivity to all drug cohorts and was unable 
to discern molecular deviations between therapeutic effects. As with the COLO-205 
treatment model, determining the metabolic effects of targeted drug therapies in HCT-
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116 has been the subject of exploration in ongoing collaborative LC-MRM proteomic 
efforts. 
 Expanding investigations to the detection of specifically expressed gene mutations, 
[18F]4-F-GLN PET was explored in genetically engineered mouse models which 
recapitulate the sequence of genetic mutation and loss of function leading to colonic 
tumors in humans. In this setting, Asct2 expression and cellular glutamine uptake were 
associated with activation of mutant Kras. By immunofluorescence, increased Asct2 
expression was observed in colon cancers arising from the Lrig1-
CreERT2/+;Apcfl/fl;KrasG12D genotype compared to Kras wild type mice; an expected 
observation given the implication of KRAS regulated glutamine dependency observed in 
pancreatic cancer (25). Ongoing works seek to expand the assessment of Asct2 
expression levels in larger cohorts of Lrig1-CreERT2/+;Apcfl/fl, Lrig1-CreERT2/+;KrasG12D, 
and Lrig1-CreERT2/+;Apcfl/fl;KrasG12D tissue samples. Concordantly, [18F]4-F-GLN PET 
imaging was capable of discerning the potential expression of mutant Kras in the distal 
colon epithelium of these mice. Validation of Kras expression in excised mouse tissues 
has been actively pursued through collaborative efforts with Emily J. Poulin in the Coffey 
lab. Recently, the recombined Kras allele has been detected in gross tissue of Lrig1-
CreERT2/+;Apcfl/fl;KrasG12D mice and provides preliminary evidence, which supports the 
presence of mutant protein in whole tissue samples.  
 Given these findings, future studies could employ [18F]4-F-GLN PET imaging to 
explore Wnt-induced tumor cell accumulation and CRC initiation due to the role that Myc 
plays as both an effector of Wnt signaling (59,60) and an inducer of glutaminolysis (45-
49). As emerging evidence suggests a therapeutic role in the blockage of Wnt in the 
treatment of CRC (61,62), glutamine-derived molecular imaging could offer potential as 
a metric of predicting clinical and histopathological response to Wnt pathway-targeted 
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therapeutics. 
 
4.6. Conclusions 
We believe that these findings not only provide a greater understanding of the 
role that glutaminolysis plays in CRC, but also illuminates the potential impact that 
glutaminolysis-derived PET could have towards guiding drug development clinical trials 
as an imaging metric for detecting early therapeutic response. If glutamine PET imaging 
agents reflect Kras activity, such modalities may be useful towards the development of 
companion diagnostics for KRAS-targeted drugs. Future studies could also explore the 
relevance of ASCT2 expression in human colon adenoma samples, as a greater 
understanding of the clinical significance of ASCT2 expression and glutamine transport 
in early and advanced disease will be key for eventual translation of glutaminolysis PET 
imaging to clinical practice. 
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CHAPTER 5 
 
TSPO AS A PET BIOMARKER FOR EARLY DETECTION IN GI CANCER 
 
5.1. Abstract 
The outer mitochondrial membrane translocator protein (TSPO) has been 
associated with many cell processes and advanced cancer states. In contrast to 
conventional reports, the studies reported here explored the significance of TSPO 
expression as a biomarker of early gastrointestinal (GI) neoplasia; primarily colonic and 
pancreatic. Using TSPO immunohistochemistry (IHC) evaluation in clinically obtained 
tissue samples, TSPO expression was found to be elevated in low-grade colon cancers 
(G1/G2) as well as colorectal adenomas, compared to normal tissue. In clinical tissue 
samples of pancreatic cancer, TSPO expression was similarly elevated not only in 
advanced cancerous lesions, but also in pre-malignant pancreatic intraepithelial 
neoplasia (PanIN). PET imaging studies utilizing the TSPO ligands [18F]VUIIS1008 and 
[18F]VUIIS8310 were assessed as imaging metrics for the detection of PanIN occurrence 
and progression and revealed increased accumulation in lesion bearing pancreas 
compared to normal. Conclusively, these studies seek to expand the conception of 
TSPO as a cancer imaging biomarker of not only advanced disease, but of also early-
stage GI neoplastic lesions. 
 
 
5.2. Introduction 
The translocator protein (TSPO), formerly termed peripheral benzodiazepine 
receptor (PBR), is an 18 kDa protein typically localized to the outer mitochondrial 
membrane and is expressed in mitochondrial-enriched tissues (i.e., skeletal muscle and 
myocardium, renal, and other steroid-producing tissues). TSPO participates in a number 
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of cellular processes (Fig. 5.1) (1), including cholesterol metabolism, steroid 
biosynthesis, cellular proliferation, and apoptosis. Elevated TSPO expression is found in 
many disease states including neuroinflammation (2), neurological disorders (3,4), as 
well as cancers of the breast (5,6), prostate (7), oral cavity (8), colon (9), liver (10), and 
brain (11,12). Furthermore, elevated TSPO levels have been linked with disease 
progression and diminished survival and is conventionally associated with aggressive, 
metastatic behavior.  
 
Figure 5.1. The molecular relationship and determinants of TSPO function. TSPO 
is a hetero-oligomeric, macromolecular complex which consists of the isoquinolone 
binding protein of 18-kDa TSPO, a voltage-dependent anion channel (VDAC) and an 
adenine nucleotide transporter (ANT). The transport of lipophilic molecules across the 
intermembrane space is facilitated by contact sites on both the outer and inner 
mitochondrial membranes (OMM and IMM, respectively). Combined, TSPO serves to: 
regulate cholesterol binding and mitochondrial transport, play a key function in 
steroidogenesis and bile salt synthesis, import proteins for membrane biogenesis and 
other cellular functions, participate in porphyrin binding and transport for heme 
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synthesis, and regulate a host of other mitochondrial functions. This figure was adapted 
from the cited work (13). 
 
TSPO ligands were first developed and utilized as cancer imaging agents when a 
tritium labelled TSPO ligand, PK-11195, was shown capable of distinguishing brain 
tumors from normal cortex using ex vivo autoradiography (14). Since this initial 
discovery, imaging studies using PK-11195 analogues modified for positron emission 
tomography (PET) (15) and near infrared optical imaging (16) have revealed the 
potential of TSPO-targeted molecular detection as an imaging metric for cancer 
detection and screening. However, there are multiple shortcomings inherent to this agent 
class; including modest signal-to-noise ratio and low blood–brain barrier permeability. 
These limitations, in part, have prompted the discovery of TSPO ligands which exhibit 
improved in vivo specificity; such as the aryloxyanilides (17), indoleacetamides (18), 
pyrazolopyrimidines (19), and imidazolepyridines (20). Several PET imaging agents 
derived from these scaffolds have been developed and subsequently explored for 
neuroinflammation imaging (21). Towards exploring oncological applications, the 
aryloxyanilide [18F]PBR06 (22) and the pyrazolopyrimidine [18F]DPA-714 (23) have been 
utilized for quantitative assessment of TSPO expression in glioma. In these studies, 
[18F]PBR06 and [18F]DPA-714 were reported to be highly specific in vivo and found to 
exhibit approximately 70% displacement of the radioactive probe when challenged by 
the cold version of the molecule; unlike [11C]PK-11195 which exhibited approximately 
30% displacement. Beyond [18F]PBR06 and [18F]DPA-714, novel TSPO imaging ligands 
are still being developed and reported. Recently, a pyrazolopyrimidine derivative 
([18F]VUIIS1008) (24) and pyridazinoindole analogue (7-chloro-N,N,5-trimethyl-4-oxo-
3(6-[18F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-cetamide, 
henceforth referred to as [18F]VUIIS8310) (25) were reported as possessing greater in 
vivo specificity towards TSPO than either [18F]PBR06 or [18F]DPA-714. 
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While TSPO expression in cancer is conventionally considered a biomarker of 
advanced tumors, emerging evidence suggests it may also be a characteristic of early 
neoplasia. In a recent report, PET imaging of [18F]VUIIS1008 in a genetically engineered 
mouse, which recapitulated many features of familial adenomatous polyposis (ADF), 
revealed localized agent accumulation in distal colon tumors which expressed high 
levels of Tspo and β-catenin (26). Encouraged by this work, the studies reported here 
explored the significance of TSPO expression as a biomarker of early gastrointestinal 
(GI) neoplasia; primarily colonic and pancreatic. Using a tissue microarray (TMA) 
comprised of 89 clinically representative colon cancers from patients, we found TSPO 
immunohistochemistry (IHC) to be elevated in low-grade colon cancers (G1/G2). In 
further histological evaluations, TSPO expression was found to be elevated in colorectal 
adenomas, compared to normal tissue, using a pool of 56 clinically obtained samples. In 
tissue samples of pancreatic cancer, TSPO expression was similarly elevated not only in 
advanced cancerous lesions, but also in a variety of pre-malignant lesions. Molecular 
imaging studies using the PET imaging agents [18F]VUIIS1008 and [18F]VUIIS8310 were 
also incorporated to assess the potential of using TSPO PET as an imaging metric for 
the detection of early pancreatic neoplasia. Conclusively, these studies seek to expand 
the conception of TSPO as a cancer imaging biomarker of not only advanced disease, 
but of also early-stage GI neoplastic lesions. 
  
5.3. Materials and Methods 
 
Colon Cancer Tissue Microarrays 
 After institutional review board approval, primary colorectal cancer and normal 
colonic mucosa tissue samples were collected from 99 patients treated at Vanderbilt 
University Medical Center. Tissue samples were histologically verified and 
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representative regions, sampled in duplicate using 1 mm cores, were selected for 
inclusion in the TMAs. Of the original 99 patient sample pool, tissues from 84 and 89 
patients, for TSPO and Ki67 respectively, were evaluable by histology. IHC biomarker 
expression for tumor samples were scored, in triplicate, on an ordinal intensity scale 
ranging from zero to three where no expression was defined as zero, weak expression 
as one, moderate expression as two, and strong expression as three.  
 
Colon Adenomas 
For evaluation of TSPO expression in early colorectal neoplasia, clinical colon 
adenoma samples were collected from 66 patients and selected to represent a range of 
cancer progression risk determinants; such as polyp size, presence of villous growth 
features, and degree of dysplasia (27). From the initial sampling, TSPO localization was 
measurable in tissue samples from 56 patients. IHC expression was assessed using an 
intensity scale system similar to that employed for TMA analysis. 
 
Tissue Microarrays of Pancreas Cancer and Pre-Malignant Lesions 
Pancreatic cancer TMAs were developed using samples collected from 155 
Vanderbilt Medical Center patients and included normal pancreas, pancreatic 
intraepithelial neoplasia (PanIN), and invasive pancreatic ductal adenocarcinoma 
(PDAC). TSPO IHC expression was assessed using an intensity score-derived 
methodology which defined none/weak expression as one, moderate expression as two, 
and strong expression as three.  
 
[18F]TSPO Imaging Agents 
[18F]VUIIS1008 and [18F]VUIIS8310 were produced using radiosynthesis 
methodologies analogous to those previously published (24,25). For small animal 
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imaging studies, radiochemical specific actives were within range of 170 ± 80 TBq/mmol 
for [18F]VUIIS1008 and as high as 206 TBq/mmol for [18F]VUIIS8310. 
 
Genetically Engineered Mouse Models 
All studies involving small animals were conducted in accordance with both 
federal and institutional guidelines. Genetically engineered mice of colon cancer were 
provided by Robert J. Coffey and colleagues as part of collaborative efforts through 
either Vanderbilt’s GI SPORE program. For colon cancer models, Lrig1-CreERT2/+ mice 
(28) were crossed with Apcfl/+ mice (The Jackson Laboratory) to generate Lrig1-
CreERT2/+;Apcfl/+ mice; similarly to published works (26). Six to eight week old mice were 
injected with 2 mg tamoxifen intraperitoneally for three consecutive days to induce tumor 
formation. Mice were imaged approximately 100 days after injection of tamoxifen and 
then sacrificed.  
Animal models of pancreatic cancer were provided by either Harold L. Moses or 
Robert J. Coffey, and colleagues, as part of collaborative efforts funded by the 
Lustgarten Foundation. Three validated genetically engineered mouse models which 
recapitulated genetic mutations relevant in human pancreatic cancer were generated 
and included: Pft1a-Cre;KrasG12D, Pft1a-Cre;KrasG12D;Trp53R172H/+, and Pft1a-
Cre;KrasG12D;Tgfbr2+/-. Pft1a-Cre;KrasG12D mice progress to higher grade PanIN lesions 
(29) and were chosen to model pre-invasive disease. Advanced disease was modeled 
using and Pft1a-Cre;KrasG12D;Trp53R172H/+ (30) and Pft1a-Cre;KrasG12D;Tgfbr2+/- mice 
(31). Animals possessing single vector (i.e. Kras, Cre, Tgfbr, or p53 only) or wild 
genotypes were utilized as age-matched controls. TSPO PET imaging was evaluated at 
regular intervals that approached the median survival for each model. Pft1a-Cre;KrasG12D 
mice were imaged up to twelve months of age while schedules were compressed for 
Pft1a-Cre;KrasG12D;Trp53R172H/+ and Pft1a-Cre;KrasG12D;Tgfbr2+/- to account for the rapid 
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progression of tumors in these models (30-32). Animals were weighed and sacrificed for 
tissue collection shortly after imaging and white light photographs obtained during tissue 
resection to document relative location, size, and shape of the pancreas. 
 
PET Imaging and Analysis 
Animal handling and preparation for and during PET imaging studies were 
performed analogously to previously described methods (33). Upon study 
commencement, animals were anesthetized using 2% isofluorane anesthesia in 100% 
oxygen at 2 L/min and kept warm throughout the duration of the PET scan. Animals 
were administered 10.4-11.8 MBq of PET imaging agent via intravenous injection and 
imaged using a dedicated Concorde Microsystems Focus 220 microPET scanner 
(Siemens Preclinical Solutions). PET images were acquired as 60 min dynamic data 
sets initiated upon PET agent injection. Images were acquired at designated time points 
which corresponded with the age of the animal.  
PET data were reconstructed using a three-dimensional (3D) ordered subset 
expectation maximization/maximum a posteriori (OSEM3D/MAP) algorithm. Dynamic 
data was binned into twelve 5 s (0-1 min) and fifty-nine 60 s (2-60 min) frames. The 
resulting three-dimensional reconstructions had an x-y voxel size of 0.474 mm and inter-
slice distance of 0.796 mm. For quantification of PET agent uptake, ASIPro software 
(Siemens Preclinical Solutions) was used to manually draw three-dimensional regions of 
interest (ROI) around the entire tumor volume and the measured counts converted to the 
percentage of the injected dose per gram of tissue (%ID/g). To aid in the localization of 
tumor and non-tumor bearing pancreas, high field anatomical magnetic resonance 
images (MRI) were collected either immediately before or after PET imaging 
acquisitions. For initial evaluations, PET and MRI images were manually proportioned 
and overlaid using commercially available image processing software. Additional studies 
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could perform voxel-by-voxel co-registration to enable exact correlations between tracer 
accumulation and anatomy. 
Supplementing the results presented in subsequent sections of this dissertation, a 
large archive of PET imaging data and tissue samples were obtained longitudinally for each 
of the three distinct mouse models of pancreatic cancer (Table 5.1). In summary, over 200 
animals were imaged using TSPO PET agents (including: [18F]VUIIS8310, [18F]VUIIS1008, 
[18F]VUIIS1009a, [18F]VUIIS1009b, and [18F]VUIIS1018a) in Pft1a-Cre;KrasG12D (N = 78), 
Pft1a-Cre;KrasG12D;Tgfbr2+/- (N = 114), and Pft1a-Cre;KrasG12D;Trp53R172H/+ (N = 25) 
animals. Though it is beyond the scope of this work to exhaustively explore the entirety of 
this data archive, further studies could rigorously evaluate the genetic implications of 
pancreatic cancer mutations, TSPO expression, and TSPO PET imaging as a consequence 
of oncogenic regulation and advancement of the disease. 
 Genotype Imaging/Sacrifice 
Pft1a-Cre;KrasG12D Month 1, 3, 6, 9, 12 
Pft1a-Cre;KrasG12D;Trp53R172H/+ Month 1, 2, 3, 4, 5 
Pft1a-Cre;KrasG12D;Tgfbr2+/- Week 4, 6, 8, 10,12 
 
Table 5.1. Summary of animal models of pancreatic cancer and imaging time 
points. Animals were sacrificed at designated time points, shown above for each model, 
shortly following imaging studies. 
 
Plasma Activity and Radiometabolite  
For future determination of the arterial input function (AIF) for TSPO imaging 
agents, arterial blood from catheterized mice (50-80 µL) was collected every 10-15 s for 
the first 90 s following retro-orbital injection of 10.4-11.8 MBq. Subsequent blood 
samples were obtained at 2, 5, 8, 12, 20, 30, 45, and 60 min following administration. 
Whole blood samples were centrifuged at 14,000 rpm for 5 min in order to separate 
arterial plasma from whole blood. Radioactivity in isolated plasma samples (10 µL) using 
a NaI well counter (Capintec). 
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 To determine the extent of arterial radiometabolism of these agents in mice, 100-
200 µL of arterial blood was collected from catheterized mice at 2, 12, 30, 45, and 60 
min immediately following agent administration. In some cases, the 45 min sample was 
eliminated dependent upon the health of the animal at that time. Arterial plasma was 
separated from whole blood by centrifuge. Proteins within isolated plasma (80 µL) were 
denatured and precipitated using a mixture of acetonitrile/water (188 µL, 7/1, v/v) and 
centrifugation at 14,000 rpm for 5 min. The resulting supernatant was spotted on 
silica/glass thin-layer chromatography (TLC) plates (GE Healthcare) and developed in a 
solution of 10% methanol in dichloromethane and scanned using an AR-2000 radio-TLC 
imaging scanner (Bioscan/TriFoil). TLC plates were evaluated by determining the ratio of 
the parent radioligand with respect to the total radioactivity in the plasma. 
 
MR Imaging and Analysis 
For MRI acquisitions, animals were secured in a prone position in a 38 mm inner 
diameter radiofrequency coil and placed in a 7.0T (16 cm bore) Varian small animal 
imaging system. Throughout scanning, animals were warmed to 37°C using heated air 
flow and maintained under anesthesia using 2% isofluorane anesthesia in 100% oxygen 
at 2 L/min. Following localization of the pancreas using multi-slice gradient echo images 
of all three imaging planes, T2-weighted fast-spin echo images were acquired over 22 
slices in the axial and coronal planes using a 25.6 mm x 25.6 mm field of view, 1.0 mm 
slice thickness, and a 256 x 256 data matrix. Additional parameters included a 2 s 
repetition time, 36 ms effective echo time, 9 ms echo spacing, and an echo train length 
of 8. A pneumatic pillow was used to monitor the respiration cycle of the animals, as well 
as trigger the imaging acquisition to collect data at the same time point in the respiration 
cycle, in order to reduce motion-induced imaging artifacts.  
 
120
Immunohistochemistry  
Human colorectal cancer (CRC) TMAs, colon adenomas, and pancreatic cancer 
TMAs were blocked in paraffin, sectioned prior to immunostaining, and stained for TSPO 
expression using incubation of primary antibody (1:1000, Novus NB100-41398) for 10 
min and subsequent incubation with the secondary antibody (Biocare Medical GHP516) 
for an additional 10 min. Additionally, human CRC TMAs were stained for β-catenin 
(1:1000, Transduction Labs 610154) and Ki67 (1:100, Dako M7240) for comparisons 
against TSPO expression. Tissues were evaluated by a group of reviewers familiar with 
TSPO expression patterns in oncology, including two expert GI pathologists (M. Kay 
Washington and Chanjuan Shi). 
For mouse pancreas samples, whole tissue was harvested shortly following 
imaging and fixed in cold (4°C) 4% paraformaldehyde prepared fresh on the day of 
tissue collection. Normal and largely normal tissue samples were fixed for 1-2 h, while 
tumor bearing pancreas samples were fixed between 16-18 h. Duration of fixation was 
lengthened for tumor bearing pancreas samples due to notable increases in tissue 
stromal density; as observed by Masson's trichrome IHC. Following fixation, tissue 
samples were blocked in paraffin and stained for TSPO expression (various dilutions, 
Novus NB100-41398 or NBP1-95674). Tissues were similarly stained using standard 
H&E and Masson’s trichrome methods and reviewed by an expert gastrointestinal 
pathologist (Chanjuan Shi).  
 
Statistical Methods 
Associations among average marker expression for adenoma characteristics 
were estimated using the Pearson’s chi-squared and Wilcoxon signed-rank tests for 
statistical significance. For other determinations of statistical significance, an unpaired 
student t-test was applied to evaluate correlations between TSPO expression in 
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adenoma and PanIN/PDAC lesions compared to normal tissue. Differences were 
assessed within the GraphPad Prism 6.01 software package and considered statistically 
significant if p < 0.05. Unless otherwise indicated, experimental replicates are reported 
as the arithmetic mean ± standard error of the mean.  
 
5.4. Results 
 
Expression of TSPO, β-Catenin, and Ki67 in Human CRC Tumors 
Initially, TSPO, β-catenin, and Ki67 protein expression were evaluated in human 
colorectal tumors to assess the potential utility of TSPO as a biomarker for targeted-
imaging in a clinical setting. From unpublished work previously performed by Eliot T. 
McKinley and colleagues in the Manning group, low TSPO and β-catenin expression 
was observed in non-tumor colon tissue, while expression of both markers were greatly 
increased in grade 1, 2 and 3 tumors, compared to normal tissue. Across 84 tumors, 
high TSPO expression was noted in 64% (54) tumors including 82% (9/11) of grade 1 
tumors (Table 5.2). In contrast, the widely used marker of proliferation, Ki67, showed 
high expression in 48% (43/89) tumors but was high in only 33% (4/12) of grade 1 
tumors.  
 
Figure 5.2. TSPO and β-catenin expression was found elevated in human in 
human CRC tissues. Representative, high-power white-light images (40x) of TSPO and 
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β-catenin histology in grades 1, 2, and 3 human CRC. For the images of TMA staining 
provided, disease grade corresponded to that of each core. 
 
 
Table 5.2. Tabulated TSPO and Ki67 IHC expression from human CRC TMAs as 
related to disease grade. The average score for each biomarker was calculated and 
considered to by high expressing if the average IHC score exceeded 1.34. 
 
Distal Colon Tumors in Lrig1-CreERT2/+;Apcfl/+ Express High Tspo Levels and Elevated 
[18F]VUIIS1008 Accumulation 
Expanding upon previous reports in the Lrig1-CreERT2/+;Apcfl/+ mouse model (26), 
the ability of [18F]VUIIS1008 PET to detect colon tumors in Lrig1-CreERT2/+;Apcfl/+ with 
known tumors was explored along with wild type control mice. Wild type animals 
demonstrated low tracer uptake in the colon (Fig. 5.3A, B). Lrig1-CreERT2/+;Apcfl/+ mice 
with colonoscopy confirmed tumors demonstrated increased focal uptake in the distal 
colon compared to adjacent non-tumor tissue and wild type controls. Similar uptake in 
the lungs, liver, and kidneys was observed across Lrig1-CreERT2/+;Apcfl/+ and wild type 
mice. For tissue acquisition, Lrig1-CreERT2/+;Apcfl/+ mice were sacrificed approximately 
100 days following induction of colorectal tumors via tomoxifen injection. Upon sacrifice, 
gross examination of tissue samples revealed multiple large tumors in the distal colon 
with few, if any, observed in other sections of the large intestine. Histological evaluation 
of fixed colons illustrated robust Tspo and β-catenin expression (Fig. 5.3C) in the tumor 
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polyp, while relatively low expression of both markers in areas of normal colon. Tspo and 
β-catenin IHC showed similar localization in the tumor polyps with greater staining 
intensity observed for regions of low differentiation.  
 
 
Figure 5.3. Elevated Tspo expression was observed in Lrig1-CreERT2/+;Apcfl/+ by 
Tspo PET and IHC. Representative [18F]VUIIS1008 coronal PET images of a 
representative wild type mouse (A) and Lrig1-CreERT2/+;Apcfl/+ mouse (B) ~95 weeks 
after tamoxifen induction. White brackets denote the relative areas defined as distal 
colon during post-processing. Representative high- and low-magnification histological 
images (5x and 20x, respectively) of Tspo and β-catenin localization in colon lesion 
tissue obtained from the genetically engineered Lrig1-CreERT2/+;Apcfl/+ mouse model (C). 
 
TSPO Expression in Human Adenoma 
Exploring TSPO as a biomarker of early CRC, TSPO expression was evaluated 
in 56 human adenoma samples possessing varied physical characteristics. Elevated 
TSPO expression was observed in sites of adenoma growth, compared to normal colon 
tissue within the same sample, for tubular (mean score of 1.12, p < 0.0001), tubulovillous 
(mean score of 1.74, p < 0.0001), and villous (mean score of 1.75, p = 0.004) lesions 
(Fig. 5.4A, B). Interestingly, when TSPO expression was compared against adenoma 
properties (i.e., growth pattern, dysplasia grade, colon location, and size) (Fig. 5.4C) and 
β-catenin localization (Fig. 5.4D), no correlations between groups were observed. TSPO 
expression was found to be consistently elevated in the majority of adenomas. 
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 Figure 5.4. TSPO expression was elevated in sites of human adenoma growth. A 
representative, high- power white-light photo micrograph (10x) of a large (≥ 1 cm), tubular, 
human adenoma illustrates localization of TSPO staining in sites of tubular growth, ‘T’, 
as compared to normal colon tissue, ‘N’, within the same tissue sample (A). IHC scoring 
of tissue sections confirmed TSPO elevation in adenomas possessing either tubular, 
tubullovillous, or villous growth features (B). Values are shown as mean ± SEM and 
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asterisks indicate p < 0.001 compared to normal colon tissue. Normal tissue segments 
corresponding to villous adenomas (N = 4) were all negative for IHC expression.  
Tabulated TSPO IHC expression as compared to adenoma physical characteristics (C) 
or β-catenin expression (D) is provided. Physical characteristics evaluated included: 
growth features (tubular, tubullovillous, and villous), the presence of high or low grade 
dysplasia (HGD and LGD, respectively), colon location, or growth size (small < 1 cm, 
large ≥ 1 cm). Column values are displayed as the percentage of positive samples and 
frequency, N, provided in parenthesis. Test statistic values were derived using the 
Pearson’s chi-squared test of statistical significance. 
 
Expression of TSPO in Early and Advanced Human Pancreatic Cancer 
In addition to human CRC, TSPO levels were evaluated in variety of early 
pancreatic cancer precursor lesions and pancreatic ductile adenocarcinoma compared 
to normal tissue and chronic pancreatitis (CP) (Fig. 5.5). Overall, TSPO expression was 
found to be very low in normal pancreas tissue with modest staining in centroascinar 
cells and normal ducts. Modest staining was also observed within the inflammatory 
infiltrate comprising chronic pancreatitis. Strikingly, both precursor lesions (PanIN1, 
PanIN2, and PanIN3) and invasive disease exhibited robust TSPO staining which 
appeared to primarily stem from ductal tissue. The mean IHC score of normal pancreas 
was approximately 1.025 ± 0.104 with CP tissue being moderately higher as 1.385 ± 
0.136 (p = 0.0382). PanIN lesions were exhibited significantly higher TSPO expression 
with mean scores of 2.500 ± 0.167 (p < 0.0001), 2.000 ± 0.333 (p = 0.0005), and 2.000 ± 
0.548 (p = 0.0074) for PanIN 1-3 lesions, respectively. Similarly, samples of PDAC 
exhibited high expression as noted by mean scores of 2.625 ± 0.183 (p < 0.0001), 2.576 
± 0.156 (p < 0.0001), and 1.923 ± 0.211 (p = 0.0001) for Grades 1-3, respectively.
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 Figure 5.5. TSPO expression was elevated in early and advanced pancreatic 
lesions. Representative TSPO histological sections (40x) of Normal, PanIN 1, PanIN 3, 
and PDAC clinical tissue samples (A). Summary of mean ± SEM TSPO 
immunohistochemistry scoring of human pancreatic cancer TMA (155 patients) by three 
independent reviewers (B). Asterisks indicate statistical significance compared to normal 
pancreas. ‘PanIN’ comprises PanIN1-3 from this patient cohort.    
 
TSPO IHC in Genetically Engineered Mouse Pancreas 
 All excised mouse pancreas tissue samples obtained to-date have been stained 
using H&E and Masson’s Trichrome methodologies (Fig. 5.6). While current TSPO IHC 
methods remain un-optimized in mouse tissues, initial staining in a small cohort of 
samples appears promising and shows elevated protein expression, compared to 
normal, in PanIN lesions and invasive disease. 
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Figure 5.6. TSPO expression in Pft1a-Cre;KrasG12D;Tgfbr2+/- pancreatic lesions. A 
comparison of high-magnitude white-light images (40x) of representative TSPO (Novus 
NB1-95674), H&E, and Masson’s Trichrome in excised tissue obtained from ≥ 12 week 
old mice. Images shown for Pft1a-Cre;KrasG12D;Tgfbr2+/- highlight different regions of a 
single tissue sample which represent high grade PanIN 3 lesions and metastatic PDAC. 
 
TSPO PET Imaging Detects Pancreatic Cancer Precursor Lesions 
Terminal PET imaging studies in three genetically engineered mouse models of 
precursor lesions and advanced pancreatic cancer (Pft1a-Cre;KrasG12D;Tgfbr2+/-, and 
Pft1a-Cre;KrasG12D;Trp53R172H/+) at pre-defined time-points throughout tumor 
development were explored with a variety imaging agents. PET imaging focused 
primarily on utilization of [18F]VUIIS1008 and [18F]VUIIS8310 and was complemented 
with high resolution MRI for voxel-by-voxel cross-platform registration. 
Exploring [18F]VUIIS1008 uptake in pancreatic neoplasia, three-dimensional 
dynamic PET data registered with high-field (7.0T) MRI data were collected. Similar to 
previous experience with this imaging agent in rats (24) and in the Lrig1-CreERT2/+;Apcfl/+ 
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mouse model, accumulation of [18F]VUIIS1008 was observed in kidney and liver as well 
as in myocardium and spleen. Importantly, focal uptake of [18F]VUIIS1008 was also 
observed in tumor pancreas tissue of Pft1a-Cre;KrasG12D;Tgfbr2+/- mice compared to 
normal pancreas (Fig. 5.7A). Tumor morphology and structural histology confirmed the 
presence of predominantly low grade PanIN 1 precursor lesions in 7-8 week old Pft1a-
Cre;KrasG12D;Tgfbr2+/- mice with more advanced disease being found in the tissues of 
11-12 week old mice. Though increases of [18F]VUIIS1008 uptake in tumor tissue only 
approached statistical significance for 11-12 week old mice (p = 0.0466) (Fig. 5.7B), 
which could be an indicator of lesion progression, both age cohorts exhibited trending 
increases in agent accumulation.  
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 Figure 5.7. [18F]VUIIS1008 localization observed in Pft1a-Cre;KrasG12D;Tgfbr2+/-  
pancreatic lesions. Representative [18F]VUIIS1008 transverse and coronal PET, MR, 
and overlaid PET/MR images of 7-8 week old control and KrasG12D;Pft1a-Cre;Tgfbr2+/- 
animals (A). PET images shown are summed frames of the last 20 minutes of a 60 
minute dynamic acquisition. Regions of interest for PET quantification were drawn as 
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indicated by white-dashed areas. High-power images of tissue resections as well as 
H&E and Masson's trichrome histological images (40x) from representative subjects of 
each animal cohort in which low-grade (PanIN1) and high-grade precursor lesions 
(PanIN2 and PanIN3) were observed for 7-8 and 11-12 week old mice, respectively. 
Quantified agent uptake (B), sown as injected dose per gram of tissue or %ID/g, of 
control (7-12 weeks of age) and Pft1a-Cre;KrasG12D;Tgfbr2+/- animals (7-8 weeks and 11-
12 weeks of age). Asterisks indicate statistical significance compared to normal 
pancreas.  
 
In other works, comparative imaging studies between [18F]VUIIS8310 and 
[18F]VUIIS1008 dynamic PET imaging in individual Pft1a-Cre;KrasG12D;Trp53R172H/+ mice 
revealed consistent increases in [18F]VUIIS8310 accumulation, compared to 
[18F]VUIIS1008, as determined using a ratio paired t-test (p = 0.0174) (Fig. 5.8). These 
results coincide with the increased specificity observed for [18F]VUIIS8310 in rat glioma 
reported in previous works (25). 
 
Figure 5.8. [18F]VUIIS8310 accumulation exceeded [18F]VUIIS1008 in Pft1a-
Cre;KrasG12D;Trp53R172H/+ pancreatic lesions. Representative [18F]VUIIS8310 transverse 
and coronal PET, MR, co-registered PET/MR, and white-lite tissue resection mages 
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of a Pft1a-Cre;KrasG12D;Trp53R172H/+ animal (A). Representative [18F]VUIIS1008 PET, MR, 
and co-registered PET/MR images in the same animal imaged 24 – 48 hours prior with 
[18F]VUIIS8310 (B). PET images shown are summed frames of the last 20 minutes of a 
60 minute dynamic acquisition. Regions of interest for PET quantification were drawn as 
indicated by white-dashed areas. Quantified agent uptake, sown as %ID/g, in individual 
animals imaged with both [18F]VUIIS1008 and [18F]VUIIS8310 are also shown (C). 
 
5.5. Discussion 
Due in part to limited detection capabilities during the early developmental 
stages, colorectal cancer is one of the most common causes of cancer related deaths in 
the Western world (34). Colonoscopy dominates the field of colorectal cancer screening 
with high detection success, however potentially cancerous lesions can still be 
overlooked with a range of miss rates reported throughout the literature (35-37). As 
such, there is a clinical need to determine and evaluate biomarkers of early disease 
progression which can serve as targets for novel, non-invasive imaging methodologies 
that may aid in patient screening. As high TSPO expression has been observed in a 
number of cancer types (5-12) and linked to cell processes commonly altered in cancer 
(i.e., apoptosis (38,39) and reactive oxygen species generation (40,41)), TSPO is an 
attractive biomarker for screening by non-invasive imaging. 
In contrast to being primarily associated with advanced tumors, the studies 
reported here revealed TSPO IHC to be elevated in a majority of low-grade colon 
cancers (G1/G2) compared to the gold standard clinical marker of proliferation, Ki67. 
Though a potential weakness of this analysis was the relatively small sampling of Grade 
1 tissue samples, this finding suggests that TSPO may be a more appropriate biomarker 
of early disease than Ki67. Interestingly, increases in TSPO expression trended with 
increases in β-catenin levels, particularly in low grade colon cancers; suggesting a 
possible relationship between TSPO and Wnt pathway activity. Exploring this 
relationship in a well-controlled setting, TSPO levels were evaluated in stem cell-derived 
tumors arising in Lrig1-CreERT2/+;Apcfl/+ mice, in which one copy of Apc is eliminated in 
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Lrig1+ progenitor cells with tamoxifen injection. In these tumors, which recapitulate many 
of the features of advanced human adenomas, Tspo was significantly elevated 
compared to the colons of wild type mice. Similarly to human tumors, Tspo levels in 
Lrig1-CreERT2/+;Apcfl/+ tumors paralleled elevated levels of β-catenin. Taking a focused 
look at early disease, increases in TSPO expression, compared to normal colon, were 
observed in human adenomas and did not correlate with clinical risk factors for cancer; 
such as lesion size (≥ 1 cm), villous growth features, and evidence of high grade 
dysplasia. Interestingly, TSPO and β-catenin expression did not correlate in human 
adenoma tissues and contradicted trends observed in Lrig1-CreERT2/+;Apcfl/+ and 
early/advanced human disease. Through western blot immunoreactivity and real time 
polymerase chain reaction (PCR) studies, no mechanistic dependencies between levels 
of TSPO and/or Wnt pathway regulators were discovered in CRC cell lines in response 
to  TSPO inhibition or Wnt pathway activation (data not shown).  
Wnt signaling activation often follows the loss of APC function, which serves as 
an initiating event for over 90% of CRCs (43-45). While TSPO gene expression has 
been observed in concordance with up-regulation of Wnt in breast cancer (42), this 
relationship is not completely understood. Despite the paralleling trends TSPO and β-
catenin increases observed in all human CRC grade tumors, the absence of correlation 
between these two biomarkers in colon adenomas as well as the difficulty in identifying a 
mechanistic link in vitro makes it difficult to determine a specific relationship between 
TSPO expression and Wnt pathway activity. Given this, it is likely that TSPO expression 
in early and late stage colon cancer is modulated by other cellular and molecular 
determinants that will require further study to comprehend. Regardless, the tendency of 
TSPO expression to correlate with low- and high-risk adenoma, as well as low grade 
disease, reveal this biomarker to be suited for colon adenoma detection and guided 
tumor-resection. Given the previously reported utility of fluorescent TSPO ligands 
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towards detecting colonic tumors (16), TSPO could serve as an essential biomarker for 
the development of chromoendoscopy agents and the improvement of colonoscopy 
screening methodologies. Given these observations, we were encouraged to explore 
TSPO expression in other GI malignancies where PET imaging could play a major role 
in guiding patient care, such as pancreatic cancer. 
 Pancreatic cancer is one of the most aggressive cancers and currently retains an 
overall 5-year survival rate of only 5%. Despite improvements in surgery and oncologic 
treatments, clinical outcome has not improved over the past 25 years. In a recent report 
by Rahib, et. al., pancreatic cancer was projected to become the second leading cause 
of cancer-related deaths by 2030; surpassing breast, prostate, and colorectal cancers 
(43). In this regard, imaging modalities capable of detecting small asymptomatic tumors 
or precursor lesions at a time when the disease is still in a curable stage could be 
imperative towards improving overall outcomes. As current diagnostic imaging methods, 
including [18F]FDG PET (44), are inadequate for detecting early lesions, there remains 
an unmet clinical need to discover and evaluate novel imaging biomarkers which could 
accelerate the development of these technologies. 
 In clinically obtained samples of human pancreatic cancer precursor lesions and 
advanced disease, we evaluated TSPO levels in pancreatic ductile adenocarcinoma and 
a variety of pancreatic cancer precursor lesions. Though increases in TSPO expression 
were found elevated in a majority of PDACs, compared to normal tissue and CP, 
perhaps more importantly, TSPO elevation was comparable for a variety of low-grade, 
pre-malignant lesions. These trends suggest both a role for TSPO in the carcinogenesis 
of pancreatic cancer and the potential suitability of TSPO to serve as a marker of early 
neoplasia in this setting and a target for molecular imaging of human pancreatic cancer. 
Expanding upon these findings, PET imaging studies using two second 
generation TSPO ligands ([18F]VUIIS1008 and [18F]VUIIS8310) revealed localized 
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accumulation in pancreas tissues bearing early and advanced pancreatic neoplasia. 
Interestingly, longitudinal evaluations of [18F]VUIIS1008 accumulation in Pft1a-
Cre;KrasG12D;Tgfbr2+/- lesions revealed only modest differences in uptake between early 
and more advanced disease states. The most substantial deviation between age cohorts 
was perhaps an observed decrease in uptake variance between older disease bearing 
animals; a phenomena which could be accounted for differences in disease growth rates 
between individuals. Interestingly, compartmental analysis of [18F]VUIIS1008 TACs 
obtained from two Pft1a-Cre;KrasG12D;Tgfbr2+/- and two control animals revealed a stark 
difference in k3/k4 ratios between lesion bearing and normal pancreas tissues. This 
pharmacokinetic profile diverges from that previously reported in rat glioma (24) and 
could be a consequence of differences in blood flow properties and tissue densities, as 
supported by the degree of stroma observed in Masson’s Trichrome stained excised tissues. 
As such, de-coupling blood flow properties in these models may be necessary in order to fully 
discern variations in TSPO agent accumulation between lesion bearing and normal 
pancreas. In this regard, we are poised to pursue these investigations in further works as 
arterial plasma activity time courses and corresponding metabolite measurements, data sets 
necessary for calculation of the arterial input function (AIF), have already been obtained. 
Alternatively, improvements in image quality may also be achieved with [18F]VUIIS8310, in 
which preliminary, direct comparisons to [18F]VUIIS1008 revealed higher uptake in pancreatic 
lesions and agreed with the higher specificity observed in rat glioma (25). Conclusively, these 
studies lay the foundation for the eventual translation of TSPO PET into the clinical setting. In 
fact, ongoing studies headed by colleagues within the Manning group are actively 
determining the suitability of TSPO PET for evaluating patients possessing intraductal 
papillary mucinous neoplasia (IPMN); early cystic precursor lesions to PDAC.  
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5.6. Conclusions 
 In contrast to conventional thought, which associates elevated TSPO expression 
with advanced tumors, these studies revealed TSPO expression to be a biomarker of 
early disease progression in GI cancers. This discovery could provide the basis for 
developing non-invasive imaging metrics for the detection and screening of patients 
possessing early colonic and pancreatic precursor lesions. 
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CHAPTER 6 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1. Summary 
Studies presented in this dissertation elucidate a fraction of the molecular 
determents involved in cancer mitochondrial reprogramming that can serve as targets for 
the detection and evaluation of cancer by positron emission tomography (PET) imaging. 
Mitochondrial homeostasis serves as a ‘gate-keeper’ for a cell’s viability and plays key 
regulatory roles in apoptotic cell death, metabolism, reactive oxygen species 
accumulation/defense, and various biosynthetic pathways (1-3). Given the complex 
intricacies between these processes in cancer, molecular imaging agents that can 
illuminate the interplay of mitochondrial pathway reprogramming could have implications 
towards improving cancer detection, drug discovery, predicting patient prognosis, and 
disease staging. 
 Working towards these objectives, Chapter 3 outlined the discovery, 
characterization, and evaluation of a novel PET imaging probe, [18F]FB-VAD-FMK, for in 
vivo caspase activity detection. These studies revealed the VAD-FMK peptide class as a 
promising scaffold for molecular imaging agent development for cell death detection (4). 
In Chapter 4, PET imaging of cancer cell nutrient uptake and metabolism was explored 
as a measure of molecular response to targeted therapy as well as means for reporting 
mutant gene expression in genetically engineered mice. Exploring novel biomarkers in 
early stage disease, Chapter 5 described the relevance of the translocator protein 
(TSPO) expression in early gastrointestinal (GI) neoplasia and explored the potential of 
PET imaging in this setting. Conclusively, the findings reported in this dissertation 
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provide a basis for ultimately translating novel, non-invasive imaging metrics into clinical 
practice.    
 
6.2. Translational Relevance 
Deviations from normal cell death programs tend to promote cell survival and 
are frequently associated with cancer. Many anti-cancer therapies aim to selectively 
induce cell death in tumor cells, however, robust non-invasive biomarkers to assess 
such molecular events are lacking. As such, a PET imaging agent enabling 
quantification of apoptotic cell death could be used to predict individualized responses to 
therapy in patients and accelerate drug development. In the reported work, [18F]FB-VAD-
FMK was shown as a first-generation PET agent that allows non-invasive, targeted 
detection of caspase activation and tumor cell death following effective drug 
treatment. While the probe evaluated here was studied within the context of 
molecularly targeted therapy, the utility of this imaging agent class could be equally 
effective towards assessing response to conventional therapeutics. 
 [18F]FDG PET has emerged as a prominent, non-invasive imaging tool in 
oncology for evaluating cell metabolism reprogramming and subsequent response to 
therapy in patients. However, as discussed primarily in Chapters 2 and 4, many 
molecular determinants involved in cancer cell metabolism remain unreported using 
this approach. Though further studies are required to fully understand the molecular 
implications of [18F]4-F-GLN PET imaging, the work presented in Chapter 4 suggests 
that this imaging metric could serve as an innovative companion diagnostic in drug 
development and personalized medicine. As collaborators through the Vanderbilt GI 
SPORE are developing novel small-molecule inhibitors of KRAS (5), glutamine-
derived PET could provide the basis of an innovative platform to prioritize novel KRAS 
inhibitors in vivo when paired with the Lrig1-CreERT2;Apcfl/fl;KrasG12D mouse model. 
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Ultimately, such investigations could provide quantitative measures of pharmacodynamic 
response in early-phase clinical trials of novel therapies in patients. 
Contrary to conventional thought associating the translocator protein with 
advanced and malignant disease, evidence presented in this dissertation suggests 
TSPO to also be a biomarker of non-malignant neoplasia in gastrointestinal cancers. 
Colorectal cancer is a significant health problem affecting one out of 20 persons in 
western countries and is one of the most common malignant tumors (6). To reduce 
colorectal cancer-related death rates world-wide, improvements to conventional 
screening and detection methodologies are needed. In this setting, TSPO may be a 
target ideally suited for developing novel chromoendoscopy agents. Ultimately, these 
advancements could lead to improved colonoscopy screening methodologies for colon 
adenoma detection and guided polyp-resection. 
The development of imaging metrics that allow for early detection of 
asymptomatic pancreatic tumors or precursor lesions at a time when the disease is at a 
curable stage is imperative to improving clinical outcomes which remains a dismal 5% 
overall 5-year survival rate. The initial evaluations of TSPO imaging in genetically 
engineered mouse models of non-cystic pancreatic intraepithelial neoplasia (PanIN) 
lesions have provided a foundation to explore the relevance of TSPO expression in other 
pancreatic cancer neoplasia, such as cystic intraductal papillary mucinous neoplasms 
(IPMNs). Cystic lesions of the pancreas are common incidental findings in routine cross 
sectional computed tomography (CT) and magnetic resonance imaging (MRI) (7). 
Though their incidence is relatively low (~10%), cystic lesions account for a 
disproportionate number of pancreatic resections (~30%). Due to the limited capability of 
determining the malignant potential of pancreatic cysts, treatment planning and 
predicting overall prognosis if lesions are left untreated can be difficult. Preliminary 
investigations by colleagues in the Manning group have correlated TSPO expression 
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with elevated malignancy potential in IPMNs. Coupled with the preclinical findings in 
PanIN and advanced disease bearing mice reported in this work, these results suggest 
that TSPO PET imaging could enable risk assessment in this setting. 
 
6.3. Considerations for Advancement 
Building upon the observations described in this dissertation, there are many 
avenues in which this work could be advanced. Leveraging VAD-FMK as a scaffold for 
probe development, the structure-activity elements that impart caspase selectivity should 
be revisited using medicinal chemistry and computational modeling in order to improve 
the in vivo pharmacokinetic properties of this probe class. Preclinical evaluations could 
also be expanded to include therapeutic cohorts which model apoptotic cell death 
induced from more conventional chemotherapeutics instead of strictly molecularly 
targeted therapies. Other studies could pursue head-to-head comparisons between 
VAD-FMK derived probes and alternative apoptotic PET imaging agents, such as the 
isatin sulfonamide class of caspase inhibitors (8-10) and [18F]ML-10 (11,12).  However, 
given the resources required to make these imaging agents available through the 
Vanderbilt Radiochemistry CORE facilities, the poor cost-effectiveness of these studies 
may preclude such pursuits. Through continued optimization of this agent class, it may 
be possible to translate a promising candidate to Phase 0 and Phase 1 clinical trials 
within 24-36 months. 
While PET imaging of cell metabolism using radiolabeled analogues of glutamine 
may prove fruitful towards developing companion diagnostics for KRAS-targeted drugs, 
an alternative means of discerning increased glutamine-dependency in cancer cells may 
be to target the sodium dependent, neutral amino acid transporter of glutamine, ASCT2. 
Initial reports supporting the clinical importance of ASCT2 expression have begun to 
emerge and set a precedence for continued work in this field (13,14). Towards this end, 
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future studies could explore the relevance of ASCT2 expression in human colon 
adenoma samples; analogous to similar studies reported in this dissertation for TSPO. 
Such studies would expand upon ASCT2 histological evaluations performed in clinical 
samples of primary and advanced disease, which revealed elevated transporter 
expression in primary tumor tissue compared to metastatic disease (65% vs. 33%) and 
normal tissue (65% vs. 5%). Conclusively, a greater understanding of the clinical 
significance of ASCT2 expression and glutamine transport in early and advanced 
disease will be key for eventual translation of glutamine-related PET imaging into the 
clinic. 
In lung cancer, ASCT2 has been demonstrated to play a key role in glutamine 
transport and controlling cancer cell metabolism, growth, and survival (15). Given this, 
PET agents targeting ASCT2 could meet critical needs in oncology. When screening 
individuals for lung cancer, the discernment of indeterminate pulmonary nodules (IPNs) 
which could be malignant tumors from benign lesions represents an enormous clinical 
challenge. PET agents targeting ASCT2 could improve the accuracy of lung cancer 
diagnosis, reduce the rate of unneeded, invasive surgical procedures, and reduce the 
overall cost of healthcare. ASCT2-specific ligands have already emerged from medicinal 
chemistry and screening efforts from other work in the Manning group. Therefore, 
radiochemical development and rigorous preclinical imaging evaluations of lead 
compounds is needed to advance this work. Once validated, future studies could 
evaluate glutamine-derived PET analogues and ASCT2-selective PET imaging agents in 
head-to-head preclinical imaging comparisons. 
In non-cystic pancreatic precursor lesions, TSPO PET imaging has already 
demonstrated potential for discerning PanIN-bearing pancreas from normal tissue. While 
these initial reports are promising, further investigations could rigorously compare the in 
vivo, pharmacokinetic differences of TSPO PET agents in lesion bearing and normal 
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pancreas tissue using quantitative compartmental modeling analysis. Additionally, future 
studies should more closely look at the genetic implications of pancreatic cancer mutations 
and TSPO expression using optimized histological methodologies. Ongoing studies headed 
by colleagues within the Manning group are actively determining the suitability of TSPO PET 
advancements to patients possessing IPMNs; early cystic precursor lesions to pancreatic 
ductile adenocarcinoma (PDAC). In fact, efforts to prepare a Phase 1 clinical trial and an 
Investigational New Drug (IND) application through the Vanderbilt Medical Center are 
already underway. These proposed trials could explore the utility of PET imaging with 
[18F]VUIIS1008 to stratify pancreatic adenocarcinoma precursor lesions in patients with 
cystic lesions. 
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 APPENDIX 1 
 
MULTISPECTRAL FLUORESCENCE IMAGING TO ASSESS pH IN BIOLOGICAL 
SPECIMENS 
 
A1.1. Introduction 
In normal mammalian tissues, intracellular and extracellular pH (pHi and pHe, 
respectively) are dynamically regulated by a variety of sophisticated mechanisms (1). 
For example, pHi is maintained by both ion exchange mechanisms and cytosolic 
buffering capacity. Within this context, pHi plays important roles in numerous 
physiological processes such as protein synthesis and the regulation of cell cycles. 
Similarly, pHe is controlled by mechanisms that include vascular delivery of physiological 
buffers and removal of lactic acid. While the observed pHe varies across tissues of 
differing origin and function, deviation from normal pHe for a given tissue coincides with a 
variety of important pathological states (e.g. renal failure, ischemia, chronic pulmonary 
disease, cancer) (1). In highly metabolic tissues, such as tumors, reduced pHe can result 
from elevated production and diminished removal of lactic acid combined with the 
reduced capability of tumor-associated vasculature to deliver blood-based pH buffers 
(2). Acidic tumor pHe can impart significant consequences upon cancer cells such as 
increased potential for invasion and likelihood of metastasis, although further elucidation 
of the role of pH within this setting is needed (3). For these reasons, there is 
considerable interest in the development and validation of novel methods capable of 
measuring pH in biological specimens. 
 The majority of tools currently available for measurement of pH in tissues tend to 
be invasive (e.g. microelectrodes) (4) and/or provide relatively modest spatiotemporal 
resolution (e.g. magnetic resonance imaging and magnetic resonance spectroscopy) 
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 (1,5). Limitations of the former techniques result from the inability to determine spatially 
resolved pH gradients without significant damage to the specimen (2). The latter 
methods are non-invasive but are significantly more costly and complicated to 
implement, limiting sample throughput and requiring highly specialized equipment and 
technical expertise (1,5). In contrast, optical imaging techniques offer an attractive 
alternative to the aforementioned techniques as they tend to be non-invasive, 
comparatively simple, analytically sensitive, cost-effective, and rapid (6,7). The most 
common optical methods rely on ratiometric fluorescence approaches. In typical assays 
utilizing exogenous organic dyes like fluorescein as an indicator, a pH-sensitive 
excitation/emission combination is compared to a pH-insensitive reference combination 
(2,8,9). Alternately, pH-sensitive dyes such as members of the seminaphthorhodafluor 
(SNARF) family can be excited at a single wavelength and emission collected at multiple 
wavelengths corresponding to the discrete spectra of protonated (HA) and deprotonated 
(A-) species in solution (10-14). Though ratiometric approaches are routine for solution 
analysis (10) and flow cytometry (11-13), others have elegantly adapted ratiometric 
assays to intravital microscopy and demonstrated imaging of interstitial pH gradients in 
normal and neoplastic tissues in preclinical studies (2). An inherent limitation of these 
approaches, which is mitigated somewhat through emission filtering at the expense of 
signal rejection, is the difficulty of de-convolving multiple fluorescence emissions (i.e. 
signal vs. reference or HA vs. A-) due to spectral overlap. Multispectral fluorescence 
imaging (MSFI) is a well-established technique that is suitable for the separation of 
multiple distinct, yet spectrally overlapping emissions (15). When utilized in preclinical 
animal studies, separation and quantification of multiple fluorescence emissions from 
imaging probes is feasible (16-19). Paired with pH-sensitive fluorochromes that generate 
unique emission spectra for HA and A- species, MSFI potentially represents an ideal 
paradigm for measurement of pH in solution and/or in tissue. Additionally, MSFI systems 
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 suitable for use in preclinical animal studies or in conjunction with microscopy are now 
readily available and relatively inexpensive.  
Here, we evaluated MSFI to quantify extracellular pH (pHe) in dye-perfused, 
surgically-resected tumor specimens with commercially available instrumentation; as 
described in work published in the Journal of Biomedical Optics (20). Utilizing a water-
soluble organic dye with pH-dependent fluorescence emission (SNARF-4F), we used 
standard fluorimetry to quantitatively assess the emission properties of the dye as a 
function of pH. By conducting these studies within the spectroscopic constraints imposed 
by the appropriate imaging filter set supplied with the imaging system, we determined 
that correction of the fluorescence emission of deprotonated dye was necessary for 
accurate determination of pH due to sub-optimal excitation. Subsequently, employing a 
fluorimetry-derived correction factor (CF), MSFI data sets of aqueous dye solutions and 
tissue-like phantoms could be spectrally unmixed to accurately quantify equilibrium 
concentrations of protonated (HA) and deprotonated (A-) dye and thus determine 
solution pH. Finally, we explored the feasibility of MSFI for high-resolution pHe mapping 
of human colorectal cancer (CRC) cell line xenografts.  
In these studies, we illustrate a simple, rapid approach to quantitatively assess 
pHe in dye-perfused biological tissues utilizing MSFI and commercially available 
instrumentation. Using the MSFI-based approach, we demonstrate the feasibility of 
mapping pHe gradients pertaining to the protonation and deprotonation equilibrium of the 
pH-sensitive dye SNARF-4F in tissue specimens. It is anticipated that this methodology 
will provide valuable information regarding ex vivo tumor pHe and will ultimately aid in the 
study of the relationship between tumors and tumor microenvironments, as well as the 
effect of therapeutic regimens upon tumor pHe. 
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 A1.2. Materials and Methods 
 
Chemicals 
All chemicals, reagents and solvents were purchased from indicated suppliers 
and used without further purification: SNARF-4F 5-(and-6)-carboxylic acid (Invitrogen; 
Carlsbad, CA), ACS grade hydrochloric acid (HCl) (EMD; Gibbstown, NJ), ACS grade 
sodium hydroxide (NaOH) (Fisher Scientific; Pittsburgh, PA), laboratory grade gelatin 
from porcine skin, type A (Sigma Aldrich; Milwaukee, WI), bovine hemoglobin (Sigma 
Aldrich; Milwaukee, WI), and intralipid 20% (Fresenius Kabi AB). 
 
Aqueous pH Solutions 
Solutions ranging from pH 3-10 in 0.5 pH increments were prepared from a 1.0 
µM aqueous stock solution of SNARF-4F separated into 10 mL aliquots. The pH of each 
aliquot was adjusted via micro-additions of concentrated HCl and/or NaOH. Solution pH 
adjustments were monitored with a calibrated pH meter (MP220 pH Meter, Mettler 
Toledo) under positive nitrogen pressure with vigorous stirring. Over the course of the 
experiment, the solutions were wrapped in aluminum foil to minimize light exposure. 
Spectroscopic analysis and/or MSFI of pH-adjusted samples were performed 
immediately following pH adjustment and stabilization. 
 
Preparation of Biological Phantoms 
To validate the ability of MSFI to measure pH in biological environments, tissue-
like phantoms with the approximate photon scattering and absorption properties of 
biological tissues were prepared (21). First, a 10% gelatin solution was prepared by 
adding gelatin to heated deionized water (40-50 °C) with constant stirring. The solution 
was then cooled to 30-40 °C, at which the desired amounts of bovine hemoglobin and 
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 intralipid were added resulting in a 42.5 µM hemoglobin and 1% intralipid phantom 
mixture. Three parts buffered dye solution [acetate buffer (pH = 4.3, 5.6), phosphate 
buffer (pH = 6.2, 7.3), tris-HCl buffer (pH = 8.4), and carbonate buffer (pH = 9.5)] and 
one part phantom mixture were combined and dispensed into a chilled well plate and 
refrigerated at 4 °C until solid.  
 
Fluorimetry 
The spectroscopic characteristics of pH adjusted aqueous SNARF-4F solutions 
were investigated using a Photon Technology International QuantaMasterTM 50 
fluorimeter (Birmingham, NJ) and a standard, 1 cm path length quartz cuvette (NSG 
Precision Cells 517BES10). An excitation wavelength (λex) of 523 nm was used for 
single wavelength studies while an excitation range of 425-650 nm in increments of 25 
nm was used for multiple wavelength studies. Emission scans were collected every 
nanometer over the emission wavelength (λem) range of 400-800 nm with an integration 
time of 0.1 s and a shutter width of 1.5 nm. Three acquisitions were averaged for each 
λex. Excitation Emission Matrices of fluorescence emission as a function of excitation 
were generated in MATLAB (The MathWorks, Inc.; Natick, MA). Fluorimetry data were 
used in conjunction with Eq. A1.1 to generate a correction factor (CF) that was later 
applied to the A- fluorescence intensity obtained in MSFI studies.  
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Equation A1.1. Calculation of Correction Factor (CF). Here, F refers to the 
fluorescence intensity at 653 nm when excited at 525 nm (λ1) or 575 nm (λ2).   
 
MSFI – Aqueous Solutions 
Aqueous SNARF-4F solutions ranging in pH from 4-8 in increments of 
approximately 1.0 pH unit were imaged using the Maestro™ Q FLEX In-Vivo Imaging 
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 System from CRi, Inc. (Woburn, MA). Solutions were imaged in 1.5 mL micro-centrifuge 
tubes that were pre-rinsed with pH-adjusted solution prior to addition of dye solution. All 
images were obtained using Maestro Q Filter Set B, which features a band-pass 
excitation filter with transmission centered at 525 nm (full width at half max. = 47 nm) 
and a long-pass emission filter with 560 nm cut in. A spectral library was generated that 
included emission spectra for fully protonated /deprotonated dye species as well as 
autofluorescence from the micro-centrifuge tube plastic. This library was used 
throughout the solution phase experiments for spectral unmixing. Quantitative analysis 
of the autofluorescence signal arising from the micro-centrifuge tubes demonstrated that 
> 95% of the autofluorescence could be removed by spectral unmixing (data not shown). 
Unmixed dye fluorescence intensity data were obtained from a manually drawn region of 
interest (ROI) shaped and sized to include the central region of the micro-centrifuge 
tube. The data were fitted to a non-linear sigmoidal model and plotted against the 
analytically measured solution pH. Un-corrected and corrected SNARF-4F pKa values 
were calculated. 
 
MSFI – Biological Phantoms 
Using a protocol similar to that used for the solution phase experiments, dye 
containing tissue-like phantoms ranging in pH from 4-9.5 were imaged with the Maestro 
Q system. Spectral unmixing was achieved by applying the previously derived solution 
phase spectral library with the inclusion of autofluorescence from tissue-like phantom 
controls. Unmixed fluorescence intensity data were obtained from an ellipse-like 
manually drawn ROI sized to include the entirety of a single well. The data were fit to a 
non-linear sigmoidal model and plotted against the analytically measured solution pH. 
Un-corrected and corrected SNARF-4F pKa values were calculated. 
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 Ex-Vivo pH Mapping of Human Xenograft Tumor Tissue  
All studies involving the use of animal models were conducted in accordance 
with Vanderbilt University Institutional Animal Care and Use Committee and applicable 
federal guidelines. To generate the human colorectal cancer (CRC) model used for 
tumor imaging, 200,000 DiFi human CRC cells were subcutaneously injected on the left 
flank of athymic nude mice, as previously described.17 Experiments were conducted 2-3 
weeks post inoculation, when tumors reached ~250 mm3. For pHe mapping, 1.0 nmol of 
SNARF-4F in 200 µL of saline was administered to xenograft-bearing mice via 
intravenous injection under inhalation of anesthesia (2% isofluorane). Following dye 
administration, mice were allowed to briefly recover from anesthesia and given access to 
food and water ad libitum during a fifteen-minute uptake period. Mice were then 
sacrificed and tumor tissue harvested. Immediately following collection (< 2 min), tumors 
were macro-dissected into two equivalent hemispheres, positioned with the intratumoral 
facets facing toward the camera, and imaged using the Maestro Q system. Fluorescence 
images were collected from 560-850 nm and unmixed using the previously described 
spectral library (excluding autofluorescence from plastic). Unmixed fluorescence 
intensity data were obtained from a manually drawn ROI (~2% of the total area) that was 
applied to multiple areas of the tumor in order to ascertain pH heterogeneity. A gradient 
pHe map was generated in MATLAB from each MSFI unmixed image using Eq. A1.2. 
(2)          log 







HA
AF
a
S
SC
pKpH  
 Equation A1.2. Calculation of pH by MSFI. Here, pKa is that of the dye while SA- and 
SHA correspond to the observed fluorescence intensity of each species, respectively.  
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 A1.3. Results and Discussion 
 
Spectroscopy 
The fluorescence spectroscopy of the SNARF family of organic dyes is 
dependent upon the protonation state of the compound. Typically, the protonated and 
deprotonated states of the compound yield distinct, yet overlapping, emission peaks that 
may be separated by as much as 60 nm. For these studies, aimed at measuring pH in 
tissue, an important determinant was selection of a dye possessing a pKa near the 
anticipated pH of the specimens being assayed. These studies utilized SNARF-4F, with 
a known pKa of 6.4. Thus, at pH values well below its pKa, the dye exists predominately 
in a protonated state and exhibits fluorescence emission at 580 nm when excited at 523 
nm (Fig. A1.1). SNARF-4F exists in a predominately deprotonated state at pH values 
well above the pKa and exhibits fluorescence emission at 640 nm when excited at 523 
nm (Fig. A1.1). Importantly, across the physiologically relevant pH range of 5 to 7, both 
HA and A- species exist in equilibrium. Due to the unique emission spectroscopy of the 
HA and A- species, spectral unmixing and quantitative measurement of each species 
facilitate determination of pH in accordance with a modified Henderson-Hasselbalch 
equation. 
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Figure A1.1. pH dependency of SNARF-4F fluorescence emission. Combined 
fluorescence emission spectra (ex. 523 nm) of aqueous SNARF-4F samples ranging in 
pH from approximately 4-7. The emission spectrum of pH 3.9 is representative of 
subsequently decreasing pH values while the emission spectrum of pH 7.2 is 
representative of subsequently increasing pH values (20). 
 
 Conceptually, the simplest pH imaging study coupling SNARF-4F and the 
Maestro system would feature utilization of a single excitation band and simultaneous 
collection and spectral unmixing of both the HA and A- emissions. However, an 
important assumption of this approach is the requirement for equivalent excitation and 
collection of both the HA and A- species, which may be thought of as two separate 
fluorophores in this experiment. Since the emission of the A- species is significantly red-
shifted (ca. 60 nm) from the HA species, it follows that equivalent excitation of each 
species using a common excitation wavelength is unlikely. Therefore, we explored the 
relationships between excitation wavelength, pH, and the resulting emission 
spectroscopy of both the HA and A- SNARF-4F species using standard fluorimetry. We 
found that the HA species exhibited maximum fluorescence emission at an excitation 
wavelength of approximately 525 nm (emission = 590 nm), while the A- species exhibited 
maximum fluorescence emission at an excitation wavelength of approximately 575 nm 
(emission = 650 nm) (Fig. A1.2). Optimization of the imaging assay to utilize only a 
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 single filter set could be accomplished using a single filter set included with the Maestro 
system (denoted as “B”, band-pass ex. 525/25 nm, long-pass em. 560 nm, Fig. A1.3). 
This filter set was ideally suited for exciting the HA species but was sub-optimal for 
exciting the A- species. We found the long-pass emission filter contained within the “B” 
filter set was suitable for simultaneous collection of both the HA and A- emission, with 
minor attenuation (~ 5 %) of the HA emission from 530-560 nm.  
 
Figure A1.2. Selection of excitation and emission filter pairing for SNARF-4F 
imaging. Excitation emission matrices of SNARF-4F fluorescence emission as a 
function of excitation wavelength for HA (A, pH 4.5) and A- (B, pH 10.0). Red ticks 
located along the excitation axis show the approximate band pass transmission of the 
Maestro Q “B” excitation filter, while the red tick on the emission axis shows the cut on 
point for the longpass emission filter. The excitation-emission coordinates for the point at 
which maximum fluorescence emission intensity is achieved are (525, 587) for (A) and 
(575, 653) for (B) (20).  
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Figure A1.3. Spectroscopic characteristics of Maestro Q imaging filters. 
Transmission spectrum for (A) bandpass excitation filter and (B) longpass emission filter 
supplied as Filter Set “B” with the Maestro Q imaging system (20). 
 
 To compensate for the sub-optimal excitation of the A- species, a correction 
factor (CF = 2.1 ± 0.03) was derived from Eq. A1.1. This equation defines the ratio of the 
observed emission intensity at 650 nm for the A- species when excited at 525 nm (λ1), 
the excitation wavelength in the Maestro, compared to the emission intensity at 650 nm 
when optimally excited at 575 nm (λ2). 
 
MSFI 
To validate CF for use in MSFI assays, aqueous SNARF-4F solutions with pH 
values between 4 and 8 and tissue-like phantoms with pH values between 4 and 9.5 
were imaged using filter set “B” and spectrally unmixed using the previously established 
spectral library. Following spectral unmixing, manual ROIs were drawn on unmixed 
images corresponding to the HA and A- species (Fig. A1.4A, B). Accordingly, the 
measured fluorescence intensities for each species were used to calculate the observed, 
uncorrected pKa for the dye using a modified Henderson-Hasselbalch equation, 
substituting the fluorescence emission intensity for each species in place of HA and A- 
concentration. Prior to correction of the A- intensity, fitting the unmixed HA and A- 
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 intensities to a sigmoidal curve and plotting versus pH (Fig. A1.4C, D) resulted in 
intersection between the two curves (by definition, pKa) at 6.7 ± 0.3 for both the solution 
phase and biological phantom data (Table A1.1). Though these observed values are 
slightly higher than the known pKa of 6.4, application of the fluorimetry determined CF to 
the A- intensities of all data resulted in indistinguishable calculated pKa values of 
approximately 6.4 (Table A1.1) using Eq. A1.2; therefore validating CF derived from the 
fluorimetry experiments in multiple mediums. 
 
Figure A1.4. MSFI successfully detected changes in pH dependent fluorescence. 
Multi-spectral fluorescence imaging of aqueous SNARF-4F solutions ranging in pH from 
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 approximately 4-8 (A) and dye containing tissue-like phantoms ranging in pH from 
approximately 4-9.5 (B). Spectrally-mixed, pseudocolor composite images are shown in 
(Ai, Bi). Spectrally-mixed composite images were unmixed to visualize emission from 
the HA (Aii, Bii) and A- (Aiii, Biii) species. Pseudocolor, unmixed composite images are 
shown in (Aiv, Biv), where the HA fluorescence emission is pseudocolorized in green 
and the A- fluorescence emission is pseudocolorized in red. Quantified average photon 
intensities from (A) are given in (C) while intensities from (B) are given in (D). HA (red) 
and A- (blue) species are displayed across pH as assessed by MSFI. Non-linear fits of 
MSFI data (solid colored lines) result in goodness of fits of 7 (C) and 33 (D) degrees of 
freedom. Observed pKa values (Table A1.1), the pH at which [HA] = [A-], are noted by 
solid black lines. Correction of the A- intensity using Cf at each point (dotted blue line) 
results in calculated pKa values (noted by dashed black lines) that are equivalent within 
one standard deviation of one another (Table A1.1) (20). 
 
Medium Observed pKa Calculated pKa 
Solution 6.7 ± 0.3 6.4 ± 0.2  
Phantom 6.7 ± 0.3 6.3 ± 0.4  
 
Table A1.1. MSFI determined pKa values. Observed (uncorrected) and calculated 
(corrected) pKa values for different SNARF-4F containing mediums (20). 
 
Ex-vivo pH mapping of xenograft tumors 
We next explored utilizing the MSFI approach for spatially resolved determination 
of pHe in freshly resected xenograft tumor tissue. Using the Maestro Q system we 
observed perfusion of SNARF-4F throughout the entire tumor, though accumulation 
tended to be heterogeneous (Fig. A1.5A). Increased levels of accumulation were noted 
in tissues exhibiting elevated necrosis. Non-uniform accumulation of dye in disorganized 
tissue such as tumors is not unexpected. It is therefore important to emphasize that the 
ratiometric nature of the proposed MSFI approach renders pH measurement inherently 
concentration independent with respect to the dye, provided that detectable quantities 
are present within tissues of interest. Applying the previously established spectral library 
for the HA and A- species to the unmixed data, fluorescence emission of the HA (Fig. 
A1.5B) and A- (Fig. A1.5C) species could be visualized within tumor tissue. To quantify 
intratumoral pHe, the fluorescence intensity for the HA and A- species was measured by 
manual ROI analysis (Fig. A1.5D). The measured intensity of the A- species was 
160
 corrected using CF, and tumor pHe for each ROI was calculated using Eq. A1.2 (Table 
A1.2). We found that pHe within the tumor was heterogeneous with a mean pH of 6.9 ± 
0.1. These observations are in agreement with those reported by previous studies where 
pHe was assessed across multiple tumor types by alternative techniques.23-26 Expanding 
upon this, to generate a high-resolution pH map of tumor tissue, the HA and corrected A- 
pixel intensities were imported into MATLAB where the pH was calculated, fit to a color 
bar, and displayed across each image pixel (Fig. A1.5E). Although much of the tumor 
could be considered acidic with respect to normal tissue, we observed that tumor 
regions exhibiting the lowest pH tended to coincide with the highest degrees of necrosis 
in this model. These results suggest the feasibility of MFSI for ex vivo measurement of 
pHe in preclinical tissue specimens. 
 
Figure A1.5. MSFI evaluation of heterogeneous tumor tissue pH. MSFI of dye-
perfused human CRC cell line xenograft. Spectrally-mixed pseudocolor fluorescence 
image (A). Spectrally-unmixed images show HA (B) and A- (C) fluorescence emission. 
Map illustrating the selected ROI placement for pH measurements performed in tumor 
regions corresponding to the values shown in Table A1.2 (D). Pixel-by-pixel pHe map 
generated using the HA fluorescence emission and the corrected A- emission (E). 
Colorbar corresponds to the calculated pH in each pixel (20).  
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ROI 
A- Photon 
Intensity 
Corrected A- Photon 
Intensity 
HA Photon 
Intensity log(A-/HA) 
Estimated 
pHe 
1 454 937 371 0.4 6.8 
2 141 290 99 0.5 6.9 
3 132 272 98 0.5 6.9 
4 139 286 67 0.6 7.0 
5 141 290 98 0.5 6.9 
6 247 509 162 0.5 6.9 
7 190 392 70 0.8 7.2 
pHe: range = 6.80-7.2, mean = 6.9 ± 0.1 
 
Table A1.2. Quantification of tissue pH values using MSFI. MSFI-measured photon 
intensities and calculated pH values for DiFi CRC xenograft tumor. Location for each 
ROI is shown in Fig. A1.5D (20).  
 
A1.4. Conclusions 
We report a novel method for simple, rapid measurement of pHe in biological 
tissue that utilizes MSFI. Given the ability to assess pH in a spatially resolved manner, 
this technique could be employed in preclinical research to further elucidate the 
relationship(s) between the pH of a tumor and its surrounding microenvironment, as well 
as the role of pH in other preclinical models of disease. We envision that this approach 
could be most useful when utilized in conjunction with other complementary molecular 
techniques such as immunohistochemistry and deployed immediately following tissue 
collection and prior to freezing or fixation. 
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 APPENDIX 2 
 
EVALUATION OF OPTICAL IMAGING TOOLS FOR PRECLINICAL CANCER 
RESEARCH 
 
A2.1. Introduction 
The scope of these studies was to carry out a broad survey of the in vivo 
performance of optical molecular imaging probes and instrumentation relevant to 
preclinical cancer imaging. The in vivo imaging characteristics of common, commercially 
available optical molecular imaging probes from multiple, predominantly major vendors, 
as of 2011, were evaluated in four optical imaging platforms. Biodistribution, 
approximate pharmacokinetics (PK), and tissue uptake were measured at multiple time-
points using common preclinical mouse models of human cancer. Probe 
pharmacokinetics were estimated from optical imaging results and do not account for 
metabolism.  
Optical imaging instruments evaluated in this study included the: 
Xenogen/IVIS200 (Fig. A2.1), Li-Cor Pearl (Fig. A2.2), CRI Maestro (Fig. A2.3), and 
VisEn FMT2500 (Fig. A2.4). All in vivo studies were conducted within the Vanderbilt 
University of Imaging Science (VUIIS) in Nashville, TN, under the authorization of the 
Vanderbilt University Institutional Animal Care and Use Committee (IACUC). These 
imaging systems differ in cost, complexity of hardware and data, thoughput, and imaging 
geometry but essentially aim to provide the end user with similar in vivo information. 
Quantitative and qualitative determinants were used to compare instrumentation 
included measurable contrast, experimental thoughput, and instrument and software 
usability and reliability. Though this study was performed using preclinical models of 
colorectal cancer (CRC), we anticipate that conclusions drawn from this study may be 
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 useful towards guiding the future design and development of molecular probes and 
imaging hardware for preclinical optical imaging research. 
 
Figure A2.1. Xenogen/IVIS200 imaging system. Images, hardware schematic, 
available filter sets used for these studies. Instrument schematics and 
excitation/emission specs were obtained from the corresponding product literature. 
 
 
Figure A2.2. Li-Cor Pearl imaging system. Images, hardware schematic, and laser 
wavelengths used for these studies. Instrument schematics and specs were obtained 
from the corresponding product literature. 
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Figure A2.3. CRI Maestro imaging system. Images, hardware schematic, and 
available filter sets used for these studies. Instrument schematics and 
excitation/emission filter specs were obtained from the corresponding product literature. 
 
 
Figure A2.4. VisEn FMT2500 imaging system. Images, hardware schematic, and 
available filter sets used for these studies. Instrument schematics and 
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 excitation/emission filter specs were obtained from the corresponding product literature. 
 
A2.2. Materials and Methods 
 
Small Animal Xenografts 
All studies involving the use of animal models were conducted in accordance 
with Vanderbilt University Institutional Animal Care and Use Committee and applicable 
federal guidelines. The DiFi model, a model of human colorectal cancer (CRC) with 
which we have much familiarity, was the primary model used to compare imaging probes 
in vivo. DiFi cells were isolated from a colorectal cancer patient with familial 
adenomatous polyposis and express very high levels of epidermal growth factor receptor 
(EGFR) (2 x 106 to 2 x 106 receptors/cell) (1,2). DiFi xenografts were generated in 
athymic nude mice following subcutaneous injection of 2x106 to 4x106 cells on the right 
flank. As expected, tumors were visible within three to four weeks post-inoculation. In 
vivo optical imaging experiments were conducted when tumors reached 100 – 200 mm3.  
In some cases imaging probes were evaluated pre- and post- treatment with a 
chemotherapeutic agent. Probes evaluated under these conditions included 2-DG and 
EGF reagents. For treatment, we utilized cetuximab (C225, Erbitux) (20mg/kg) 
administered as monotherapy by intraperitoneal (i.p.) injection once every three days for 
seven days (maximum of three total injections). The monoclonal antibody cetuximab 
binds the ectodomain of the EGF receptor, and blocks ligand engagement and receptor 
activation, causing tumor size reduction, increased cellular apoptosis, and decreased 
cellular proliferation in DiFi xenografts. DiFi cells express wild-type KRAS and have 
EGFR amplification and are therefore sensitive to C225 treatment (2). In conjunction 
with treatment, vehicle (control) mice were prepared using i.p. saline injection. Treated 
and vehicle mice were administered optical probe after the third C225 administration. 
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Bone Metastasis Mouse Model of Breast Cancer 
All studies involving the use of animal models were conducted in accordance 
with Vanderbilt University Institutional Animal Care and Use Committee and applicable 
federal guidelines. Optical imaging experiments investigating probes which target bone 
growth were performed using mice previously inoculated with GFP-labeled MDA-MB-231 
tumor cells, a mouse model of bone metastasis of human breast cancer (BC). This 
model was prepared in athymic nude mice by infusion of MDA-MB-231 cells into the left 
ventricle of the heart (3,4). Prior to optical imaging with fluorescent probes, osteolytic 
lesions were confirmed by x-ray and GFP fluorescence imaging and subsequently used 
for probe evaluation studies. 
 
Animal Diet 
At least 24 h prior optical imaging, mice were transferred to clean cages and 
provided access to Harlan 2920X low fluorescence chow to reduce detectable 
autofluorescence. The utility of low fluorescence chow is observed when imaged in 
conjunction with normal chow across the IVIS, Pearl, and Maestro imaging systems 
using excitation/emission settings in the 650-750 nm range (Fig. A2.5). A 5-fold increase 
in detectable fluorescence for normal chow compared to Harlan 2920X low fluorescence 
chow was measured across the IVIS, Pearl, and Maestro. The difference in measurable 
counts between normal and low fluorescence chow likely stemmed from alfalfa meal. 
Chlorophyll in alfalfa meal can be detectable in both the deep red and near infrared 
spectrum, thus increasing autofluorescence in the abdominal region of an animal. We 
have determined in previous studies performed by our group that a minimum of 24 h on 
a low fluorescence diet is needed to reduce autofluorescence to levels of minimal 
attenuation. 
169
  
Figure A2.5. Overview of imaging protocols used for subsequent optical imaging 
studies. Imaging studies were carried out on all instruments immediately and 24 h post 
injection. Additional one and six h imaging time points were implemented in studies 
utilizing the Pearl imaging system. A comparison of low fluorescence animal chow 
(Harlan 2920X) and normal chow across the IVIS (Cy5.5 filter), Pearl (700 channel), and 
Maestro (DR filter) is also provided. Photon counts/area were normalized so the 
magnitude measured for normal chow across instruments is 10. Probe concentrations, 
as recommended by the product literature, was administered via intravenous injection. 
 
In Vivo Optical Imaging Protocol 
Data acquisition for all time points and imaging platforms was acquired while 
animals were under anesthesia (2% isoflurane in O2 at 2 L/min). Animals were imaged 
on each platform prior probe injection to establish baseline. Optical probes were 
administered via intravenous retro-orbital injection using amounts recommended by 
associated product literature (Table A2.1). Complete dynamic imaging profiles from 0-24 
h were collected at regular intervals (1, 6, and 24 h post-injection (p.i.)) using the Pearl 
system. Further acquisitions were collected in the IVIS, Maestro, and FMT at 24 h p.i. 
When collecting data across multiple platforms, data was acquired for each mouse ± 60 
min. across all instruments. 
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    Systems and Filter/Channel Settings 
Probes Probes 
Injected 
(nmol) 
Pearl Maestro IVIS FMT (ex./em.) 
LI-COR IRDye 800cw 2-DG 10 800 NIR ICG 790/805+ 
 
IRDye 800cw RGD 1 800 NIR ICG 790/805+ 
 
IRDye 800cw PEG 1 800 NIR ICG 790/805+ 
 
IRDye 800cw EGF 2 800 NIR ICG 790/805+ 
 
IRDye 750 RGD 1 800 DR ICG 745/770-800 
 
IRDye 680rd RGD 2 700 DR Cy5.5 670/690-740 
 
IRDye 680rd EGF 2 700 DR Cy5.5 670/690-740 
 
IRDye 680 Bone Tag 4 700 DR Cy5.5 670/690-740 
  
 
    
Caliper XenoLight 2-DG-750 10 800 DR ICG 745/770-800 
 
XenoLight Integrin probe 
750 
2 800 DR ICG 745/770-800 
 
XenoLight Bone Probe 
680 
2 700 DR Cy5.5 670/690-740 
  
 
    
Perkin 
Elmer 
OsteoSense 800 2 800 NIR ICG 790/805+ nm 
 
AngioSense 750 2 800 DR ICG 745/770-800 
 
ProSense 750 2 800 DR ICG 745/770-800 
 
IntegriSense 750 2 800 DR ICG 745/770-800 
 
OsteoSense 750 2 800 DR ICG 745/770-800 
 
ProSense 680 2 700 DR Cy5.5 670/690-740 
 
IntegriSense 680 2 700 DR Cy5.5 670/690-740 
  
 
    
 
Table A2.1. Comprehensive listing of utilized optical probes and imaging systems. 
Black text identifies probes studied using DiFi CRC xenografts while red text identifies 
probes studied using the MDA-231 BC model. Chosen filter settings/excitation-emission 
channels are provided for each instrument and probe. Settings were selected and 
optimized based on the spectroscopy of the dyes and the excitation/emission 
parameters of the chosen instrument.  
 
Imaging and Optical Settings 
For single animal field of view (F.O.V.), data sets were acquired on the Pearl 
using default settings across all three channels (700 nm, 800 nm, and white light). 
Maestro data sets for single animal F.O.V. were acquired using the #2 stage and light 
settings, 500 ms integration, and either the Blue (B) (for GFP imaging), Deep Red (DR), 
or Near InfraRed (NIR) excitation/emission filter settings (ex. 445-490/em. 515 nm 
longpass; ex. 671-705/em. 750 nm longpass; and ex. 710-760/em. 800 nm longpass 
respectively), as appropriate for the spectroscopy of the chosen probe. IVIS data sets for 
multiple animal F.O.V. were acquired using stage setting D, 5 s integration, F/stop 2, and 
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 either the Cy5.5 or ICG excitation/emission filter settings (ex. 615-665/em. 695-770 nm 
and ex. 710-760/em. 810-875 nm respectively). FMT data sets for single animal F.O.V. 
were acquired using one of four laser channels (ex. 635/em. 650-670 nm, ex. 670/em. 
690-740 nm, ex. 745/em. 770-800 nm, and ex. 790/em. 805+ nm) after calibrating using 
a 1 nM/mL standard solution of optical probe. Filter setting choices for data sets are 
indicated in Table A2.1. 
 
Data Quantification 
Imaging data was processed using the Pearl Impulse software (v2.0.16), IVIS 
Living Image software (v4.2), Maestro Imaging software (v3.0.1), and FMT True Quant 
3D software (v3.0). For the DiFi xenograft model, data analysis was performed by 
manually drawing 2D ellipse regions of interest (roi’s) over the tumor region and the hind 
limb (defined as ‘normal’ tissue) and used to measure fluorescence (photon counts) per 
pixel (area). Tumor regions were identified using corresponding white light reflectance 
images. Using the Pearl fluorescence data acquired at multiple time points, time activity 
curves (TACs) were developed and used to assess approximate probe 
pharmacokinetics (PK). Using fluorescence data acquired across all instruments at the 
24 h time point, tumor-to-normal (T/N) ratios were developed and used to assess 
contrast.  
Maestro image sets were spectrally unmixed using spectral libraries developed 
specifically for the spectroscopy of each probe and the autofluorescence measured for 
each animal prior to probe injection. This means of analysis was based on previously 
established methodologies.5 Spectral unmixing makes it possible to achieve high levels 
of image contrast (T/N) that may not be readily achieved using other platforms. As such, 
the T/N ratios measured for Maestro data sets are likely to be higher than that measured 
for other instruments based largely on data analysis capabilities and not necessarily 
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 indicative of the absolute sensitivity of the instrument. As an optical tomography system, 
the imaging data obtained using the FMT can provide a 3D map of probe uptake 
heterogeneity that may not be as discernable when using reflectance imaging 
techniques. 
 
Voxel-Wise Correlative Analysis 
This experiment was designed to correlate optical 2-DG tissue uptake with 18F-
fluorodeoxyglucose ([18F]FDG) on a voxel-wise basis across multiple imaging modalities 
to obtain visualization of probe characteristics. Following in vivo optical imaging, DiFi 
tumor bearing animals were intravenously injected with 700 – 800 µCi of [18F]FDG by 
retro-orbital injection. Animals were fasted at least 7 h prior administration of [18F]FDG. 
After an uptake period of at least one hour, animals were sacrificed by cervical 
dislocation, flash frozen in a 50 mL conical tube using liquid N2, and subsequently 
imaged using a microCAT II (Imtek) to obtain whole body CT images. Approximately 1 
cm of the tumor bearing mid-section was isolated by band saw and mounted on a 
cryomicrotome. Sequential white light images were taken every 120 μm using a Canon 
EOS Rebel XS Digital SLR Camera. Additionally, 40 μm thick tissue sections were 
preserved for autoradiography (Biospace Lab) ([18F]FDG localization), Odyssey (LiCor) 
(NIR optical probe localization), and histopathological analysis. Serial images were 
concatenated and aligned to form a single digital image volume of the sample for each 
data set (i.e., white light, NIR, and autoradiography). These image volumes were co-
registered to CT images, allowing visualization and correlation of these imaging metrics. 
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 A2.3. Results and Discussion 
 
LiCor RGD Optical Probes 
This class of imaging probe utilizes the tripeptide RGD (Arg-Gly-Asp) which binds 
to integrin receptors such as integrin αvβ3. RGD probes conjugated with IRDyes 680rd, 
750, and 800cw were utilized using recommended doses (2 nmol, 1 nmol, and 1 nmol 
respectively). A comparison of Pearl images and TACs for all three RGD probes showed 
the fastest clearance was for RGD-680rd (t1/2 = 13.4 hr) (Fig. A2.6). RGD-750 and -
800cw showed slower clearance rates at t1/2 = 20.4 hr and t1/2 > 24 hr respectively 
(Table A2.2). Further comparison of these probes across platforms showed comparable 
detection of probe uptake in tumor across all four instruments; with primary fluorescence 
detection being localized to tumor (Fig. A2.7). High contrast was observed with the 
Maestro imaging system for RGD-680rd (T/N = 36.4) and is likely attributed to the low 
background noise achieved upon spectral unmixing. Analysis of the 3D images obtained 
using the FMT revealed whole body and tumor region fluorescence heterogeneity that 
was not obvious using 2D visualization. While 2D FMT images revealed non-tumor 
fluorescence throughout the animal, 3D visualization revealed increased measurable 
fluorescence in tumor region.  
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Figure A2.6. LiCor RGD-optical probe evaluation using the Pearl imaging system. 
Pearl images were acquired using protocols listed in the written report. Each column of 
images corresponds to a specific RGD probe and time point p.i. (as listed above). 
Images for an individual probe across time points are set to the same scale (ex. The 1, 
6, and 24 hr images for RGD-680 are scaled the same). Time activity curves (TACs) are 
provided for each probe in regards to tumor and normal tissue uptake. Fluorescence 
measurements were normalized to counts/area to account for discrepancies in ROI size 
across images. 
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T/N 
 
Probes Pearl Maestro IVIS FMT Half-Life (hr) 
800cw 2-DG 3.15 4.07 1.48 1.20 3.8 
800cw RGD 2.79 7.31 1.88 1.39 20.4 
800cw PEG 3.58 3.34 2.02 1.62 >> 24 
800cw EGF 4.75 11.20 1.71 1.51 10.50 
750 RGD 3.12 2.67 1.87 2.15 > 24 
680rd RGD 6.36 36.40 3.21 3.92 13.4 
680rd EGF 11.31 8.11 3.26 5.07 4.1 
      
2-DG-750 3.79 3.39 2.68 2.80 > 24 
Integrin probe 750 1.47 1.58 1.18 - 12.4 
      
AngioSense 750 3.27 2.51 2.56 2.29 >> 24 
ProSense 750 2.37 1.87 1.17 1.40 5.4 
IntegriSense 750 4.87 4.17 2.84 3.69 > 24 
ProSense 680 1.87 1.57 1.57 1.67 >> 24 
IntegriSense 680 2.42 2.00 1.54 1.68 > 24 
      
 
Table A2.2. Comparison of optical imaging probes across imaging systems. Probe 
performance on each imaging system was evaluated in terms of contrast (T/N ratio) and 
tumor clearance rate (half-life). Half-life was determined using the Pearl developed TACs 
(presented throughout this report). Peak uptake was universally marked at 1 h p.i. A 
dash (-) mark corrupt data sets that could not be quantified.  
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Figure A2.7. Comparison of LiCor RGD-optical probes across imaging systems. 
Images were acquired across instruments using protocols listed in the written report. 
Each column of images corresponds to the 24 h time point for a specific RGD probe and 
instrument. A comparison of tumor-normal ratios for each probe across instruments is 
also provided. 
 
Caliper and VisEn Integrin Optical Probes 
The Caliper RediJect integrin optical probe binds αvβ3 integrin expression on the 
cell surface. For this study, the RediJect integrin XenoLight 750 probe was used utilizing 
the recommended dose of 2 nmol. The VisEn IntegriSense optical probes are non-
peptide small molecules which act as integrin αvβ3 and αvβ5 antagonists. For this study, 
the Integrisense 680 and 750 NIR fluorochromes were used utilizing the recommended 
doses of 2 nmol for each probe. A comparison of Pearl images and TACs for these 
probes showed specific uptake in tumor tissue with arguably higher uptake being 
observed for the IntegriSense probes based on photon counts/pixel (Fig. A2.8). Further 
comparison of these probes showed comparable detection of probe uptake in tumor 
across all four instruments; with primary fluorescence detection being localized to tumor 
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 (Fig. A2.9). The IntegriSense probes and the Caliper RediJect probe showed similar 
contrast across all four instruments based on T/N ratios (Table A2.2). Analysis of the 3D 
images obtained using the FMT revealed whole body and tumor region fluorescence 
heterogeneity that was not obvious using 2D visualization. While 2D FMT images 
revealed non-tumor fluorescence throughout the animal, 3D visualization revealed 
increased measurable fluorescence in tumor region.  
Compared to the LiCor RGD probes, the Caliper and VisEn integrin probes 
showed slower tissue clearance rates based on probe half-life (Table A2.2). RediJect 
integrin XenoLight 750 probe was the exception to this trend possessing the fastest 
clearance rate at t1/2 = 12.4 h. T/N profiles of the LiCor, Caliper, and VisEn probes 
across imaging platforms were very similar, though the highest contrast was achieved 
with the RGD-680rd and -800cw on the Maestro imaging system. 
 
Figure A2.8. Integrin-optical probe evaluation using the Pearl imaging system. 
Pearl images were acquired using protocols listed in the written report. Each column of 
images corresponds to a specific probe and time point p.i. (as listed above). Images for 
an individual probe across time points are set to the same scale. Time activity curves 
(TACs) are provided for each probe in regards to tumor and normal tissue uptake. 
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 Fluorescence measurements were normalized to counts/area to account for 
discrepancies in ROI size across images. 
. 
 
Figure A2.9. Comparison of Integrin-specific probes across imaging systems. 
Pearl images were acquired using protocols listed in the written report. Each column of 
images corresponds to a specific probe and time point p.i. (as listed above). Images for 
an individual probe across time points are set to the same scale. Time activity curves 
(TACs) are provided for each probe in regards to tumor and normal tissue uptake. 
Fluorescence measurements were normalized to counts/area to account for 
discrepancies in ROI size across images. 
 
VisEn AngioSense Optical Probe 
The VisEn AngioSense 750 optical probe acts as a blood pooling agent by 
accumulating in areas of vascular leakage. For this study, the recommended dose of 2 
nmol was utilized. The Pearl derived TAC revealed increased measured fluorescence in 
tumor region that continued to increase even 24 h p.i. (t1/2 >> 24 h); a profile typical of 
large biomolecules and blood pooling agents (Fig. A2.10). Primary fluorescence 
detection was localized to tumor region across platforms with limited fluorescence being 
detected in normal tissue based on total photon counts. T/N ratios were similar for all 
179
 four instruments; ranging between 2-3 (Table A2.2). Rotation of 3D FMT images 
revealed probe uptake heterogeneity that was not obvious across the reflectance 
imaging platforms. 
 
Figure A2.10. Evaluation of AngioSense-750 across imaging systems. Pearl images 
were acquired using protocols listed in the written report. All Pearl images were set to 
the same scale. The time activity curve (TAC) was provided in regards to tumor and 
normal tissue uptake. Fluorescence measurements were normalized to counts/area to 
account for discrepancies in ROI size across images. Images were acquired across 
multiple instruments using protocols listed in the written report. Each column of images 
corresponds to the 24 h time point. The white ellipse on the FMT image outlines the 
tumor area for clarity. A comparison of tumor-normal ratios for each probe across 
instruments is also provided. 
 
LiCor PEG Optical Probe 
The LiCor PEG 800cw optical probe acts as a non-specific binding agent that 
exploits tumor enhanced permeability and retention (EPR). For this study, the 
recommended dose of 2 nmol was utilized. The Pearl derived TAC revealed increased 
measured fluorescence in tumor region that continued to increase even 24 h p.i. (t1/2 >> 
24 h); a profile typical of large biomolecules and blood pooling agents (Fig. A2.11). 
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 Primary fluorescence detection was localized to tumor region across platforms with 
limited fluorescence being detected in normal tissue based on total photon counts. 
Investigations across platforms revealed similar image contrast, with T/N ratios ranging 
between 1.6-3.6 for all four instruments (Table A2.2). Based on optical images, TACs, 
half-life, and T/N ratios, the LiCor PEG and VisEn AngioSense optical probes displayed 
similar optical and pharmacokinetic properties. Rotation of 3D FMT images revealed 
probe uptake heterogeneity that was not obvious across the reflectance imaging 
platforms. 
 
Figure A2.11. Evaluation of PEG-800cw across imaging systems. Pearl images 
were acquired using protocols listed in the written report. All Pearl images were set to 
the same scale. The time activity curve (TAC) was provided in regards to tumor and 
normal tissue uptake. Fluorescence measurements were normalized to counts/area to 
account for discrepancies in ROI size across images. Images were acquired across 
multiple instruments using protocols listed in the written report. Each column of images 
corresponds to the 24 h time point. The white ellipse on the FMT image outlines the 
tumor area for clarity. A comparison of tumor-normal ratios for each probe across 
instruments is also provided. 
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 VisEn ProSense Optical Probes 
The ProSense optical probes are activated by proteases of the cathespin family 
(i.e., cathespin B, L, and S). According to product literature, these probes are optically 
silent in the inactivated state but become highly fluorescent when activated. ProSense 
probes conjugated with NIR fluorochromes 680 and 750were utilized using the 
recommended dose of 2 nmol. The Pearl derived TACs of both probes showed 
drastically different uptake and clearance profiles (Fig. A2.12). ProSense 680 showed 
slow tissue clearance over the 24 h uptake period (t1/2 > 24 h) (Table A2.2). Due to non-
specific fluorescence detection (primarily from what appears to be kidney), it is difficult to 
determine if counts/pixel measured by ROI placement for tumor region was the result of 
tumor region fluorescence or the result of adjacent non-specific kidney uptake. Unlike 
ProSense 680, ProSense 750 showed fast tissue clearance (t1/2 > 5.4 h) and marginal, if 
any, tumor specific uptake. Images for both ProSense probes across all platforms 
revealed little fluorescence detection in tumor region (Fig. A2.13). Upon rotation of 3D 
FMT images, the absence of fluorescence detection in tumor was confirmed for both 
probes. 
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Figure A2.12. ProSense-optical probe evaluation using the Pearl imaging system. 
Pearl images were acquired using protocols listed in the written report. Each column of 
images corresponds to a specific probe and time point p.i. (as listed above). Images for 
an individual probe across time points are set to the same scale. Time activity curves 
(TACs) are provided for each probe in regards to tumor and normal tissue uptake. 
Fluorescence measurements were normalized to counts/area to account for 
discrepancies in ROI size across images. White ellipses were drawn across all images in 
order to outline tumor area for clarity.  
 
 
Figure A2.13. Comparison of ProSense imaging probes across imaging systems. 
Images were acquired across instruments using protocols listed in the written report. 
Each column of images corresponds to the 24 h time point for a specific probe and 
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 instrument. White ellipses were drawn across all images in order to outline tumor area 
for clarity. A comparison of tumor-normal ratios for each probe across instruments is 
also provided. 
 
LiCor and Caliper 2-DG Optical Probes 
 Both LiCor’s 2-DG optical probe and Caliper’s RediJect 2-DG optical probe are 
fluorescent analogues of 2-deoxy-D-glucose that targets elevated rates of glycolysis in 
tumor cells. LiCor 2-DG conjugated with IRDye 800cw and Caliper RediJect 2-DG 
conjugated with XenoLight 750 were utilized using the recommended doses of 10 nmol. 
For in vivo evaluation of these two probes, the protocol for optical imaging using vehicle 
and C225 treated DiFi mice was implemented. Pearl derived TACs for LiCor and Caliper 
probes showed elevated tumor fluorescence (based on counts/pixel) in both vehicle and 
treated mice (Fig. A2.14-15). Few, if any, differences between vehicle and treated tumor 
measurable fluorescence were observed for the LiCor and Caliper 2-DG probes across 
all four imaging systems (Fig. A2.16-17). Rotation of 3D FMT images revealed 
fluorescence heterogeneity for Caliper 2-DG that was not obvious across the reflectance 
imaging platforms. 3D FMT analysis of the LiCor 2-DG probe confirmed background 
detectable fluorescence for tumor region. Though unclear at the time of data collection, 
we anticipate that this discrepancy was due to tumor positioning in the FMT and did not 
reflect the FMT’s inability to detect fluorescence from the LiCor 2-DG reagent. Rapid 
clearance was noted for the LiCor probe (t1/2 > 3.8 h) while the Caliper probe showed 
much slower clearance (t1/2 > 24 h) (Table A2.2). 
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Figure A2.14. Efficacy of 2-DG-800cw optical imaging as a measure of therapeutic 
response using the Pearl imaging system. Pearl images were acquired using 
protocols listed in the written report. Each column of images corresponds to a specific 
time point p.i. (as listed above). Images across time points are set to the same scale. 
Time activity curves (TACs) in regards to tumor and normal tissue uptake. Fluorescence 
measurements were normalized to counts/area to account for discrepancies in ROI size 
across images. 
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Figure A2.15. Efficacy of RediJect 2-DG optical imaging as a measure of 
therapeutic response using the Pearl imaging system. Pearl images were acquired 
using protocols listed in the written report. Each column of images corresponds to a 
specific time point p.i. (as listed above). Images across time points are set to the same 
scale. Time activity curves (TACs) in regards to tumor and normal tissue uptake. 
Fluorescence measurements were normalized to counts/area to account for 
discrepancies in ROI size across images. 
 
 
 
Figure A2.16. Comparison of 2-DG-800cw optical imaging as a measure of 
therapeutic response across imaging systems. Images were acquired across 
186
 instruments using protocols listed in the written report. Each column of images 
corresponds to the 24 h time point for a specific probe and instrument. White ellipses 
were drawn across FMT images in order to outline tumor area for clarity. A comparison 
of tumor-normal ratios for each probe across instruments is also provided. 
 
 
Figure A2.17. Comparison of RediJect 2-DG optical imaging as a measure of 
therapeutic response across imaging systems. Images were acquired across 
instruments using the protocols described. Each column of images corresponds to the 
24 h time point for a specific probe and instrument. A comparison of tumor-normal ratios 
for each probe across instruments is also provided. 
 
In previous studies, the inhibition of EGFR by C225 and resulting physiological 
effects of treatment (i.e., decreased cell proliferation, increased cell apoptosis, etc.) were 
detectable by [18F]FDG PET. Compartmental modeling showed decreased [18F]FDG 
uptake in DiFi mice after C225 treatment. The optical imaging data acquired for both 2-
DG probes contradict these results and disagree with the expected result of decreased 
tumor uptake in treated animals.  
To further compare LiCor 2-DG probe with [18F]FDG, an ex-vivo cross-sectional 
slicing experiment was performed in accordance to the protocol described previously. 
[18F]FDG autoradiography of a cross sectional whole body tissue slice (40 µm thick) 
provided some understanding of the heterogeneous tumor tissue uptake in an untreated 
DiFi mouse (Fig. A2.18). Optical analysis using the LiCor Odyssey of the same tissue 
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 slice showed relatively homogenous uptake of the optical 2-DG probe. 2-DG probe 
accumulation did not correlate with the heterogeneous distribution of [18F]FDG, which 
was primarily detected within solid tumor tissue and showed peripheral accumulation 
around perceived areas of tissue necrosis.  
 
Figure A2.18. Multi-modality comparison of measures of cellular glycolysis. 
Individual registered images collected during cryosectioning of digital blockface, H&E 
staining, [18F]FDG autoradiography, and optical Odessey images (top-700 (red) and 800 
(green) channel overlay, middle-800 channel, and bottome-700 channel). Also shown is 
a coregistered image of digital blockface imaging and CT. 
 
LiCor EGF Optical Probes 
 The EGF optical probe targets over expression of EGFR that is typically related with 
increased cellular proliferation and tumor cell growth. LiCor EGF probe conjugated with 
IRDye 680rd was utilized using the recommended dose of 2 nmol. For in vivo evaluation 
of this probe, the protocol for optical imaging using vehicle and C225 treated DiFi mice 
was implemented. The Pearl derived TAC showed elevated tumor specific uptake in 
vehicle mice and minimal tumor uptake in treated mice (Fig. A2.19). Similar uptake 
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 profiles were observed across all four imaging systems and agreed with the Pearl TACs 
(Fig. A2.20). Rotation of the 3D FMT image provided a map of probe uptake 
heterogeneity that was not discernable when using reflectance imaging. All data 
acquired for the EGF-680rd agrees with previous work where optical imaging studies in 
C225 treated DiFi mice using EGF and Annexin-V conjugated with optical dyes showed 
minimal specific tumor tissue probe uptake (2). 
 
Figure A2.19. EGF optical probe evaluation using the Pearl imaging system. Pearl 
images were acquired using protocols listed in the written report. Each column of images 
corresponds to a specific time point p.i. (as listed above). Images across time points are 
set to the same scale. Time activity curves (TACs) in regards to tumor and normal tissue 
uptake. Fluorescence measurements were normalized to counts/area to account for 
discrepancies in ROI size across images. 
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Figure A2.20. Comparison of EGF imaging probes across imaging systems. 
Images were acquired across instruments using protocols listed in the written report. 
Each column of images corresponds to the 24 h time point for a specific probe and 
instrument. White ellipses were drawn across FMT images in order to outline tumor area 
for clarity. A comparison of tumor-normal ratios for each probe across instruments is 
also provided. 
 
LiCor, Caliper, and Visen Bone Optical Probes 
The LiCor, Caliper, and VisEn optical bone probes target areas of active bone 
growth. LiCor BoneTag conjugated with IRDye 680, Caliper RediJect bone probe 
conjugated with XenoLight 750, and VisEn OsteoSense conjugated with NIR 
fluorochrome 750 were utilized using the recommended dose of 4, 2, and 2 nmol 
respectively. All three probes showed similar uptake profiles across instruments in the 
human breast cancer (BC) GFP-labeled MDA-MB-231 mouse model (Fig. A2.21-23). 
Increased fluorescence was detected in the femur, spine, and skull. In the case of 
Caliper’s RediJect-750, non-specific probe uptake (suspected as kidney uptake) was 
also observed. GFP imaging with the Maestro was performed on all MDA-MB-231 
animals in order to correlate GFP detection with bone probe uptake. GFP tumors were 
detected, bus as expected, probe accumulation did not correlate with regions of tumor 
detection. For the OsteoSense-750 animal set, rib cage/spine and fore/hind limb bones 
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 were harvested after in vivo imaging and imaged ex vivo on the Maestro (Blue filter 
setting) and Pearl (Fig. A2.24). In the ex vivo studies using OsteoSense-750, no 
correlation between positive GFP detection and probe uptake was observed. 
 
Figure A2.21. Comparison of LiCor Bone Tag 680 imaging across imaging 
systems. Images were acquired across instruments using protocols listed in the written 
report. Each column of images corresponds to the 24 h time point for a specific probe 
and instrument. Top row of images were taken with the animal in the supine position 
while bottom row images were taken with the animal in the prone position. GFP 
expression was imaged using the Maestro with the Blue filter setting (far left).  
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Figure A2.22. Comparison of Caliper RediJect Bone Probe 680 imaging probe 
across imaging systems. Images were acquired across instruments using protocols 
listed in the written report. Each column of images corresponds to the 24 h time point for 
a specific probe and instrument. Top row of images were taken with the animal in the 
supine position while bottom row images were taken with the animal in the prone 
position. GFP expression was imaged using the Maestro with the Blue filter setting (far 
left).  
 
 
Figure A2.23. Comparison of VisEn OsteoSense 750 imaging across imaging 
systems. Images were acquired across instruments using protocols listed in the written 
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 report. Each column of images corresponds to the 24 h time point for a specific probe 
and instrument. Top row of images were taken with the animal in the supine position 
while bottom row images were taken with the animal in the prone position. GFP 
expression was imaged using the Maestro with the Blue filter setting (far left).  
 
 
Figure A2.24. Ex vivo imaging of bone tissue samples using VisEn OsteoSense 
750 optical imaging. Images were acquired on the Maestro and Pearl using protocols 
listed in the written report. Top images show rib cage and spine in two different positions 
(left, spine is facing camera; right, rib cage is facing camera). Bottom images show 
fore/hind limbs. 
 
Optical Imaging Instrument Comparison 
The Vandebilt IVIS system is an IVIS200 combination 
bioluminescence/fluorescence imaging system that was purchased new from Xenogen 
in approximately 2002 for ~$400,000. The Maestro imaging system was purchased new 
from CRi in 2006 for ~$90,000. The LiCor Pearl imaging system was purchased from 
LiCor in 2010 for $48,000. The FMT2500 imaging system was purchased from VisEn in 
2010 for $350,000. The IVIS200, Maestro, and Pearl systems were purchased using 
institutional funds and the FMT2500 was purchased using funds to Dr. Manning from a 
NIH shared institutional grant.  
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 Our experiences with this study have led to a group of conclusions regarding the 
utilization of these imaging systems. In terms of measured contrast observed in this 
study, the Maestro typically provided the highest T/N ratios likely due to the benefits of 
spectral unmixing (Table A2.2). The Pearl frequently demonstrated higher contrast than 
IVIS or FMT, though contrast did not consistently exceed that of the Maestro. The FMT 
showed the most variation in measured contrast, which might be the result of the 
transillumination geometry that this system utilizes. 
Point of Comparison Pearl Maestro IVIS FMT 
Throughput *** ** **** * 
Reliability **** ** **** * 
Ease of use (instrument) **** *** *** ** 
Ease of use (software) **** *** *** ** 
 
Table A2.3. Qualitative comparisons of practical instrument usability. Imaging 
systems were evaluated in terms of throughput, reliability, ease of instrument use, and 
ease of software use. A single asterisk (*) signifies ‘fair’, double asterisk (**) for 
‘moderate’, triple asterisk (***) for ‘good’, and quadruple asterisk (****) for ‘excellent’. 
 
Throughout the course of this study, many practical characteristics (both positive 
and negative) of the four optical imaging platforms investigated became apparent. A 
qualitative comparison of instrument usability in terms of throughput, reliability, ease of 
instrument use, ease of software use is provided in Table A2.3. Qualitative measures of 
each category were made using an asterisk based system: a single asterisk (*) for fair, 
double asterisk (**) for moderate, triple asterisk (***) for good, and quadruple asterisk 
(****) for excellent. Unlike the FMT, Maestro, and Pearl, the IVIS is capable of imaging 
multiple mice simultaneously, thus permitting greater throughput when working with 
large cohorts of mice (> 25 animals). Though the Pearl is limited to one mouse per scan, 
the speed of acquisition and the ability to simultaneously image across the 700 nm and 
800 nm channels allows the Pearl to become a fairly high-throughput instrument and 
comparable to the IVIS for small to moderate cohorts (1 – 25 animals). The throughput 
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 of the Maestro is comparable to the Pearl when using short integration times (< 500 ms) 
and a single filter set. However, for experiments that require long integration times (> 1 
s) and/or require multiple filter settings (as can be the case with co-injections of multi-
wavelength probes), scan time can increase drastically and significantly impede 
throughput. Out of all four platforms, the FMT is the slowest in terms of animal 
throughput due to lengthy acquisition times. While scan times may vary depending on 
region size, acquisitions using a single channel routinely averaged 5 min. For any 
experiments which require more than five animals and/or multiple channel acquisitions, a 
5 min acquisition time can cause the FMT to become a major bottle neck for multi-
platform experiments and likewise hinder time point sensitive experiments (such as time 
course developments). For these reasons, in terms of throughput the Pearl was ranked 
‘good’, the Maestro ‘moderate’, the IVIS ‘excellent’, and the FMT ‘fair.’  
The point of comparison ‘reliability’ was termed in regards to the frequency of 
technical difficulties experienced while performing extensive optical imaging 
experiments. Throughout the course of multiple imaging experiments, the Pearl and IVIS 
rarely experienced software or instrument errors that would prevent image acquisition. 
As such, these instruments were ranked ‘excellent.’ While the Maestro was frequently 
reliable, on occasion the software would fail to acknowledge the presence of the 
instrument when starting the system. Failure to collect fluorescence data due to faulty 
camera mechanics was another technical error occasionally encountered. These 
occasional disruptions typically required a complete system reset; delaying a given 
experiment up to 5 or 10 min. The Maestro was ranked ‘moderate’ for reliability. 
Technical difficulties were most frequent when using the FMT and associated TrueQuant 
software. Throughout use, a variety of instrument and software errors (such as the 
software freezing up, the instrument failing to initiate correctly, staging errors, etc.) would 
occur that could drastically delay or even prevent experiment completion. Frequently, 
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 correction of the errors required repeatedly resetting the system until the instrument 
began functioning correctly. During the course of these studies, approximately five 
service calls were made to VisEn technical support to resolve these issues promptly. As 
such, the FMT was ranked ‘fair’ for reliability.  
Ease of instrument/software use was defined in terms of how quickly and easily a 
new user could successfully learn to operate the imaging instrument without external 
guidance. The Pearl was the easiest and quickest instrument to use and train others 
how to use as operation can be achieved by the click of a button. Training a new user on 
the Maestro and IVIS was also easily accomplished once new users gained an 
understanding of what optical/acquisition settings worked best for their experiments. The 
FMT was perhaps the most difficult instrument to introduce to new users. Most of this 
difficulty stemmed from the windowing set-up implemented by the TrueQuant imaging 
software, which can at first be slightly confusing to new users. In addition, the need for 
calibrating the instrument for a specific optical probe is something many users are not 
accustomed to doing. While laser channel calibration is performed only the first time a 
new optical probe is used, it is a step in instrument operation that can sometimes be new 
for first time users. For these reasons, in terms of ‘ease of use’, the Pearl was ranked 
‘excellent’, the Maestro ‘good’, the IVIS ‘good’, and the FMT ‘moderate.’ 
 
A2.4. Conclusions 
In this study we have compared an array of small animal in vivo optical imaging 
probes from VisEn, Perkin Elmer, and LiCor across four imaging systems (IVIS, 
Maestro, Pearl, and FMT) to evaluate probes in animal models of cancer. Molecular 
imaging probes were assessed and compared based on images obtained across all four 
systems, Pearl derived TACs, T/N ratios, and probe half-life. Imaging instruments were 
compared qualitatively using a variety of practical based parameters. We feel that the 
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 results of this study will help guide future developments of imaging technologies and 
optical imaging probes. 
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 APPENDIX 3 
 
MICROFLUIDIC RADIOCHEMISTRY FOR PET PROBE DISCOVERY 
 
A3.1. Introduction 
The development and optimization of novel radiochemistries can be a bottleneck 
within the molecular imaging probe development paradigm as the ability to make 
compounds often exceeds radiolabeling capabilities. Traditional radiochemical 
preparations are inherently low throughput and limit the ease and efficiency at which 
protocol optimization and utilization can be achieved. Microfluidic radiochemistry offers a 
high throughput alternative approach to classical, box-based radiosyntheses (1-5) and 
provides: precise delivery of small isotope/precursor quantities, use of a linear, high 
surface-to-volume ratio reactor, laminar flow mixing of reagents, control over solvent 
backpressure, and rapid/sequential production of multiple tracers in relatively short 
periods of time. More specifically, the high-throughput nature of microfluidic approaches 
enables rapid optimization and evaluation of various radiochemical conditions, which 
may subsequently inform the feasibility of larger scale production. 
In this work, utilization of the Advion NanoTek LF system (Fig. A3.1) and 
microfluidic radiochemistry were explored as a means for rapidly developing and 
optimizing novel and unconventional radiochemistries (Fig. A3.2). Leveraging previous 
experience involving the development of translocator protein (TSPO) specific positron 
emission tomography (PET) tracers, extensive focus was given towards evaluating 
microfluidic radiolabeling of known (i.e., [18F]PBR06 (6,7) and [18F]DPA714 (8,9)) and 
novel (10,11) TSPO ligands typically prepared using traditional means. 
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Figure A3.1. Advion NanoTek LF radiochemistry module. Images and hardware 
schematic of the microfluidic system used for these studies. Instrument schematic was 
obtained from the corresponding product literature. 
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Figure A3.2. Work-flow for microfluidic radiochemical screening. Development 
paradigm for employing the NanoTek Microfluidic system towards triaging precursors 
and optimizing radiolabeling conditions for transition to full-scale production. 
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 A3.2. Materials and Methods 
 
Chemicals 
Unless otherwise indicated, all other chemicals, reagents, and solvents were 
purchased from Sigma-Aldrich and used as received. Radiochemical precursors were 
obtained from collaborating synthetic chemists affiliated with the Vanderbilt Institute of 
Imaging Science, the Vanderbilt Radiochemistry Core, and/or the Manning research 
group. 
 
Microfluidic Radiochemistry 
The Advion NanoTekTM LF system was used to perform microfluidic radiolabeling 
of a variety of aryloxyanilide and pyrazolo-pyrimidine based TSPO ligands with fluorine-
18. Additional compounds, such as indomethacin and crizotinib derivatives as well as a 
class of small molecule BRAF inhibitors, were also explored. In the following 
discussions, the term discovery will be used to describe small volume, high-throughput 
microfluidic experiments where the objective was to explore, optimize, and characterize 
reaction conditions and properties. The term production will be used to describe high 
volume, low-throughput microfluidic experiments where the object was to synthesize a 
specific radiolabeled-product in sufficient yield and purity for use in small animal imaging 
studies. 
Upon radiosynthesis, [18F]fluoride ion (10-30 µCi) was trapped on an anion 
exchange cartridge and released upon complexation with K1-K1-2.2.2/K2CO3. Iterative 
azeotropic drying was performed at 110 °C by addition of acetonitrile. Reaction solvent 
was then added to the [18F]fluoride-kryptofix solution and loaded into the pump 3 loop. 
Subsequently, precursor solution (4 mg/mL) was then loaded into the pump 1 loop. Prior 
to synthesis, transfer-lines 1 and 3 were filled with [18F]fluoride and precursor solutions, 
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 30 µL each, and swept through the reactor by reaction solvent via pump 3 at 60 µL/min. 
For discovery runs, a bolus of 10-20 µL each of [18F]fluoride and precursor each were 
flushed through the reactor at a flow rate of 60 µL/min. Reaction solvents were typically 
acetonitrile, dimethyl sulfoxide (DMSO), or dimethylformamide (DMF). Reaction 
temperatures varied between 60 – 200 °C. For production runs, a bolus of 150 uL each 
of [18F]fluoride and precursor were flushed through the reactor at a flow rate of 60 uL/min 
at a single temperature; as selected based on results from discovery experiments. 
 
Chromatography  
Radiochemical yield for most compounds was estimated by normal phase radio-
thin layer chromatography (TLC) analysis using a BioScan radio-TLC plate reader. TLC 
plates were developed using an water:acetonitrile (MeCN) (10:90) mobile phase for 
aryloxyanilides, pyrazolo-pyrimidines, and indomethacin derivatives; where unlabeled 
fluorine-18 remained at the origin and [18F]-radiolabeled compound traveled with the 
solvent front. For BRAF inhibitors, crizotinib derivatives, and amino acid complexes, 
plates were developed using a methanol (MeOH): dichloromethane (DCM) (10:90) 
mobile phase. Uncomplexed amino acid final product was developed using a n-butanol 
(n-BuOH): acetic acid: water: ethanol (EtOH) (4:1:1.6:0.5) mobile phase. 
Radiochemical stability and standard curve derived specific activities (SA) were 
determined using a reversed-phase, high pressure liquid chromatography (HPLC) 
approach. Unless otherwise stated, a wavelength of 254 nm was used for acquisition of 
all HPLC UV-chromatograms. For aryloxyanilides, a water:MeCN (40:60) mobile phase 
was run at 1 mL/min on a C18 Dynamax 250·4.6 mm (Varian) column. For pyrazolo-
pyrimidines, a 0.5 M aqueous ammonium acetate (NH4)OAc (pH 10):MeCN (35:65) 
mobile phase was run at 1 mL/min on a C18 Dynamax 250 x 4.6 mm (Varian) column. 
Indomethacin derivatives were analyzed using the following water:MeCN gradient at 1 
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 mL/min on a C18 Dynamax 250 x 4.6 mm (Varian) column: 50% MeCN, 0-1 min; 50-
95% MeCN, 1-15 min; 95% MeCN, 15-20 min; 95%-50% MeCN, 20-21 min. BRAF 
inhibitors and crizotinib derivatives were analyzed using the following water:MeCN 
gradient at 1 mL/min on a C18 Dynamax 250 x 4.6 mm (Varian) column: 30-90% MeCN, 
0-10 min; 90% MeCN, 10-30 min. Uncomplexed amino acid final product was analyzed 
using a ammonium acetate:ethanol (45:55) isocratic mobile system on an Luna NH2 250 
x 4.6 mm (Phenomenex) column using a flow of 1 mL/min and a UV-wavelength of 207 
nm. 
Low resolution mass spectra were obtained on an Agilent 1200 liquid 
chromatography–mass spectrometry (LC-MS) with electrospray ionization available 
through the Chemical Synthesis CORE at Vanderbilt.  
 
A3.3. Results and Discussion 
 
TSPO Ligands 
Initial discovery experiments revealed that optimizing reaction temperatures had 
a major impact on the radiochemical yields of aryloxyanilides ([18F]PBR-06) and 
pyrazolo-pyrimidines ([18F]DPA-714, VUIIS 7004, VUIIS 1012, VUIIS 1016) (Fig. A3.3, 
Fig. A3.4) upon substitution of a Br or tosyl-leaving group (aryloxyanilide and pyrazolo-
pyrimidines, respectively) with fluorine-18. Radiolabeling Labeling efficiencies up to and 
greater than 90% could be achieved for all compounds when characterized at optimal 
temperatures. Importantly, optimized microfluidic conditions were informative towards 
accelerating development of high-specific activity, large-scale production methodologies 
developed in a GE Tracer Labs FX module.  
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Figure A3.3. Microfluidic discovery of TSPO PET ligands for the optimization of 
reaction temperatures. Relative radiochemical yields, as measured by radio-TLC, of 
sequential microfluidic productions of TSPO ligands at different temperatures using 
acetonitrile as the reaction solvent. ‘Position’ refers to the distance traveled by 
compounds along the TLC-plate, where the origin is 60 mm and the solvent front is 120 
mm. In all cases shown, radio-labeled product traveled with the solvent front (120 mm), 
while free fluorine-18 remained at the origin (60 mm). 
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Figure A3.4. Two-dimensional representation of fluorine-18 percent incorporation 
temperature dependency of TSPO ligand discovery radiolabelings in acetonitrile. 
Compounds shown: black = [18F]PBR06, orange = [18F]DPA-714, red = VUIIS 1016, 
green = VUIIS 1012, blue/purple = VUIIS 1004. 
 
Given the promising results of the discovery experiments, full-scale production 
experiments were explored to evaluate the potential of utilizing the Advion NanoTek for 
the synthesis of preclinical probe doses alternatively to more traditional methodologies, 
such as the GE Tracer Labs FX module. The bulk of these studies focused on the 
production of [18F]PBR06 (Table A3.1), but radiochemical production of [18F]DPA-714 
(Table A3.2) was also explored. Interestingly, production runs often resulted in 
radiochemical yields, or percent fluorine-18 incorporation, that were significantly higher 
than that predicted by initial discovery experiments for similar reaction conditions. This 
difference was thought to be related to the increased conditioning of the microfluidic 
reactor resulting from the constant flow of fluorine-18 and precursor compound. 
Accordingly, the effects of reaction solvent on radiochemical incorporation were made 
more apparent in these experiments, as choice of reaction solvent was found to have a 
profound effect on radiochemical yield for pyrazolo-pyrimidines, compared to 
aryloxyanilides, where at least 150-160 °C was needed to reach ≥90% labeling in 
acetonitrile while as low as 100-110 °C was needed to achieve similar yields in 
dimethylformamide.  
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SA (Ci/mmol) SA (TBq/mmol) % Labeling Temp (°C) Solvent 
22.8 0.8 70 160 MeCN 
35.1 1.3 42 160 MeCN 
34.2 1.3 66 160 MeCN 
58.7 2.2 95 160 MeCN 
22.0 0.8 58 160 MeCN 
46.1 1.7 44 140 MeCN 
307.0 11.4 95 150 DMF 
81.0 3.0 98 150 DMF 
19.1 0.7 86 140 DMF 
2.8 0.1 90 140 DMF 
10.3 0.4 97 110 DMF 
8.9 0.3 89 100 DMF 
27.2 1.0 97 100 DMF 
110.3 4.1 99 110 DMF 
4.5 0.2 92 110 DMF 
5.4 0.2 35 110 DMF 
 
Table A3.1. Representative summary of multiple [18F]PBR06 productions using the 
Advion NanoTek. Specific activities (SA), Decay corrected radiochemical yields (% 
Labeling), reaction temperatures (Temp), and reaction solvents (acetonitrile (MeCN) or 
dimethylformamide (DMF)) for seven representative [18F]PBR06 production runs. 
 
SA (Ci/mmol) SA (TBq/mmol) % Labeling Temp (°C) Solvent 
630.79 23.34 80.8 180 MeCN 
175.71 6.50 58.5 160 MeCN 
125.43 4.64 83.6 160 MeCN 
1.6 0.06 10 130 DMF 
3.9 0.15 24 130 DMF 
3.6 0.13 8 140 DMF 
15.8 0.59 31 140 DMF 
 
Table A3.2. Representative summary of multiple [18F]DPA-714 productions using 
the Advion NanoTek. Specific activities (SA), Decay corrected radiochemical yields (% 
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 Labeling), reaction temperatures (Temp), and reaction solvents (acetonitrile (MeCN) or 
dimethylformamide (DMF)) for seven representative [18F]DPA-714  production runs. 
 
Despite the very promising radiochemical yields obtained in microfluidic 
production runs, a reoccurring limitation was found in the form of below average specific 
activities (SA). Initially, the efficiency of fluorine-18 transfer with the NanoTek system, 
fluoride trapping efficiency, as well as the potential introduction of fluorine-19 through 
precursor preparation and/or through the NanoTek system itself were all explored, and 
eventually eliminated, as possible causes of the low specific activity measurements. 
Even with assistance from Lee Collier, PhD, Advion’s lead radiochemist for the NanoTek 
system at the time, the SA for production runs remained low for both [18F]PBR06 and 
[18F]DPA-714. After extensive evaluation of both the NanoTek system and subsequent 
production methodology, up to three by-products that co-eluted with radiolabeled probed 
were identified by LC-MS and reversed-phase HPLC analysis (Fig. A3.5) for [18F]PBR06 
production runs and were suspected as being the cause of the low SA measurements. 
This observation was unique to microfluidic reactions as these by-products were not 
found in decayed [18F]PBR06 samples prepared using traditional radiochemistry 
approaches. Initially, these products were suspected to be the result of hydroxyl by-
product formation. However, subsequent LC-MS studies revealed that while hydroxyl by-
product formation was occurring during radiosynthesis, this by-product did not co-elute 
with authentic radiolabeled probe (Fig. A3.6). Chemical structures of the by-products 
were never identified as quantities sufficient for more rigorous chemical analysis (i.e. 
NMR and high resolution MS) were difficult to obtain due to the inherently poor chemical 
yields of radiochemical methodologies. Project directions changed before similar studies 
could be explored for [18F]DPA-714 microfluidic productions. 
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Figure A3.5. LC-MS and HPLC analysis of decayed [18F]PBR06 microfluidic 
radiolabeled products revealed unknown co-eluting by-products. LC-MS analysis of 
a representative decayed [18F]PBR06 sample and co-injection with [19F]PBR06 (A) as 
well as a reversed-phase HPLC, UV chromatogram of a similar sample (B). A 
magnification of the outlined region in (B) is shown as an over-lay to a chromatogram of 
[19F]PBR06 (magenta). Red squared outline the elution of the by-products.  
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Figure A3.6. Hydroxyl by-product did not co-elute with [18F]PBR06. LC-MS analysis 
of the hydroxyl by-product (top) and [18F]PBR06 (bottom). 
 
Indomethacin Derivative 
 Given the low SA limitation experienced with TSPO ligand radiolabeling, 
utilization of the NanoTek system was shifted to primarily discovery experiments and the 
optimization and evaluation of novel radiochemical strategies. Towards this effort, 
strategies for labeling a novel indomethacin derivative with fluorine-18 for PET imaging 
of COX2 expression was explored as part of a collaborative effort with Larry Marnett, 
PhD, and colleagues (Fig. A3.7). Using the NanoTek, it was possible to triage multiple 
variations of the indomethacin precursor and effectively eliminate compounds, which due 
to instability, were difficult to label (Fig. A3.8, A3.9). At a reaction temperature of 140°C, 
precursor 1 was found thermally unstable by HPLC analysis and exhibited no 
radiolabeling potential. Conversely, precursor 2 was thermally stable at 140°C, but only 
showed modest fluorine-18 incorporation. Similarly, precursor 3 was found stable but to 
possess time-dependent radiolabeling potential. Finally, a reaction temperature-based 
discovery experiment was performed using precursor 4 and revealed the highest 
radiolabeling potential out of the four potential compounds. However, the sample 
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 provided was found to have impurities of compound 2, and thus further stability studies 
were suspended until higher purity precursor samples could be obtained. 
 
Figure A3.7. Indomethacin precursors for radiochemical screening. Through use of 
the NanoTek, it was possible to triage multiple variations of the indomethacin precursors 
and effectively eliminate compounds which, due to instability in common reaction 
solvents, were difficult to label. 
  
 
Figure A3.8. Radiolabeling precursor stability studies for indomethacin 
derivatives. TLC measured fluorine-18 incorporation for the radiolabeling precursors 1 
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 (mesyl), 2 (chloro), and 3 (tosyl) at 140 °C (A). Relative decomposition products, as 
determined by HPLC quantification (B). Representative UV-chromatograms of precursor 
stability, 30 min post precursor preparation in reaction solvent: red = precursor 3, green 
= precursor 2, blue = precursor 1 (C). The point at which precursor was dissolved in 
reaction solvent was defined as time zero. The state of precursor degradation was 
checked at 30 min post solution preparation both before and after radiolabeling at 140 
°C (“30 min” and “30 min*” samples, respectively).  
 
 
 
Figure A3.9. The Br-precursor showed the greatest promise for translation to 
further radiochemical development. Radiolabeling temperature-based discovery runs 
for compound 4. 
 
Crizotinib 
The NanoTek was used to select the optimal labeling conditions needed for the 
development of [18F]crizotinib (compound 7) (Fig. A3.10). Dimethyl sulfoxide (DMSO) 
was found to be the preferred reaction solvent at all temperatures evaluated compared 
to DMF. At the time of these studies, authentic [19F]crizotinib had yet to be provided by 
collaborators within the Manning group. As such, HPLC validation of radiolabeled 
‘product’, as determined by TLC, was never performed. 
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Figure A3.10. Microfluidic fluorine-18 radiolabeling of crizotinib, bromo-precursor. 
Radiolabeling temperature-based discovery runs for [18F crizotinib, compound 7. 
 
Inhibitors of mutant BRAF 
The NanoTek has been used to both screen and optimize the radiolabeling 
potential of novel derivatives of a known BRAF inhibitor from Plexxikon. Using DMF as a 
reaction solvent, it was found that over a range of temperatures, compound 10 showed 
greater feasibility towards radiolabeling than compound 8.  
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Figure A3.11. Microfluidic fluorine-18 radiolabeling of inhibitors of mutant BRAF. 
Radiolabeling temperature-based discovery runs for compounds 9 and 11. 
 
Amino Acid Complexes  
 Similarly, the NanoTek was instrumental towards optimizing the radiochemical 
production of [18F]4-fluoro-glutamine (a complex three-step radiochemical production) 
due to the system’s through-put, versatility, and capabilities of performing successful 
radiolabelings with low tracer levels (<100mCi). In this manner, this system was used to 
develop reaction conditions for the novel 3-step radiolabeling of [18F]4-fluoro-glutamine 
(Fig. A3.12). These improvements aided in accelerating the development of novel 
probes that were actively being explored in programs such as the Vanderbilt ICMIC 
program, Digestive Disease Research Center (DDRC) and GI SPORE Program. 
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Figure A3.12. Utilization of NanoTek for development of radiolabeling conditions 
for amino acid complexes. Generalized reaction scheme for microfluidic applications 
towards a complex, multi-step radiolabeling of [18F]4-fluoro-glutamine (HPLC 
chromatography shown above). 
 
A3.4. Conclusions 
While preliminary data suggested the feasibility of [18F]PBR06 production, the 
improved labeling efficiency of the system came at a cost in the form of accelerated 
production of by-products. Despite certain limitations, the improved throughput NanoTek 
system has demonstrated utility towards determining labeling feasibility, probe stability, 
and optimal reaction conditions prior to transitioning to full-scale hot-cell based 
production. Pre-production method optimization could streamline probe development 
capabilities achievable by traditional radiochemistries. Given this, microfluidic 
radiochemistry and the Advion NanoTek system could be a useful component of PET 
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 probe development in a discovery capacity and offers potential towards better 
understanding and optimizing radiochemical productions.  
 
A3.5. Works Cited 
1. Date SV, Marcotte EM. Protein function prediction using the Protein Link 
EXplorer (PLEX). Bioinformatics 2005;21(10):2558-9. 
2. Strain MC, Letendre S, Pillai SK, Russell T, Ignacio CC, Gunthard HF, et al. 
Genetic composition of human immunodeficiency virus type 1 in cerebrospinal 
fluid and blood without treatment and during failing antiretroviral therapy. J Virol 
2005;79(3):1772-88. 
3. Kang S, Zhao J, Liu Q, Zhou R, Wang N, Li Y. Vascular endothelial growth factor 
gene polymorphisms are associated with the risk of developing adenomyosis. 
Environ Mol Mutagen 2009;50(5):361-6. 
4. Jia J, Yang Z, Li G, Liu C, Lei M, Zhang T, et al. Isolation and chromosomal 
distribution of a novel Ty1-copia-like sequence from Secale, which enables 
identification of wheat-Secale africanum introgression lines. J Appl Genet 
2009;50(1):25-8. 
5. Zhou L, Beuerman RW, Ang LP, Chan CM, Li SF, Chew FT, et al. Elevation of 
human alpha-defensins and S100 calcium-binding proteins A8 and A9 in tear 
fluid of patients with pterygium. Invest Ophthalmol Vis Sci 2009;50(5):2077-86. 
6. Buck JR, McKinley ET, Hight MR, Fu A, Tang D, Smith RA, et al. Quantitative, 
preclinical PET of translocator protein expression in glioma using 18F-N-
fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline. J Nucl Med 
2011;52(1):107-14. 
7. Zhou L, Long R, Pu X, Qi J, Zhang W. Studies of a naturally occurring sulfur-
induced copper deficiency in Przewalski's gazelles. Can Vet J 2009;50(12):1269-
72. 
8. Zhou JL, Liu SQ, Qiu B, Hu QJ, Ming JH, Peng H. The protective effect of 
sodium hyaluronate on the cartilage of rabbit osteoarthritis by inhibiting 
peroxisome proliferator-activated receptor-gamma messenger RNA expression. 
Yonsei Med J 2009;50(6):832-7. 
215
 9. Tang D, Hight MR, McKinley ET, Fu A, Buck JR, Smith RA, et al. Quantitative 
preclinical imaging of TSPO expression in glioma using N,N-diethyl-2-(2-(4-(2-
18F-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimi din-3-yl)acetamide. J 
Nucl Med 2012;53(2):287-94. 
10. Tang D, McKinley ET, Hight MR, Uddin MI, Harp JM, Fu A, et al. Synthesis and 
Structure-Activity Relationships of 5,6,7-Substituted Pyrazolopyrimidines: 
Discovery of a Novel TSPO PET Ligand for Cancer Imaging. J Med Chem 2013. 
11. Wang Z, Zhao C, Yu L, Zhou W, Li K. Regional metabolic changes in the 
hippocampus and posterior cingulate area detected with 3-Tesla magnetic 
resonance spectroscopy in patients with mild cognitive impairment and Alzheimer 
disease. Acta Radiol 2009;50(3):312-9. 
 
216
